US7393851B2 - Azaindole derivatives as inhibitors of p38 kinase - Google Patents
Azaindole derivatives as inhibitors of p38 kinase Download PDFInfo
- Publication number
- US7393851B2 US7393851B2 US10/683,656 US68365603A US7393851B2 US 7393851 B2 US7393851 B2 US 7393851B2 US 68365603 A US68365603 A US 68365603A US 7393851 B2 US7393851 B2 US 7393851B2
- Authority
- US
- United States
- Prior art keywords
- alkyl
- compound
- aryl
- alkenyl
- heteroalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 title abstract description 29
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 title abstract description 29
- 125000005334 azaindolyl group Chemical class N1N=C(C2=CC=CC=C12)* 0.000 title abstract description 4
- 239000003112 inhibitor Substances 0.000 title description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 93
- 125000004122 cyclic group Chemical group 0.000 claims abstract description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 56
- 125000001424 substituent group Chemical group 0.000 claims description 52
- 239000000203 mixture Substances 0.000 claims description 51
- 125000003118 aryl group Chemical group 0.000 claims description 50
- 125000003342 alkenyl group Chemical group 0.000 claims description 36
- 125000005843 halogen group Chemical group 0.000 claims description 25
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 24
- 125000001072 heteroaryl group Chemical group 0.000 claims description 24
- -1 heteroalkenyl Chemical group 0.000 claims description 22
- 125000005842 heteroatom Chemical group 0.000 claims description 18
- 125000000304 alkynyl group Chemical group 0.000 claims description 17
- 125000002252 acyl group Chemical group 0.000 claims description 16
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 16
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 12
- 125000000520 N-substituted aminocarbonyl group Chemical group [*]NC(=O)* 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 125000003435 aroyl group Chemical group 0.000 claims description 9
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 9
- 229920006395 saturated elastomer Polymers 0.000 claims description 9
- 125000004429 atom Chemical group 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 125000004450 alkenylene group Chemical group 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical compound ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 claims description 5
- 150000002923 oximes Chemical class 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- 238000000034 method Methods 0.000 abstract description 41
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract description 10
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 122
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 101
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 84
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 57
- 235000019439 ethyl acetate Nutrition 0.000 description 49
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 47
- 239000000243 solution Substances 0.000 description 44
- 239000000047 product Substances 0.000 description 41
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 34
- 238000002360 preparation method Methods 0.000 description 31
- 239000011541 reaction mixture Substances 0.000 description 31
- 239000000741 silica gel Substances 0.000 description 28
- 229910002027 silica gel Inorganic materials 0.000 description 28
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 25
- 229940093499 ethyl acetate Drugs 0.000 description 23
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- 229910052938 sodium sulfate Inorganic materials 0.000 description 21
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 20
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 19
- 239000012267 brine Substances 0.000 description 18
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 18
- 239000002904 solvent Substances 0.000 description 17
- 235000011152 sodium sulphate Nutrition 0.000 description 16
- 102000004127 Cytokines Human genes 0.000 description 14
- 108090000695 Cytokines Proteins 0.000 description 14
- 238000004587 chromatography analysis Methods 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 13
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical group CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 13
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 11
- 239000002158 endotoxin Substances 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- 229920006008 lipopolysaccharide Polymers 0.000 description 10
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 10
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 125000001183 hydrocarbyl group Chemical group 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- QMCHBUZMYHKNIO-UHFFFAOYSA-N [4-[(4-fluorophenyl)methyl]piperidin-1-yl]-(6-methoxy-1h-pyrrolo[2,3-b]pyridin-5-yl)methanone Chemical compound COC1=NC=2NC=CC=2C=C1C(=O)N(CC1)CCC1CC1=CC=C(F)C=C1 QMCHBUZMYHKNIO-UHFFFAOYSA-N 0.000 description 8
- 230000008878 coupling Effects 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 239000011630 iodine Substances 0.000 description 8
- 229910052740 iodine Inorganic materials 0.000 description 8
- FZPXVUQHMAPXQZ-UHFFFAOYSA-N 1-[1-(4-fluorophenyl)ethyl]-3-methylpiperazine Chemical compound C=1C=C(F)C=CC=1C(C)N1CCNC(C)C1 FZPXVUQHMAPXQZ-UHFFFAOYSA-N 0.000 description 7
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- 239000012971 dimethylpiperazine Substances 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- IEVMFAWRTJEFCF-UHFFFAOYSA-N 2,6-difluoropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=C(F)N=C1F IEVMFAWRTJEFCF-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- 206010040070 Septic Shock Diseases 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 125000005647 linker group Chemical group 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 5
- 239000007832 Na2SO4 Substances 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 5
- 239000012346 acetyl chloride Substances 0.000 description 5
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 0 *CC1CCN(CC)CC1.CC.CC.c1c-c2ccccc2C1 Chemical compound *CC1CCN(CC)CC1.CC.CC.c1c-c2ccccc2C1 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 102000043136 MAP kinase family Human genes 0.000 description 4
- 108091054455 MAP kinase family Proteins 0.000 description 4
- 206010040047 Sepsis Diseases 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000012317 TBTU Substances 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- LIWAQLJGPBVORC-UHFFFAOYSA-N ethylmethylamine Chemical group CCNC LIWAQLJGPBVORC-UHFFFAOYSA-N 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 125000004193 piperazinyl group Chemical group 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 4
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 4
- 235000019345 sodium thiosulphate Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 206010063837 Reperfusion injury Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 238000005576 amination reaction Methods 0.000 description 3
- 125000005251 aryl acyl group Chemical group 0.000 description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 125000005253 heteroarylacyl group Chemical group 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 150000004885 piperazines Chemical class 0.000 description 3
- 150000003053 piperidines Chemical class 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000013389 whole blood assay Methods 0.000 description 3
- NPIPCQHHNIFPQW-SNVBAGLBSA-N (3r)-1-[(4-fluorophenyl)methyl]-3-methylpiperazine Chemical compound C1CN[C@H](C)CN1CC1=CC=C(F)C=C1 NPIPCQHHNIFPQW-SNVBAGLBSA-N 0.000 description 2
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- NRXXCFFOTIFBGX-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperidine Chemical compound C1=CC(F)=CC=C1CN1CCCCC1 NRXXCFFOTIFBGX-UHFFFAOYSA-N 0.000 description 2
- PAJXWHKULPVBEQ-UHFFFAOYSA-N 1-[5-[4-[(4-fluorophenyl)methyl]piperidine-1-carbonyl]-6-methoxy-1h-pyrrolo[2,3-b]pyridin-3-yl]-2-pyrrolidin-1-ylethane-1,2-dione Chemical compound C1=2C=C(C(=O)N3CCC(CC=4C=CC(F)=CC=4)CC3)C(OC)=NC=2NC=C1C(=O)C(=O)N1CCCC1 PAJXWHKULPVBEQ-UHFFFAOYSA-N 0.000 description 2
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 2
- AJPKQSSFYHPYMH-UHFFFAOYSA-N 2,6-dichloropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=C(Cl)N=C1Cl AJPKQSSFYHPYMH-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical group NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- XYEUCELLASJYAP-CQSZACIVSA-N 2-[5-[(2r)-4-[(4-fluorophenyl)methyl]-2-methylpiperazine-1-carbonyl]-6-methoxy-1h-pyrrolo[2,3-b]pyridin-3-yl]-n-methyl-2-oxoacetamide Chemical compound C1=C2C(C(=O)C(=O)NC)=CNC2=NC(OC)=C1C(=O)N([C@@H](C1)C)CCN1CC1=CC=C(F)C=C1 XYEUCELLASJYAP-CQSZACIVSA-N 0.000 description 2
- GABFJOKCNVICBF-UHFFFAOYSA-N 2-[5-[4-[(4-fluorophenyl)methyl]piperidine-1-carbonyl]-6-methoxy-1h-pyrrolo[2,3-b]pyridin-3-yl]-2-oxo-n-pyrrolidin-1-ylacetamide Chemical compound C1=2C=C(C(=O)N3CCC(CC=4C=CC(F)=CC=4)CC3)C(OC)=NC=2NC=C1C(=O)C(=O)NN1CCCC1 GABFJOKCNVICBF-UHFFFAOYSA-N 0.000 description 2
- CEABUZXXYHKGMV-UHFFFAOYSA-N 2-[5-[4-[(4-fluorophenyl)methyl]piperidine-1-carbonyl]-6-methoxy-1h-pyrrolo[2,3-b]pyridin-3-yl]-2-oxoacetamide Chemical compound COC1=NC=2NC=C(C(=O)C(N)=O)C=2C=C1C(=O)N(CC1)CCC1CC1=CC=C(F)C=C1 CEABUZXXYHKGMV-UHFFFAOYSA-N 0.000 description 2
- IQMHIWGFFHMUGO-UHFFFAOYSA-N 2-[5-[4-[(4-fluorophenyl)methyl]piperidine-1-carbonyl]-6-methoxy-1h-pyrrolo[2,3-b]pyridin-3-yl]-n,n-dimethyl-2-oxoacetamide Chemical compound COC1=NC=2NC=C(C(=O)C(=O)N(C)C)C=2C=C1C(=O)N(CC1)CCC1CC1=CC=C(F)C=C1 IQMHIWGFFHMUGO-UHFFFAOYSA-N 0.000 description 2
- PJKYEJOPDVRTRH-UHFFFAOYSA-N 2-[5-[4-[(4-fluorophenyl)methyl]piperidine-1-carbonyl]-6-methoxy-1h-pyrrolo[2,3-b]pyridin-3-yl]-n-(2-hydroxyethyl)-2-oxoacetamide Chemical compound COC1=NC=2NC=C(C(=O)C(=O)NCCO)C=2C=C1C(=O)N(CC1)CCC1CC1=CC=C(F)C=C1 PJKYEJOPDVRTRH-UHFFFAOYSA-N 0.000 description 2
- YOZHVHDDFYLGBX-UHFFFAOYSA-N 2-[5-[4-[(4-fluorophenyl)methyl]piperidine-1-carbonyl]-6-methoxy-1h-pyrrolo[2,3-b]pyridin-3-yl]-n-methyl-2-oxoacetamide Chemical compound C1=C2C(C(=O)C(=O)NC)=CNC2=NC(OC)=C1C(=O)N(CC1)CCC1CC1=CC=C(F)C=C1 YOZHVHDDFYLGBX-UHFFFAOYSA-N 0.000 description 2
- FSFFQFRSFMNKAL-UHFFFAOYSA-N 2-[6-ethoxy-5-[4-[(4-fluorophenyl)methyl]piperidine-1-carbonyl]-1h-pyrrolo[2,3-b]pyridin-3-yl]-2-oxoacetamide Chemical compound CCOC1=NC=2NC=C(C(=O)C(N)=O)C=2C=C1C(=O)N(CC1)CCC1CC1=CC=C(F)C=C1 FSFFQFRSFMNKAL-UHFFFAOYSA-N 0.000 description 2
- OPRLHZSJIDIFAY-UHFFFAOYSA-N 2-[6-ethoxy-5-[4-[(4-fluorophenyl)methyl]piperidine-1-carbonyl]-1h-pyrrolo[2,3-b]pyridin-3-yl]-n-methyl-2-oxoacetamide Chemical compound CCOC1=NC=2NC=C(C(=O)C(=O)NC)C=2C=C1C(=O)N(CC1)CCC1CC1=CC=C(F)C=C1 OPRLHZSJIDIFAY-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 2
- OFECBEHVWNGOTM-UHFFFAOYSA-N 6-methoxy-1h-pyrrolo[2,3-b]pyridine-5-carboxylic acid Chemical compound C1=C(C(O)=O)C(OC)=NC2=C1C=CN2 OFECBEHVWNGOTM-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- VDXGVQWTTALRET-MQQHOJABSA-N CC1=C(C(=O)N2C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]2C)C=C2C(C(=O)C(=O)N3CCC3)=CNC2=N1.CC1=C(C(=O)N2C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]2C)C=C2C(C(=O)C(=O)N3CCCC3)=CNC2=N1.CC1=C(C(=O)N2C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]2C)C=C2C(C(=O)C(=O)NN3CCCC3)=CNC2=N1.CCNC(=O)C(=O)C1=CNC2=NC(C)=C(C(=O)N3C[C@H](C)N(CC4=CC=C(F)C=C4)C[C@H]3C)C=C12.CON(C)C(=O)C(=O)C1=CNC2=NC(C)=C(C(=O)N3C[C@H](C)N(CC4=CC=C(F)C=C4)C[C@H]3C)C=C12 Chemical compound CC1=C(C(=O)N2C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]2C)C=C2C(C(=O)C(=O)N3CCC3)=CNC2=N1.CC1=C(C(=O)N2C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]2C)C=C2C(C(=O)C(=O)N3CCCC3)=CNC2=N1.CC1=C(C(=O)N2C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]2C)C=C2C(C(=O)C(=O)NN3CCCC3)=CNC2=N1.CCNC(=O)C(=O)C1=CNC2=NC(C)=C(C(=O)N3C[C@H](C)N(CC4=CC=C(F)C=C4)C[C@H]3C)C=C12.CON(C)C(=O)C(=O)C1=CNC2=NC(C)=C(C(=O)N3C[C@H](C)N(CC4=CC=C(F)C=C4)C[C@H]3C)C=C12 VDXGVQWTTALRET-MQQHOJABSA-N 0.000 description 2
- ZOZCBIBDVKFXTI-JKSUJKDBSA-N CCOC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(=O)NC)=CN2 Chemical compound CCOC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(=O)NC)=CN2 ZOZCBIBDVKFXTI-JKSUJKDBSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 206010063094 Cerebral malaria Diseases 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102100023401 Dual specificity mitogen-activated protein kinase kinase 6 Human genes 0.000 description 2
- 206010014824 Endotoxic shock Diseases 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 206010018634 Gouty Arthritis Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 108010061414 Hepatocyte Nuclear Factor 1-beta Proteins 0.000 description 2
- 102100022123 Hepatocyte nuclear factor 1-beta Human genes 0.000 description 2
- 108010084680 Heterogeneous-Nuclear Ribonucleoprotein K Proteins 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108010068306 MAP Kinase Kinase 6 Proteins 0.000 description 2
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 201000010001 Silicosis Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 206010044248 Toxic shock syndrome Diseases 0.000 description 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 208000019664 bone resorption disease Diseases 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000006353 environmental stress Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical group O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 102000057041 human TNF Human genes 0.000 description 2
- 150000002475 indoles Chemical group 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- OATKRFSWBXGFJT-UHFFFAOYSA-N methyl 6-amino-2-methoxypyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(N)N=C1OC OATKRFSWBXGFJT-UHFFFAOYSA-N 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- AYNIAWNIJPJHDR-UHFFFAOYSA-N n-ethyl-2-[5-[4-[(4-fluorophenyl)methyl]piperidine-1-carbonyl]-6-methoxy-1h-pyrrolo[2,3-b]pyridin-3-yl]-2-oxoacetamide Chemical compound C1=C2C(C(=O)C(=O)NCC)=CNC2=NC(OC)=C1C(=O)N(CC1)CCC1CC1=CC=C(F)C=C1 AYNIAWNIJPJHDR-UHFFFAOYSA-N 0.000 description 2
- NCHFDAGPSZDSJB-UHFFFAOYSA-N n-ethyl-2-[5-[4-[(4-fluorophenyl)methyl]piperidine-1-carbonyl]-6-methoxy-1h-pyrrolo[2,3-b]pyridin-3-yl]-n-methyl-2-oxoacetamide Chemical compound C1=C2C(C(=O)C(=O)N(C)CC)=CNC2=NC(OC)=C1C(=O)N(CC1)CCC1CC1=CC=C(F)C=C1 NCHFDAGPSZDSJB-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical group OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000006433 tumor necrosis factor production Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- PQIVPKLJKJFGIV-UHFFFAOYSA-N (2,6-difluoropyridin-3-yl)-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1CC1CCN(C(=O)C=2C(=NC(F)=CC=2)F)CC1 PQIVPKLJKJFGIV-UHFFFAOYSA-N 0.000 description 1
- PUYZIPGROFWHIT-UHFFFAOYSA-N (6-amino-2-fluoropyridin-3-yl)-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]methanone Chemical compound FC1=NC(N)=CC=C1C(=O)N1CCC(CC=2C=CC(F)=CC=2)CC1 PUYZIPGROFWHIT-UHFFFAOYSA-N 0.000 description 1
- LBMLNZIXBPQCNT-UHFFFAOYSA-N (6-amino-2-methoxypyridin-3-yl)-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]methanone Chemical compound COC1=NC(N)=CC=C1C(=O)N1CCC(CC=2C=CC(F)=CC=2)CC1 LBMLNZIXBPQCNT-UHFFFAOYSA-N 0.000 description 1
- SPCQVFJQVCZFMO-UHFFFAOYSA-N (6-amino-5-iodo-2-methoxypyridin-3-yl)-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]methanone Chemical compound COC1=NC(N)=C(I)C=C1C(=O)N1CCC(CC=2C=CC(F)=CC=2)CC1 SPCQVFJQVCZFMO-UHFFFAOYSA-N 0.000 description 1
- GMMAUOYFJYXINN-AOZJVWGDSA-N *.B.C.C.CC1=CC=C(N)N=C1C.CC1=NC(N(CC2=CC=CC=C2)CC2=CC=CC=C2)=CC=C1C(F)(F)F.CC1=NC(N)=CC=C1C(F)(F)F.COC(OC)(OC)C1=CC=C(N)N=C1C.FC(F)(F)C1=CC=C(Cl)N=C1Cl.FC(F)(F)C1=CC=C(N(CC2=CC=CC=C2)CC2=CC=CC=C2)N=C1Cl.[2HH] Chemical compound *.B.C.C.CC1=CC=C(N)N=C1C.CC1=NC(N(CC2=CC=CC=C2)CC2=CC=CC=C2)=CC=C1C(F)(F)F.CC1=NC(N)=CC=C1C(F)(F)F.COC(OC)(OC)C1=CC=C(N)N=C1C.FC(F)(F)C1=CC=C(Cl)N=C1Cl.FC(F)(F)C1=CC=C(N(CC2=CC=CC=C2)CC2=CC=CC=C2)N=C1Cl.[2HH] GMMAUOYFJYXINN-AOZJVWGDSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- PHGMUOJCQCLPBD-UHFFFAOYSA-N 1-(1-bromoethyl)-4-fluorobenzene Chemical compound CC(Br)C1=CC=C(F)C=C1 PHGMUOJCQCLPBD-UHFFFAOYSA-N 0.000 description 1
- PSDSORRYQPTKSV-UHFFFAOYSA-N 1-(4-fluorophenyl)ethanol Chemical compound CC(O)C1=CC=C(F)C=C1 PSDSORRYQPTKSV-UHFFFAOYSA-N 0.000 description 1
- JNFARRUAVZLJII-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperidine;hydrochloride Chemical compound Cl.C1=CC(F)=CC=C1CN1CCCCC1 JNFARRUAVZLJII-UHFFFAOYSA-N 0.000 description 1
- NXSZHFZVVYODGS-UHFFFAOYSA-N 1-[5-[4-[(4-fluorophenyl)methyl]piperidine-1-carbonyl]-6-methoxy-1-(methoxymethyl)pyrrolo[2,3-b]pyridin-3-yl]-2-pyrrolidin-1-ylethane-1,2-dione Chemical compound C12=CC(C(=O)N3CCC(CC=4C=CC(F)=CC=4)CC3)=C(OC)N=C2N(COC)C=C1C(=O)C(=O)N1CCCC1 NXSZHFZVVYODGS-UHFFFAOYSA-N 0.000 description 1
- VQMOYAKVKALDLE-UHFFFAOYSA-N 1-[5-[4-[(4-fluorophenyl)methyl]piperidine-1-carbonyl]-6-methoxy-1-methylpyrrolo[2,3-b]pyridin-3-yl]-2-pyrrolidin-1-ylethane-1,2-dione Chemical compound C1=2C=C(C(=O)N3CCC(CC=4C=CC(F)=CC=4)CC3)C(OC)=NC=2N(C)C=C1C(=O)C(=O)N1CCCC1 VQMOYAKVKALDLE-UHFFFAOYSA-N 0.000 description 1
- XYGUUQVRKQDWSB-UHFFFAOYSA-N 1-[5-[4-[(4-fluorophenyl)methyl]piperidine-1-carbonyl]-6-methoxy-1h-pyrrolo[2,3-b]pyridin-3-yl]-2-(3-hydroxypyrrolidin-1-yl)ethane-1,2-dione Chemical compound C1=2C=C(C(=O)N3CCC(CC=4C=CC(F)=CC=4)CC3)C(OC)=NC=2NC=C1C(=O)C(=O)N1CCC(O)C1 XYGUUQVRKQDWSB-UHFFFAOYSA-N 0.000 description 1
- ZGCHLAJIRWDGFE-UHFFFAOYSA-N 1-aminopropane-1,1-diol Chemical compound CCC(N)(O)O ZGCHLAJIRWDGFE-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- MBTGBRYMJKYYOE-UHFFFAOYSA-N 2,6-difluoropyridine Chemical compound FC1=CC=CC(F)=N1 MBTGBRYMJKYYOE-UHFFFAOYSA-N 0.000 description 1
- ZULDGRNBRXJAPC-GICMACPYSA-N 2-[5-[(2r)-4-[1-(4-fluorophenyl)ethyl]-2-methylpiperazine-1-carbonyl]-6-methoxy-1h-pyrrolo[2,3-b]pyridin-3-yl]-n-methyl-2-oxoacetamide Chemical compound C1=C2C(C(=O)C(=O)NC)=CNC2=NC(OC)=C1C(=O)N([C@@H](C1)C)CCN1C(C)C1=CC=C(F)C=C1 ZULDGRNBRXJAPC-GICMACPYSA-N 0.000 description 1
- FFNVQNRYTPFDDP-UHFFFAOYSA-N 2-cyanopyridine Chemical compound N#CC1=CC=CC=N1 FFNVQNRYTPFDDP-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- TZZLIARCVQOPQS-UHFFFAOYSA-N 6-amino-2-methylpyridine-3-carboxylic acid Chemical compound CC1=NC(N)=CC=C1C(O)=O TZZLIARCVQOPQS-UHFFFAOYSA-N 0.000 description 1
- LWQIPNHJSKATMP-UHFFFAOYSA-N 6-methyl-1h-pyrrolo[2,3-b]pyridine-5-carboxylic acid Chemical compound C1=C(C(O)=O)C(C)=NC2=C1C=CN2 LWQIPNHJSKATMP-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- QLEALCBYQBYMRC-RKKUYXDDSA-N B.C.C.C.CC.CC(=O)NC1=C(C#C[Si](C)(C)C)C=C(C)C(C)=N1.CC1=CC(C#C[Si](C)(C)C)=C(N)N=C1C.CC1=CC(I)=C(N)N=C1C.CC1=CC2=C(N=C1C)NC=C2.CC1=CC=C(N)N=C1C.CC1=NC2=C(C=CN2)C=C1C(=O)N1CCC(C[Ar])CC1.CC1=NC2=C(C=CN2)C=C1C(=O)O.F.[2HH] Chemical compound B.C.C.C.CC.CC(=O)NC1=C(C#C[Si](C)(C)C)C=C(C)C(C)=N1.CC1=CC(C#C[Si](C)(C)C)=C(N)N=C1C.CC1=CC(I)=C(N)N=C1C.CC1=CC2=C(N=C1C)NC=C2.CC1=CC=C(N)N=C1C.CC1=NC2=C(C=CN2)C=C1C(=O)N1CCC(C[Ar])CC1.CC1=NC2=C(C=CN2)C=C1C(=O)O.F.[2HH] QLEALCBYQBYMRC-RKKUYXDDSA-N 0.000 description 1
- MLYRPCUVYMVPCC-MXGYIUITSA-N B.C.CC1=CC=C(Cl)N=C1C.CC1=CC=C(Cl)N=C1Cl.CC1=CC=C(N)N=C1C.COC1=CC=C(CNC2=CC=C(C)C(C)=N2)C=C1.O=C(O)C1=CC=C(Cl)N=C1Cl.[2HH] Chemical compound B.C.CC1=CC=C(Cl)N=C1C.CC1=CC=C(Cl)N=C1Cl.CC1=CC=C(N)N=C1C.COC1=CC=C(CNC2=CC=C(C)C(C)=N2)C=C1.O=C(O)C1=CC=C(Cl)N=C1Cl.[2HH] MLYRPCUVYMVPCC-MXGYIUITSA-N 0.000 description 1
- XHBSOLQMFNVLHP-DJLOMXGRSA-N BrC(C1=CC=CC=C1)C1=CC=CC=C1.CC#N.COC1=C(C(=O)N2C[C@H](C)N(C(C3=CC=CC=C3)C3=CC=CC=C3)C[C@H]2C)C=C2C(C(=O)C(=O)N(C)C)=CNC2=N1.C[C@H]1CN(C(=O)OC(C)(C)C)[C@H](C)CN1.C[C@H]1CN(C(=O)OC(C)(C)C)[C@H](C)CN1C(C1=CC=CC=C1)C1=CC=CC=C1.C[C@H]1CN[C@H](C)CN1C(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound BrC(C1=CC=CC=C1)C1=CC=CC=C1.CC#N.COC1=C(C(=O)N2C[C@H](C)N(C(C3=CC=CC=C3)C3=CC=CC=C3)C[C@H]2C)C=C2C(C(=O)C(=O)N(C)C)=CNC2=N1.C[C@H]1CN(C(=O)OC(C)(C)C)[C@H](C)CN1.C[C@H]1CN(C(=O)OC(C)(C)C)[C@H](C)CN1C(C1=CC=CC=C1)C1=CC=CC=C1.C[C@H]1CN[C@H](C)CN1C(C1=CC=CC=C1)C1=CC=CC=C1 XHBSOLQMFNVLHP-DJLOMXGRSA-N 0.000 description 1
- AUNAHBHNICGEQG-QHVCBYHUSA-N C#C[SiH](C)C.COC1=NC(NC(C)=O)=C(C#C[Si](C)(C)C)C=C1C(=O)N1C[C@H](C)N(CC2=CC=C(F)C=C2)C[C@H]1C.COC1=NC(NC(C)=O)=C(I)C=C1C(=O)N1C[C@H](C)N(CC2=CC=C(F)C=C2)C[C@H]1C Chemical compound C#C[SiH](C)C.COC1=NC(NC(C)=O)=C(C#C[Si](C)(C)C)C=C1C(=O)N1C[C@H](C)N(CC2=CC=C(F)C=C2)C[C@H]1C.COC1=NC(NC(C)=O)=C(I)C=C1C(=O)N1C[C@H](C)N(CC2=CC=C(F)C=C2)C[C@H]1C AUNAHBHNICGEQG-QHVCBYHUSA-N 0.000 description 1
- UYDNVXROAPOGCS-UHFFFAOYSA-N C#C[Si](C)(C)C.COC1=NC(NC(C)=O)=C(C#C[SiH](C)C)C=C1C(=O)N1CCC(CC2=CC=C(F)C=C2)CC1.COC1=NC(NC(C)=O)=C(I)C=C1C(=O)N1CCC(CC2=CC=C(F)C=C2)CC1 Chemical compound C#C[Si](C)(C)C.COC1=NC(NC(C)=O)=C(C#C[SiH](C)C)C=C1C(=O)N1CCC(CC2=CC=C(F)C=C2)CC1.COC1=NC(NC(C)=O)=C(I)C=C1C(=O)N1CCC(CC2=CC=C(F)C=C2)CC1 UYDNVXROAPOGCS-UHFFFAOYSA-N 0.000 description 1
- ZSYOYECAGFHVBM-UHFFFAOYSA-N C.C#C[Si](C)(C)C.COC(=O)C1=C(C)N=C(NC(C)=O)C(C#C[Si](C)(C)C)=C1.COC(=O)C1=C(C)N=C(NC(C)=O)C(I)=C1 Chemical compound C.C#C[Si](C)(C)C.COC(=O)C1=C(C)N=C(NC(C)=O)C(C#C[Si](C)(C)C)=C1.COC(=O)C1=C(C)N=C(NC(C)=O)C(I)=C1 ZSYOYECAGFHVBM-UHFFFAOYSA-N 0.000 description 1
- ILQOSSJJRVJCQS-UHFFFAOYSA-N C.C.COC(=O)C1=C(C)N=C(N)C(I)=C1.COC(=O)C1=C(C)N=C(NC(C)=O)C(I)=C1 Chemical compound C.C.COC(=O)C1=C(C)N=C(N)C(I)=C1.COC(=O)C1=C(C)N=C(NC(C)=O)C(I)=C1 ILQOSSJJRVJCQS-UHFFFAOYSA-N 0.000 description 1
- LUZGGNVUWLXMJQ-UHFFFAOYSA-N C.CC1=C(C(=O)O)C=CC(N)=N1.CO.COC(=O)C1=C(C)N=C(N)C=C1 Chemical compound C.CC1=C(C(=O)O)C=CC(N)=N1.CO.COC(=O)C1=C(C)N=C(N)C=C1 LUZGGNVUWLXMJQ-UHFFFAOYSA-N 0.000 description 1
- PSDWJZUGGGSEGZ-RPVFEGDWSA-N C.COC1=NC(N)=C(I)C=C1C(=O)N1C[C@H](C)N(CC2=CC=C(F)C=C2)C[C@H]1C.COC1=NC(N)=CC=C1C(=O)N1C[C@H](C)N(CC2=CC=C(F)C=C2)C[C@H]1C.II Chemical compound C.COC1=NC(N)=C(I)C=C1C(=O)N1C[C@H](C)N(CC2=CC=C(F)C=C2)C[C@H]1C.COC1=NC(N)=CC=C1C(=O)N1C[C@H](C)N(CC2=CC=C(F)C=C2)C[C@H]1C.II PSDWJZUGGGSEGZ-RPVFEGDWSA-N 0.000 description 1
- BEFBHUCTQCAOMC-UHFFFAOYSA-N C1CCNC1.COC1=NC2=C(C=C1C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)C(C(=O)C(=O)N1CCCC1)=CN2.COC1=NC2=C(C=CN2)C=C1C(=O)N1CCC(CC2=CC=C(F)C=C2)CC1.ClCCl Chemical compound C1CCNC1.COC1=NC2=C(C=C1C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)C(C(=O)C(=O)N1CCCC1)=CN2.COC1=NC2=C(C=CN2)C=C1C(=O)N1CCC(CC2=CC=C(F)C=C2)CC1.ClCCl BEFBHUCTQCAOMC-UHFFFAOYSA-N 0.000 description 1
- DNUYJTPKHZUOMI-UHFFFAOYSA-N C1CCNC1.COC1=NC2=C(C=C1C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)C(C(=O)C(=O)N1CCCC1)=CN2C.COC1=NC2=C(C=CN2C)C=C1C(=O)N1CCC(CC2=CC=C(F)C=C2)CC1.ClCCl Chemical compound C1CCNC1.COC1=NC2=C(C=C1C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)C(C(=O)C(=O)N1CCCC1)=CN2C.COC1=NC2=C(C=CN2C)C=C1C(=O)N1CCC(CC2=CC=C(F)C=C2)CC1.ClCCl DNUYJTPKHZUOMI-UHFFFAOYSA-N 0.000 description 1
- NAFHZVGZOKWJEA-JJUUOPLKSA-N C1CCNC1.COC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(=O)N1CCCC1)=CN2.COC1=NC2=C(C=CN2)C=C1C(=O)N1C[C@H](C)N(CC2=CC=C(F)C=C2)C[C@H]1C.ClCCl Chemical compound C1CCNC1.COC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(=O)N1CCCC1)=CN2.COC1=NC2=C(C=CN2)C=C1C(=O)N1C[C@H](C)N(CC2=CC=C(F)C=C2)C[C@H]1C.ClCCl NAFHZVGZOKWJEA-JJUUOPLKSA-N 0.000 description 1
- PJSNPTXNUFOPRD-UHFFFAOYSA-N C1CCNC1.COCN1C=C(C(=O)C(=O)N2CCCC2)C2=C1N=C(OC)C(C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)=C2.COCN1C=CC2=C1N=C(OC)C(C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)=C2.ClCCl Chemical compound C1CCNC1.COCN1C=C(C(=O)C(=O)N2CCCC2)C2=C1N=C(OC)C(C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)=C2.COCN1C=CC2=C1N=C(OC)C(C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)=C2.ClCCl PJSNPTXNUFOPRD-UHFFFAOYSA-N 0.000 description 1
- OMDLTIAFMVEYCB-UHFFFAOYSA-N C1CCOC1.COC1=C(C(=O)N2CCC(CC3=CC=C(F)C=C3)CC2)C=C2C(C(=O)C(=O)N3CCCC3)=CNC2=N1.FC1=CC=CC(F)=N1.O=C(O)C1=CC=C(F)N=C1F Chemical compound C1CCOC1.COC1=C(C(=O)N2CCC(CC3=CC=C(F)C=C3)CC2)C=C2C(C(=O)C(=O)N3CCCC3)=CNC2=N1.FC1=CC=CC(F)=N1.O=C(O)C1=CC=C(F)N=C1F OMDLTIAFMVEYCB-UHFFFAOYSA-N 0.000 description 1
- SFODKSXQUIXORI-UHFFFAOYSA-N C1CCOC1.COC1=NC(NC(C)=O)=C(C#C[Si](C)(C)C)C=C1C(=O)N1CCC(CC2=CC=C(F)C=C2)CC1.COC1=NC2=C(C=CN2)C=C1C(=O)N1CCC(CC2=CC=C(F)C=C2)CC1 Chemical compound C1CCOC1.COC1=NC(NC(C)=O)=C(C#C[Si](C)(C)C)C=C1C(=O)N1CCC(CC2=CC=C(F)C=C2)CC1.COC1=NC2=C(C=CN2)C=C1C(=O)N1CCC(CC2=CC=C(F)C=C2)CC1 SFODKSXQUIXORI-UHFFFAOYSA-N 0.000 description 1
- MQOQILBDUWSAOQ-UZKGMRHWSA-N C1CCOC1.COC1=NC(NC(C)=O)=C(C#C[Si](C)(C)C)C=C1C(=O)N1C[C@H](C)N(CC2=CC=C(F)C=C2)C[C@H]1C.COC1=NC2=C(C=CN2)C=C1C(=O)N1C[C@H](C)N(CC2=CC=C(F)C=C2)C[C@H]1C Chemical compound C1CCOC1.COC1=NC(NC(C)=O)=C(C#C[Si](C)(C)C)C=C1C(=O)N1C[C@H](C)N(CC2=CC=C(F)C=C2)C[C@H]1C.COC1=NC2=C(C=CN2)C=C1C(=O)N1C[C@H](C)N(CC2=CC=C(F)C=C2)C[C@H]1C MQOQILBDUWSAOQ-UZKGMRHWSA-N 0.000 description 1
- VDHROIVORDNNCM-UHFFFAOYSA-N CC(=O)Cl.COC1=NC(N)=C(I)C=C1C(=O)N1CCC(CC2=CC=C(F)C=C2)CC1.COC1=NC(NC(C)=O)=C(I)C=C1C(=O)N1CCC(CC2=CC=C(F)C=C2)CC1 Chemical compound CC(=O)Cl.COC1=NC(N)=C(I)C=C1C(=O)N1CCC(CC2=CC=C(F)C=C2)CC1.COC1=NC(NC(C)=O)=C(I)C=C1C(=O)N1CCC(CC2=CC=C(F)C=C2)CC1 VDHROIVORDNNCM-UHFFFAOYSA-N 0.000 description 1
- FVYLBUQXDALCSE-FBDYLXADSA-N CC(=O)Cl.COC1=NC(N)=C(I)C=C1C(=O)N1C[C@H](C)N(CC2=CC=C(F)C=C2)C[C@H]1C.COC1=NC(NC(C)=O)=C(I)C=C1C(=O)N1C[C@H](C)N(CC2=CC=C(F)C=C2)C[C@H]1C Chemical compound CC(=O)Cl.COC1=NC(N)=C(I)C=C1C(=O)N1C[C@H](C)N(CC2=CC=C(F)C=C2)C[C@H]1C.COC1=NC(NC(C)=O)=C(I)C=C1C(=O)N1C[C@H](C)N(CC2=CC=C(F)C=C2)C[C@H]1C FVYLBUQXDALCSE-FBDYLXADSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N CC(=O)O Chemical compound CC(=O)O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- GVELYHMTCNYKDW-IMDUSZBCSA-N CC(Br)C1=CC=C(F)C=C1.CC(C1=CC=C(F)C=C1)N1CCN[C@H](C)C1.C[C@@H]1CNCCN1 Chemical compound CC(Br)C1=CC=C(F)C=C1.CC(C1=CC=C(F)C=C1)N1CCN[C@H](C)C1.C[C@@H]1CNCCN1 GVELYHMTCNYKDW-IMDUSZBCSA-N 0.000 description 1
- VKRQDSTWFWNQCF-FXUMYAARSA-N CC(Br)C1=CC=C(F)C=C1.CC(O)C1=CC=C(F)C=C1.CNC(=O)C(=O)C1=CNC2=NC(OC)=C(C(=O)N3CCN([C@H](C)C4=CC=C(F)C=C4)C[C@H]3C)C=C12 Chemical compound CC(Br)C1=CC=C(F)C=C1.CC(O)C1=CC=C(F)C=C1.CNC(=O)C(=O)C1=CNC2=NC(OC)=C(C(=O)N3CCN([C@H](C)C4=CC=C(F)C=C4)C[C@H]3C)C=C12 VKRQDSTWFWNQCF-FXUMYAARSA-N 0.000 description 1
- FUOZJYASZOSONT-UHFFFAOYSA-N CC(C)C1=NC=CN1 Chemical compound CC(C)C1=NC=CN1 FUOZJYASZOSONT-UHFFFAOYSA-N 0.000 description 1
- RFFXUEDBNNOGDO-UHFFFAOYSA-N CC(C)C1=NN=NN1 Chemical compound CC(C)C1=NN=NN1 RFFXUEDBNNOGDO-UHFFFAOYSA-N 0.000 description 1
- XSJJCKWFLFUIKO-UHFFFAOYSA-N CC.CC1CCN(C)CC1 Chemical compound CC.CC1CCN(C)CC1 XSJJCKWFLFUIKO-UHFFFAOYSA-N 0.000 description 1
- UMCRWYXFYBRNQT-SLAHTUFOSA-N CC1=C(Br)C=CC(N)=N1.CC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(=O)N(C)C)=CN2.[C-]#[N+]C1=C(C)N=C(N)C=C1 Chemical compound CC1=C(Br)C=CC(N)=N1.CC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(=O)N(C)C)=CN2.[C-]#[N+]C1=C(C)N=C(N)C=C1 UMCRWYXFYBRNQT-SLAHTUFOSA-N 0.000 description 1
- SUTZVWKTKOFSSE-UHFFFAOYSA-M CC1=C(C(=O)O)C=C2C=CNC2=N1.COC(=O)C1=C(C)N=C2NC=CC2=C1.O=COO[K].[KH] Chemical compound CC1=C(C(=O)O)C=C2C=CNC2=N1.COC(=O)C1=C(C)N=C2NC=CC2=C1.O=COO[K].[KH] SUTZVWKTKOFSSE-UHFFFAOYSA-M 0.000 description 1
- DGDUGAASNSLHDG-UHFFFAOYSA-L CC1=C(C(=O)O)C=CC(N)=N1.O=C=O.O[Ba]O.[C-]#[N+]C1=C(C)N=C(N)C=C1 Chemical compound CC1=C(C(=O)O)C=CC(N)=N1.O=C=O.O[Ba]O.[C-]#[N+]C1=C(C)N=C(N)C=C1 DGDUGAASNSLHDG-UHFFFAOYSA-L 0.000 description 1
- VSNWPYLQRCUJJC-UHFFFAOYSA-N CC1=C(C(C)C)NN=N1 Chemical compound CC1=C(C(C)C)NN=N1 VSNWPYLQRCUJJC-UHFFFAOYSA-N 0.000 description 1
- IWHZSSBGSUADAF-QVJVTXPLSA-N CC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(=O)N(C)C)=CN2.CC1=NC2=C(C=CN2)C=C1C(=O)N1C[C@H](C)N(CC2=CC=C(F)C=C2)C[C@H]1C.ClCCl Chemical compound CC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(=O)N(C)C)=CN2.CC1=NC2=C(C=CN2)C=C1C(=O)N1C[C@H](C)N(CC2=CC=C(F)C=C2)C[C@H]1C.ClCCl IWHZSSBGSUADAF-QVJVTXPLSA-N 0.000 description 1
- SFQCBBDVRGRIBO-NJSNAPAPSA-N CC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(=O)N1CC[C@@H](O)C1)=CN2.CC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(=O)NCCO)=CN2.CC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(N)=O)=CN2.CCN(C)C(=O)C(=O)C1=CNC2=NC(C)=C(C(=O)N3C[C@H](C)N(CC4=CC=C(F)C=C4)C[C@H]3C)C=C12.CNC(=O)C(=O)C1=CNC2=C1C=C(C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C)=N2 Chemical compound CC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(=O)N1CC[C@@H](O)C1)=CN2.CC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(=O)NCCO)=CN2.CC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(N)=O)=CN2.CCN(C)C(=O)C(=O)C1=CNC2=NC(C)=C(C(=O)N3C[C@H](C)N(CC4=CC=C(F)C=C4)C[C@H]3C)C=C12.CNC(=O)C(=O)C1=CNC2=C1C=C(C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C)=N2 SFQCBBDVRGRIBO-NJSNAPAPSA-N 0.000 description 1
- DBTSGRGITXLMRI-JQOOXTBLSA-N CC1=NC2=C(C=CN2)C=C1C(=O)N1C[C@H](C)N(CC2=CC=C(F)C=C2)C[C@H]1C.CC1=NC2=C(C=CN2)C=C1C(=O)O.C[C@H]1CN[C@H](C)CN1CC1=CC=C(F)C=C1 Chemical compound CC1=NC2=C(C=CN2)C=C1C(=O)N1C[C@H](C)N(CC2=CC=C(F)C=C2)C[C@H]1C.CC1=NC2=C(C=CN2)C=C1C(=O)O.C[C@H]1CN[C@H](C)CN1CC1=CC=C(F)C=C1 DBTSGRGITXLMRI-JQOOXTBLSA-N 0.000 description 1
- LDTVMYHINZSUPV-UHFFFAOYSA-N CC1=NNC(C(C)C)=N1 Chemical compound CC1=NNC(C(C)C)=N1 LDTVMYHINZSUPV-UHFFFAOYSA-N 0.000 description 1
- MTZOPKQKFNYXSN-YAVGSXOASA-N CCN(C)C(=O)C(=O)C1=CN(C)C2=NC(OC)=C(C(=O)N3CCC(CC4=CC=C(F)C=C4)CC3)C=C12.CNC(=O)C(=O)C1=CN(C)C2=C1C=C(C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)C(OC)=N2.COC1=NC2=C(C=C1C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)C(C(=O)C(=O)N(C)C)=CN2C.COC1=NC2=C(C=C1C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)C(C(=O)C(=O)N1CC[C@H](O)C1)=CN2C.COC1=NC2=C(C=C1C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)C(C(=O)C(N)=O)=CN2C Chemical compound CCN(C)C(=O)C(=O)C1=CN(C)C2=NC(OC)=C(C(=O)N3CCC(CC4=CC=C(F)C=C4)CC3)C=C12.CNC(=O)C(=O)C1=CN(C)C2=C1C=C(C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)C(OC)=N2.COC1=NC2=C(C=C1C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)C(C(=O)C(=O)N(C)C)=CN2C.COC1=NC2=C(C=C1C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)C(C(=O)C(=O)N1CC[C@H](O)C1)=CN2C.COC1=NC2=C(C=C1C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)C(C(=O)C(N)=O)=CN2C MTZOPKQKFNYXSN-YAVGSXOASA-N 0.000 description 1
- LHWRACOGRICIMR-VHUXTPGUSA-N CCN(C)C(=O)C(=O)C1=CN(C)C2=NC(OC)=C(C(=O)N3C[C@H](C)N(CC4=CC=C(F)C=C4)C[C@H]3C)C=C12.CNC(=O)C(=O)C1=CN(C)C2=C1C=C(C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(OC)=N2.COC1=C(C(=O)N2C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]2C)C=C2C(C(=O)C(=O)N3CCCC3)=CN(C)C2=N1.COC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(=O)N(C)C)=CN2C.COC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(=O)N1CC[C@H](O)C1)=CN2C.COC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(N)=O)=CN2C Chemical compound CCN(C)C(=O)C(=O)C1=CN(C)C2=NC(OC)=C(C(=O)N3C[C@H](C)N(CC4=CC=C(F)C=C4)C[C@H]3C)C=C12.CNC(=O)C(=O)C1=CN(C)C2=C1C=C(C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(OC)=N2.COC1=C(C(=O)N2C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]2C)C=C2C(C(=O)C(=O)N3CCCC3)=CN(C)C2=N1.COC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(=O)N(C)C)=CN2C.COC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(=O)N1CC[C@H](O)C1)=CN2C.COC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(N)=O)=CN2C LHWRACOGRICIMR-VHUXTPGUSA-N 0.000 description 1
- SGLFHVLGPPUBSI-WUDICJIASA-N CCN(C)C(=O)C(=O)C1=CN(COC)C2=NC(OC)=C(C(=O)N3CCC(CC4=CC=C(F)C=C4)CC3)C=C12.CNC(=O)C(=O)C1=CN(COC)C2=C1C=C(C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)C(OC)=N2.COCN1C=C(C(=O)C(=O)N(C)C)C2=C1N=C(OC)C(C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)=C2.COCN1C=C(C(=O)C(=O)N2CC[C@H](O)C2)C2=C1N=C(OC)C(C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)=C2.COCN1C=C(C(=O)C(N)=O)C2=C1N=C(OC)C(C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)=C2 Chemical compound CCN(C)C(=O)C(=O)C1=CN(COC)C2=NC(OC)=C(C(=O)N3CCC(CC4=CC=C(F)C=C4)CC3)C=C12.CNC(=O)C(=O)C1=CN(COC)C2=C1C=C(C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)C(OC)=N2.COCN1C=C(C(=O)C(=O)N(C)C)C2=C1N=C(OC)C(C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)=C2.COCN1C=C(C(=O)C(=O)N2CC[C@H](O)C2)C2=C1N=C(OC)C(C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)=C2.COCN1C=C(C(=O)C(N)=O)C2=C1N=C(OC)C(C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)=C2 SGLFHVLGPPUBSI-WUDICJIASA-N 0.000 description 1
- CTGZPMXVJIPXQD-QLHTUIDYSA-N CCN(C)C(=O)C(=O)C1=CN(COC)C2=NC(OC)=C(C(=O)N3C[C@H](C)N(CC4=CC=C(F)C=C4)C[C@H]3C)C=C12.CNC(=O)C(=O)C1=CN(COC)C2=C1C=C(C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(OC)=N2.COCN1C=C(C(=O)C(=O)N(C)C)C2=C1N=C(OC)C(C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)=C2.COCN1C=C(C(=O)C(=O)N2CC[C@H](O)C2)C2=C1N=C(OC)C(C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)=C2.COCN1C=C(C(=O)C(N)=O)C2=C1N=C(OC)C(C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)=C2 Chemical compound CCN(C)C(=O)C(=O)C1=CN(COC)C2=NC(OC)=C(C(=O)N3C[C@H](C)N(CC4=CC=C(F)C=C4)C[C@H]3C)C=C12.CNC(=O)C(=O)C1=CN(COC)C2=C1C=C(C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(OC)=N2.COCN1C=C(C(=O)C(=O)N(C)C)C2=C1N=C(OC)C(C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)=C2.COCN1C=C(C(=O)C(=O)N2CC[C@H](O)C2)C2=C1N=C(OC)C(C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)=C2.COCN1C=C(C(=O)C(N)=O)C2=C1N=C(OC)C(C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)=C2 CTGZPMXVJIPXQD-QLHTUIDYSA-N 0.000 description 1
- GYMSYUAZWDHMLJ-QMKYUQMLSA-N CCN(C)C(=O)C(=O)C1=CN(N)C2=NC(OC)=C(C(=O)N3CCC(CC4=CC=C(F)C=C4)CC3)C=C12.CNC(=O)C(=O)C1=CN(N)C2=C1C=C(C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)C(OC)=N2.COC1=NC2=C(C=C1C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)C(C(=O)C(=O)N(C)C)=CN2N.COC1=NC2=C(C=C1C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)C(C(=O)C(=O)N1CC[C@H](O)C1)=CN2N.COC1=NC2=C(C=C1C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)C(C(=O)C(N)=O)=CN2N Chemical compound CCN(C)C(=O)C(=O)C1=CN(N)C2=NC(OC)=C(C(=O)N3CCC(CC4=CC=C(F)C=C4)CC3)C=C12.CNC(=O)C(=O)C1=CN(N)C2=C1C=C(C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)C(OC)=N2.COC1=NC2=C(C=C1C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)C(C(=O)C(=O)N(C)C)=CN2N.COC1=NC2=C(C=C1C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)C(C(=O)C(=O)N1CC[C@H](O)C1)=CN2N.COC1=NC2=C(C=C1C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)C(C(=O)C(N)=O)=CN2N GYMSYUAZWDHMLJ-QMKYUQMLSA-N 0.000 description 1
- GVRIXHBGLYYSOQ-BWFRVSJHSA-N CCN(C)C(=O)C(=O)C1=CN(N)C2=NC(OC)=C(C(=O)N3C[C@H](C)N(CC4=CC=C(F)C=C4)C[C@H]3C)C=C12.CNC(=O)C(=O)C1=CN(N)C2=C1C=C(C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(OC)=N2.COC1=C(C(=O)N2C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]2C)C=C2C(C(=O)C(=O)N3CCCC3)=CN(N)C2=N1.COC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(=O)N(C)C)=CN2N.COC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(=O)N1CC[C@H](O)C1)=CN2N.COC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(N)=O)=CN2N Chemical compound CCN(C)C(=O)C(=O)C1=CN(N)C2=NC(OC)=C(C(=O)N3C[C@H](C)N(CC4=CC=C(F)C=C4)C[C@H]3C)C=C12.CNC(=O)C(=O)C1=CN(N)C2=C1C=C(C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(OC)=N2.COC1=C(C(=O)N2C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]2C)C=C2C(C(=O)C(=O)N3CCCC3)=CN(N)C2=N1.COC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(=O)N(C)C)=CN2N.COC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(=O)N1CC[C@H](O)C1)=CN2N.COC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(N)=O)=CN2N GVRIXHBGLYYSOQ-BWFRVSJHSA-N 0.000 description 1
- CTRTZAOYECJSGA-KMEFTBJCSA-N CCN(C)C(=O)C(=O)C1=CN(N)C2=NC(OC)=C(C(=O)N3C[C@H](C)N(CC4=CC=C(F)C=C4)C[C@H]3C)C=C12.CNC(=O)C(=O)C1=CNC2=NC(OC)=C(C(=O)N3CCN([C@H](C)C4=CC=C(F)C=C4)C[C@H]3C)C=C12.COC1=C(C(=O)N2C[C@H](C)N(C(C3=CC=CC=C3)C3=CC=CC=C3)C[C@H]2C)C=C2C(C(=O)C(=O)N(C)C)=CNC2=N1.COC1=C(C(=O)N2C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]2C)C=C2C(C(=O)C(=O)N3CCCC3)=CN(N)C2=N1.COC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(=O)N1CC[C@H](O)C1)=CN2N Chemical compound CCN(C)C(=O)C(=O)C1=CN(N)C2=NC(OC)=C(C(=O)N3C[C@H](C)N(CC4=CC=C(F)C=C4)C[C@H]3C)C=C12.CNC(=O)C(=O)C1=CNC2=NC(OC)=C(C(=O)N3CCN([C@H](C)C4=CC=C(F)C=C4)C[C@H]3C)C=C12.COC1=C(C(=O)N2C[C@H](C)N(C(C3=CC=CC=C3)C3=CC=CC=C3)C[C@H]2C)C=C2C(C(=O)C(=O)N(C)C)=CNC2=N1.COC1=C(C(=O)N2C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]2C)C=C2C(C(=O)C(=O)N3CCCC3)=CN(N)C2=N1.COC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(=O)N1CC[C@H](O)C1)=CN2N CTRTZAOYECJSGA-KMEFTBJCSA-N 0.000 description 1
- KPDXQKJCHSIKPD-DLBZAZTESA-N CCN(C)C(=O)C(=O)C1=CNC2=C1C=C(C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(OC)=N2 Chemical compound CCN(C)C(=O)C(=O)C1=CNC2=C1C=C(C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(OC)=N2 KPDXQKJCHSIKPD-DLBZAZTESA-N 0.000 description 1
- GBLKUHNTRZMAGC-LSDHHAIUSA-N CCOC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(N)=O)=CN2 Chemical compound CCOC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(N)=O)=CN2 GBLKUHNTRZMAGC-LSDHHAIUSA-N 0.000 description 1
- IPFKUUXPDOZSJF-NAJMUYKWSA-N CNC(=O)C(=O)C1=CNC2=C1C=C(C(=O)N1CCN([C@H](C)C3=CC=C(F)C=C3)C[C@H]1C)C(OC)=N2.COC1=NC2=C(C=CN2)C=C1C(=O)N1CCN([C@H](C)C2=CC=C(F)C=C2)C[C@H]1C Chemical compound CNC(=O)C(=O)C1=CNC2=C1C=C(C(=O)N1CCN([C@H](C)C3=CC=C(F)C=C3)C[C@H]1C)C(OC)=N2.COC1=NC2=C(C=CN2)C=C1C(=O)N1CCN([C@H](C)C2=CC=C(F)C=C2)C[C@H]1C IPFKUUXPDOZSJF-NAJMUYKWSA-N 0.000 description 1
- OFVQPCYMXCDCBB-VQTJNVASSA-N CNC(=O)C(=O)C1=CNC2=C1C=C(C(=O)N1C[C@H](C)N(C(C3=CC=CC=C3)C3=CC=CC=C3)C[C@H]1C)C(OC)=N2 Chemical compound CNC(=O)C(=O)C1=CNC2=C1C=C(C(=O)N1C[C@H](C)N(C(C3=CC=CC=C3)C3=CC=CC=C3)C[C@H]1C)C(OC)=N2 OFVQPCYMXCDCBB-VQTJNVASSA-N 0.000 description 1
- QXRWDTKRRJSNHT-LSDHHAIUSA-N CNC(=O)C(=O)C1=CNC2=C1C=C(C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(OC)=N2 Chemical compound CNC(=O)C(=O)C1=CNC2=C1C=C(C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(OC)=N2 QXRWDTKRRJSNHT-LSDHHAIUSA-N 0.000 description 1
- ZRVWATADIMAXLO-AWEJMWJKSA-N CNC.COC1=C(C(=O)N2C[C@H](C)N(C(C3=CC=CC=C3)C3=CC=CC=C3)C[C@H]2C)C=C2C=CNC2=N1.COC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(C(C3=CC=CC=C3)C3=CC=CC=C3)C[C@H]1C)C(C(=O)C(=O)N(C)C)=CN2.ClCCl Chemical compound CNC.COC1=C(C(=O)N2C[C@H](C)N(C(C3=CC=CC=C3)C3=CC=CC=C3)C[C@H]2C)C=C2C=CNC2=N1.COC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(C(C3=CC=CC=C3)C3=CC=CC=C3)C[C@H]1C)C(C(=O)C(=O)N(C)C)=CN2.ClCCl ZRVWATADIMAXLO-AWEJMWJKSA-N 0.000 description 1
- MOQUIEFZGIVXIF-UHFFFAOYSA-N CO.COC1=NC(N)=CC=C1C(=O)N1CCC(CC2=CC=C(F)C=C2)CC1.C[K].NC1=CC=C(C(=O)N2CCC(CC3=CC=C(F)C=C3)CC2)C(F)=N1 Chemical compound CO.COC1=NC(N)=CC=C1C(=O)N1CCC(CC2=CC=C(F)C=C2)CC1.C[K].NC1=CC=C(C(=O)N2CCC(CC3=CC=C(F)C=C3)CC2)C(F)=N1 MOQUIEFZGIVXIF-UHFFFAOYSA-N 0.000 description 1
- UGDJTKWEFVFOBT-IBZCXHEQSA-N CO.COC1=NC(N)=CC=C1C(=O)N1C[C@H](C)N(CC2=CC=C(F)C=C2)C[C@H]1C.C[C@H]1CN(C(=O)C2=CC=C(N)N=C2F)[C@H](C)CN1CC1=CC=C(F)C=C1.C[K] Chemical compound CO.COC1=NC(N)=CC=C1C(=O)N1C[C@H](C)N(CC2=CC=C(F)C=C2)C[C@H]1C.C[C@H]1CN(C(=O)C2=CC=C(N)N=C2F)[C@H](C)CN1CC1=CC=C(F)C=C1.C[K] UGDJTKWEFVFOBT-IBZCXHEQSA-N 0.000 description 1
- RPVDRHOFEJMLKA-FFOUBCEFSA-N CO.C[C@H]1CN(C(=O)C2=CC=C(F)N=C2F)[C@H](C)CN1CC1=CC=C(F)C=C1.C[C@H]1CN(C(=O)C2=CC=C(N)N=C2F)[C@H](C)CN1CC1=CC=C(F)C=C1.N Chemical compound CO.C[C@H]1CN(C(=O)C2=CC=C(F)N=C2F)[C@H](C)CN1CC1=CC=C(F)C=C1.C[C@H]1CN(C(=O)C2=CC=C(N)N=C2F)[C@H](C)CN1CC1=CC=C(F)C=C1.N RPVDRHOFEJMLKA-FFOUBCEFSA-N 0.000 description 1
- HIUIZHUTEWJDOF-UHFFFAOYSA-N CO.N.NC1=CC=C(C(=O)N2CCC(CC3=CC=C(F)C=C3)CC2)C(F)=N1.O=C(C1=CC=C(F)N=C1F)N1CCC(CC2=CC=C(F)C=C2)CC1 Chemical compound CO.N.NC1=CC=C(C(=O)N2CCC(CC3=CC=C(F)C=C3)CC2)C(F)=N1.O=C(C1=CC=C(F)N=C1F)N1CCC(CC2=CC=C(F)C=C2)CC1 HIUIZHUTEWJDOF-UHFFFAOYSA-N 0.000 description 1
- FXRQHCVGRMPCOP-UHFFFAOYSA-N COC(=O)C1=C(C)N=C(NC(C)=O)C(C#C[Si](C)(C)C)=C1.COC(=O)C1=C(C)N=C2NC=CC2=C1 Chemical compound COC(=O)C1=C(C)N=C(NC(C)=O)C(C#C[Si](C)(C)C)=C1.COC(=O)C1=C(C)N=C2NC=CC2=C1 FXRQHCVGRMPCOP-UHFFFAOYSA-N 0.000 description 1
- MAVLDKTWEWMQMD-UHFFFAOYSA-N COC(=O)C1=CC(C#C[Si](C)(C)C)=C(N)N=C1OC.COC(=O)C1=CC(C#C[Si](C)(C)C)=C(NC(C)=O)N=C1OC Chemical compound COC(=O)C1=CC(C#C[Si](C)(C)C)=C(N)N=C1OC.COC(=O)C1=CC(C#C[Si](C)(C)C)=C(NC(C)=O)N=C1OC MAVLDKTWEWMQMD-UHFFFAOYSA-N 0.000 description 1
- MVAMLKVPXGFWIM-UHFFFAOYSA-N COC(=O)C1=CC(C#C[Si](C)(C)C)=C(N)N=C1OC.COC(=O)C1=CC(I)=C(N)N=C1OC Chemical compound COC(=O)C1=CC(C#C[Si](C)(C)C)=C(N)N=C1OC.COC(=O)C1=CC(I)=C(N)N=C1OC MVAMLKVPXGFWIM-UHFFFAOYSA-N 0.000 description 1
- DSYYQTHCKBHKSF-UHFFFAOYSA-N COC(=O)C1=CC(C#C[Si](C)(C)C)=C(NC(C)=O)N=C1OC.COC(=O)C1=CC2=C(N=C1OC)NC=C2 Chemical compound COC(=O)C1=CC(C#C[Si](C)(C)C)=C(NC(C)=O)N=C1OC.COC(=O)C1=CC2=C(N=C1OC)NC=C2 DSYYQTHCKBHKSF-UHFFFAOYSA-N 0.000 description 1
- UGFJTKBCHCBVPD-UHFFFAOYSA-N COC(=O)C1=CC(I)=C(N)N=C1OC.COC(=O)C1=CC=C(N)N=C1OC.II.O=I(=O)(=O)O[Na] Chemical compound COC(=O)C1=CC(I)=C(N)N=C1OC.COC(=O)C1=CC=C(N)N=C1OC.II.O=I(=O)(=O)O[Na] UGFJTKBCHCBVPD-UHFFFAOYSA-N 0.000 description 1
- DJAKVZURCNYDEF-UHFFFAOYSA-M COC(=O)C1=CC2=C(N=C1OC)NC=C2.COC1=NC2=C(C=CN2)C=C1C(=O)O.O[Na] Chemical compound COC(=O)C1=CC2=C(N=C1OC)NC=C2.COC1=NC2=C(C=CN2)C=C1C(=O)O.O[Na] DJAKVZURCNYDEF-UHFFFAOYSA-M 0.000 description 1
- ZFCVEGGOLUVJTM-UHFFFAOYSA-N COC(=O)C1=CC=C(Cl)N=C1Cl.COC(=O)C1=CC=C(Cl)N=C1OC Chemical compound COC(=O)C1=CC=C(Cl)N=C1Cl.COC(=O)C1=CC=C(Cl)N=C1OC ZFCVEGGOLUVJTM-UHFFFAOYSA-N 0.000 description 1
- FATQEDHLQJITQF-UHFFFAOYSA-N COC(=O)C1=CC=C(Cl)N=C1Cl.O=C(O)C1=CC=C(Cl)N=C1Cl Chemical compound COC(=O)C1=CC=C(Cl)N=C1Cl.O=C(O)C1=CC=C(Cl)N=C1Cl FATQEDHLQJITQF-UHFFFAOYSA-N 0.000 description 1
- ROSNOZSKIVTHGW-UHFFFAOYSA-N COC(=O)C1=CC=C(Cl)N=C1OC.COC(=O)C1=CC=C(NCC2=CC=C(OC)C=C2)N=C1OC.COC1=CC=C(CN)C=C1 Chemical compound COC(=O)C1=CC=C(Cl)N=C1OC.COC(=O)C1=CC=C(NCC2=CC=C(OC)C=C2)N=C1OC.COC1=CC=C(CN)C=C1 ROSNOZSKIVTHGW-UHFFFAOYSA-N 0.000 description 1
- YYUDSPGXCGBXNF-UHFFFAOYSA-N COC(=O)C1=CC=C(N)N=C1OC.COC(=O)C1=CC=C(NCC2=CC=C(OC)C=C2)N=C1OC Chemical compound COC(=O)C1=CC=C(N)N=C1OC.COC(=O)C1=CC=C(NCC2=CC=C(OC)C=C2)N=C1OC YYUDSPGXCGBXNF-UHFFFAOYSA-N 0.000 description 1
- KRVMSEJOWXSMNQ-UHFFFAOYSA-N COC1=C(C(=O)N2CCC(CC3=CC=C(F)C=C3)CC2)C=C2C(C(=O)C(=O)N3CCCC3)=CN(N)C2=N1.COC1=C(C(=O)N2CCC(CC3=CC=C(F)C=C3)CC2)C=C2C(C(=O)C(=O)N3CCCC3)=CNC2=N1.COC1=NC2=C(C=C1C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)C(C(=O)C(=O)N1CCCC1)=CN2N Chemical compound COC1=C(C(=O)N2CCC(CC3=CC=C(F)C=C3)CC2)C=C2C(C(=O)C(=O)N3CCCC3)=CN(N)C2=N1.COC1=C(C(=O)N2CCC(CC3=CC=C(F)C=C3)CC2)C=C2C(C(=O)C(=O)N3CCCC3)=CNC2=N1.COC1=NC2=C(C=C1C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)C(C(=O)C(=O)N1CCCC1)=CN2N KRVMSEJOWXSMNQ-UHFFFAOYSA-N 0.000 description 1
- XYGUUQVRKQDWSB-LJQANCHMSA-N COC1=C(C(=O)N2CCC(CC3=CC=C(F)C=C3)CC2)C=C2C(C(=O)C(=O)N3CC[C@@H](O)C3)=CNC2=N1 Chemical compound COC1=C(C(=O)N2CCC(CC3=CC=C(F)C=C3)CC2)C=C2C(C(=O)C(=O)N3CC[C@@H](O)C3)=CNC2=N1 XYGUUQVRKQDWSB-LJQANCHMSA-N 0.000 description 1
- YTOUZXVIRAOISI-XZOQPEGZSA-N COC1=C(C(=O)N2C[C@H](C)N(C(C3=CC=CC=C3)C3=CC=CC=C3)C[C@H]2C)C=C2C(C(=O)C(=O)N3CCCC3)=CNC2=N1 Chemical compound COC1=C(C(=O)N2C[C@H](C)N(C(C3=CC=CC=C3)C3=CC=CC=C3)C[C@H]2C)C=C2C(C(=O)C(=O)N3CCCC3)=CNC2=N1 YTOUZXVIRAOISI-XZOQPEGZSA-N 0.000 description 1
- UFMJZYGDSPRTCS-DWBAWAQESA-N COC1=C(C(=O)N2C[C@H](C)N(C(C3=CC=CC=C3)C3=CC=CC=C3)C[C@H]2C)C=C2C=CNC2=N1.COC1=NC2=C(C=CN2)C=C1C(=O)O.C[C@H]1CN[C@H](C)CN1C(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound COC1=C(C(=O)N2C[C@H](C)N(C(C3=CC=CC=C3)C3=CC=CC=C3)C[C@H]2C)C=C2C=CNC2=N1.COC1=NC2=C(C=CN2)C=C1C(=O)O.C[C@H]1CN[C@H](C)CN1C(C1=CC=CC=C1)C1=CC=CC=C1 UFMJZYGDSPRTCS-DWBAWAQESA-N 0.000 description 1
- YLZSYYTWMXCGSP-YBAXSONGSA-N COC1=C(C(=O)N2C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]2C)C=C2C(C(=O)C(=O)N3CCCC3)=CNC2=N1.C[C@H]1CN(C(=O)C2=CC=C(F)N=C2F)[C@H](C)CN1CC1=CC=C(F)C=C1.C[C@H]1CN[C@H](C)CN1CC1=CC=C(F)C=C1.O=C(O)C1=CC=C(F)N=C1F Chemical compound COC1=C(C(=O)N2C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]2C)C=C2C(C(=O)C(=O)N3CCCC3)=CNC2=N1.C[C@H]1CN(C(=O)C2=CC=C(F)N=C2F)[C@H](C)CN1CC1=CC=C(F)C=C1.C[C@H]1CN[C@H](C)CN1CC1=CC=C(F)C=C1.O=C(O)C1=CC=C(F)N=C1F YLZSYYTWMXCGSP-YBAXSONGSA-N 0.000 description 1
- FLVYPSAELKJOII-UHFFFAOYSA-N COC1=NC(N)=C(I)C=C1C(=O)N1CCC(CC2=CC=C(F)C=C2)CC1.COC1=NC(N)=CC=C1C(=O)N1CCC(CC2=CC=C(F)C=C2)CC1.II Chemical compound COC1=NC(N)=C(I)C=C1C(=O)N1CCC(CC2=CC=C(F)C=C2)CC1.COC1=NC(N)=CC=C1C(=O)N1CCC(CC2=CC=C(F)C=C2)CC1.II FLVYPSAELKJOII-UHFFFAOYSA-N 0.000 description 1
- JZJMALVFNLNLJE-UHFFFAOYSA-N COC1=NC2=C(C=C1C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)C(C(=O)C(=O)N1CCCC1)=CN2C.COC1=NC2=C(C=CN2)C=C1C(=O)N1CCC(CC2=CC=C(F)C=C2)CC1.COC1=NC2=C(C=CN2C)C=C1C(=O)N1CCC(CC2=CC=C(F)C=C2)CC1 Chemical compound COC1=NC2=C(C=C1C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)C(C(=O)C(=O)N1CCCC1)=CN2C.COC1=NC2=C(C=CN2)C=C1C(=O)N1CCC(CC2=CC=C(F)C=C2)CC1.COC1=NC2=C(C=CN2C)C=C1C(=O)N1CCC(CC2=CC=C(F)C=C2)CC1 JZJMALVFNLNLJE-UHFFFAOYSA-N 0.000 description 1
- YQBDJPJROPILKZ-CYBMUJFWSA-N COC1=NC2=C(C=C1C(=O)N1CCN(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(N)=O)=CN2 Chemical compound COC1=NC2=C(C=C1C(=O)N1CCN(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(N)=O)=CN2 YQBDJPJROPILKZ-CYBMUJFWSA-N 0.000 description 1
- KGORAGFILIVHPG-XZOQPEGZSA-N COC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(C(C3=CC=CC=C3)C3=CC=CC=C3)C[C@H]1C)C(C(=O)C(=O)NC1CCCC1)=CN2 Chemical compound COC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(C(C3=CC=CC=C3)C3=CC=CC=C3)C[C@H]1C)C(C(=O)C(=O)NC1CCCC1)=CN2 KGORAGFILIVHPG-XZOQPEGZSA-N 0.000 description 1
- HMIMLPIKWLXNGZ-JKSUJKDBSA-N COC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(=O)N(C)C)=CN2 Chemical compound COC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(=O)N(C)C)=CN2 HMIMLPIKWLXNGZ-JKSUJKDBSA-N 0.000 description 1
- YZZZLNAAMZCAJW-SQGPQFPESA-N COC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(=O)N1CC[C@@H](O)C1)=CN2 Chemical compound COC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(=O)N1CC[C@@H](O)C1)=CN2 YZZZLNAAMZCAJW-SQGPQFPESA-N 0.000 description 1
- HMVVOBWZZRDQAG-UONOGXRCSA-N COC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(N)=O)=CN2 Chemical compound COC1=NC2=C(C=C1C(=O)N1C[C@H](C)N(CC3=CC=C(F)C=C3)C[C@H]1C)C(C(=O)C(N)=O)=CN2 HMVVOBWZZRDQAG-UONOGXRCSA-N 0.000 description 1
- AZZIUVXUOURDMO-UHFFFAOYSA-N COC1=NC2=C(C=CN2)C=C1C(=O)N1CCC(CC2=CC=C(F)C=C2)CC1.COCN1C=C(C(=O)C(=O)N2CCCC2)C2=C1N=C(OC)C(C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)=C2.COCN1C=CC2=C1N=C(OC)C(C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)=C2 Chemical compound COC1=NC2=C(C=CN2)C=C1C(=O)N1CCC(CC2=CC=C(F)C=C2)CC1.COCN1C=C(C(=O)C(=O)N2CCCC2)C2=C1N=C(OC)C(C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)=C2.COCN1C=CC2=C1N=C(OC)C(C(=O)N1CCC(CC3=CC=C(F)C=C3)CC1)=C2 AZZIUVXUOURDMO-UHFFFAOYSA-N 0.000 description 1
- NXBITMIUXWUDAV-FSVUINJGSA-N COC1=NC2=C(C=CN2)C=C1C(=O)N1CCN([C@H](C)C2=CC=C(F)C=C2)C[C@H]1C.COC1=NC2=C(C=CN2)C=C1C(=O)O.C[C@@H]1CN([C@H](C)C2=CC=C(F)C=C2)CCN1 Chemical compound COC1=NC2=C(C=CN2)C=C1C(=O)N1CCN([C@H](C)C2=CC=C(F)C=C2)C[C@H]1C.COC1=NC2=C(C=CN2)C=C1C(=O)O.C[C@@H]1CN([C@H](C)C2=CC=C(F)C=C2)CCN1 NXBITMIUXWUDAV-FSVUINJGSA-N 0.000 description 1
- GYPDIRZSJYEPPP-VQTJNVASSA-N COCN1C=C(C(=O)C(=O)N2CCCC2)C2=CC(C(=O)N3C[C@H](C)N(CC4=CC=C(F)C=C4)C[C@H]3C)=C(OC)N=C21 Chemical compound COCN1C=C(C(=O)C(=O)N2CCCC2)C2=CC(C(=O)N3C[C@H](C)N(CC4=CC=C(F)C=C4)C[C@H]3C)=C(OC)N=C21 GYPDIRZSJYEPPP-VQTJNVASSA-N 0.000 description 1
- IEEAROXOGKFYJX-ZWKOTPCHSA-N C[C@@H](C1)N(Cc(cc2)ccc2F)C[C@@H](C)N1C(c(cc(c(C(C(N1CCCC1)=O)=O)c[nH]1)c1n1)c1OC)=O Chemical compound C[C@@H](C1)N(Cc(cc2)ccc2F)C[C@@H](C)N1C(c(cc(c(C(C(N1CCCC1)=O)=O)c[nH]1)c1n1)c1OC)=O IEEAROXOGKFYJX-ZWKOTPCHSA-N 0.000 description 1
- GNKMQWCEHOIFPP-LSDHHAIUSA-N C[C@@H](C1)N(Cc(cc2)ccc2F)C[C@@H](C)N1C(c(cc(cc[nH]1)c1n1)c1OC)=O Chemical compound C[C@@H](C1)N(Cc(cc2)ccc2F)C[C@@H](C)N1C(c(cc(cc[nH]1)c1n1)c1OC)=O GNKMQWCEHOIFPP-LSDHHAIUSA-N 0.000 description 1
- FZPXVUQHMAPXQZ-GHMZBOCLSA-N C[C@@H]1CN([C@H](C)C2=CC=C(F)C=C2)CCN1 Chemical compound C[C@@H]1CN([C@H](C)C2=CC=C(F)C=C2)CCN1 FZPXVUQHMAPXQZ-GHMZBOCLSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- 208000018652 Closed Head injury Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- OAYMFEXJBOQKNM-UHFFFAOYSA-N FC1=CC=C(CC2CCNCC2)C=C1.O=C(C1=CC=C(F)N=C1F)N1CCC(CC2=CC=C(F)C=C2)CC1.O=C(O)C1=CC=C(F)N=C1F Chemical compound FC1=CC=C(CC2CCNCC2)C=C1.O=C(C1=CC=C(F)N=C1F)N1CCC(CC2=CC=C(F)C=C2)CC1.O=C(O)C1=CC=C(F)N=C1F OAYMFEXJBOQKNM-UHFFFAOYSA-N 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 229910017912 NH2OH Inorganic materials 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L PdCl2(PPh3)2 Substances [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 239000004133 Sodium thiosulphate Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- HMJJUQJVLUPGQP-UHFFFAOYSA-N [4-[(4-fluorophenyl)methyl]piperidin-1-yl]-(6-methoxy-1-methylpyrrolo[2,3-b]pyridin-5-yl)methanone Chemical compound COC1=NC=2N(C)C=CC=2C=C1C(=O)N(CC1)CCC1CC1=CC=C(F)C=C1 HMJJUQJVLUPGQP-UHFFFAOYSA-N 0.000 description 1
- LVTUVSJDSVAHNG-UHFFFAOYSA-N [4-[1-(4-fluorophenyl)ethyl]-2-methylpiperazin-1-yl]-(6-methoxy-1h-pyrrolo[2,3-b]pyridin-5-yl)methanone Chemical compound COC1=NC=2NC=CC=2C=C1C(=O)N(C(C1)C)CCN1C(C)C1=CC=C(F)C=C1 LVTUVSJDSVAHNG-UHFFFAOYSA-N 0.000 description 1
- JLGIFTRDDJWDRI-UHFFFAOYSA-N [N].CC(Cl)=O Chemical compound [N].CC(Cl)=O JLGIFTRDDJWDRI-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003927 aminopyridines Chemical class 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- DCBDOYDVQJVXOH-UHFFFAOYSA-N azane;1h-indole Chemical compound N.C1=CC=C2NC=CC2=C1 DCBDOYDVQJVXOH-UHFFFAOYSA-N 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- PPDJNZTUDFPAHX-UHFFFAOYSA-N benzyltrimethylammonium dichloroiodate Chemical compound Cl[I-]Cl.C[N+](C)(C)CC1=CC=CC=C1 PPDJNZTUDFPAHX-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- OQROAIRCEOBYJA-UHFFFAOYSA-N bromodiphenylmethane Chemical compound C=1C=CC=CC=1C(Br)C1=CC=CC=C1 OQROAIRCEOBYJA-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 125000006575 electron-withdrawing group Chemical group 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical group CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- IFVVGOJYWCHRCT-UHFFFAOYSA-N methyl 2,6-dichloropyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(Cl)N=C1Cl IFVVGOJYWCHRCT-UHFFFAOYSA-N 0.000 description 1
- GXSUADAWTDGKEZ-UHFFFAOYSA-N methyl 2-methoxy-6-[(4-methoxyphenyl)methylamino]pyridine-3-carboxylate Chemical compound N1=C(OC)C(C(=O)OC)=CC=C1NCC1=CC=C(OC)C=C1 GXSUADAWTDGKEZ-UHFFFAOYSA-N 0.000 description 1
- RAOIEDAVDRWTPN-UHFFFAOYSA-N methyl 6-acetamido-2-methoxy-5-(2-trimethylsilylethynyl)pyridine-3-carboxylate Chemical compound COC(=O)C1=CC(C#C[Si](C)(C)C)=C(NC(C)=O)N=C1OC RAOIEDAVDRWTPN-UHFFFAOYSA-N 0.000 description 1
- LUUZILNGGXJAMN-UHFFFAOYSA-N methyl 6-acetamido-2-methyl-5-(2-trimethylsilylethynyl)pyridine-3-carboxylate Chemical compound COC(=O)C1=CC(C#C[Si](C)(C)C)=C(NC(C)=O)N=C1C LUUZILNGGXJAMN-UHFFFAOYSA-N 0.000 description 1
- QGZWLNPRILYVKU-UHFFFAOYSA-N methyl 6-acetamido-5-iodo-2-methylpyridine-3-carboxylate Chemical compound COC(=O)C1=CC(I)=C(NC(C)=O)N=C1C QGZWLNPRILYVKU-UHFFFAOYSA-N 0.000 description 1
- FTEVWMZAZULDPG-UHFFFAOYSA-N methyl 6-amino-2-methylpyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(N)N=C1C FTEVWMZAZULDPG-UHFFFAOYSA-N 0.000 description 1
- SIJSAAOROIUMFR-UHFFFAOYSA-N methyl 6-amino-5-iodo-2-methoxypyridine-3-carboxylate Chemical compound COC(=O)C1=CC(I)=C(N)N=C1OC SIJSAAOROIUMFR-UHFFFAOYSA-N 0.000 description 1
- VSALUGPPMYAXEV-UHFFFAOYSA-N methyl 6-amino-5-iodo-2-methylpyridine-3-carboxylate Chemical compound COC(=O)C1=CC(I)=C(N)N=C1C VSALUGPPMYAXEV-UHFFFAOYSA-N 0.000 description 1
- KUJLWEWWBOZDRR-UHFFFAOYSA-N methyl 6-chloro-2-methoxypyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(Cl)N=C1OC KUJLWEWWBOZDRR-UHFFFAOYSA-N 0.000 description 1
- NOQGVEMELSFYPB-UHFFFAOYSA-N methyl 6-methoxy-1h-pyrrolo[2,3-b]pyridine-5-carboxylate Chemical compound N1=C(OC)C(C(=O)OC)=CC2=C1NC=C2 NOQGVEMELSFYPB-UHFFFAOYSA-N 0.000 description 1
- LHAHLXKZWRIQNR-UHFFFAOYSA-N methyl 6-methyl-1h-pyrrolo[2,3-b]pyridine-5-carboxylate Chemical compound N1=C(C)C(C(=O)OC)=CC2=C1NC=C2 LHAHLXKZWRIQNR-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical group CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
- PYZPILAXZWSJPP-UHFFFAOYSA-N n-[5-[4-[(4-fluorophenyl)methyl]piperidine-1-carbonyl]-3-iodo-6-methoxypyridin-2-yl]acetamide Chemical compound COC1=NC(NC(C)=O)=C(I)C=C1C(=O)N1CCC(CC=2C=CC(F)=CC=2)CC1 PYZPILAXZWSJPP-UHFFFAOYSA-N 0.000 description 1
- IPAADJWJUUYIGT-UHFFFAOYSA-N n-[5-[4-[(4-fluorophenyl)methyl]piperidine-1-carbonyl]-6-methoxy-3-(2-trimethylsilylethynyl)pyridin-2-yl]acetamide Chemical compound COC1=NC(NC(C)=O)=C(C#C[Si](C)(C)C)C=C1C(=O)N1CCC(CC=2C=CC(F)=CC=2)CC1 IPAADJWJUUYIGT-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical group OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BUUPQKDIAURBJP-UHFFFAOYSA-N sulfinic acid Chemical compound OS=O BUUPQKDIAURBJP-UHFFFAOYSA-N 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- WIOADUFWOUUQCV-UHFFFAOYSA-N triphenylphosphanium dichloride Chemical compound [Cl-].[Cl-].C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 WIOADUFWOUUQCV-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention relates to compounds useful in treating various disorders associated with enhanced activity of kinase p38. More specifically, it concerns compounds that are related to azaindole coupled through piperazine or piperidine moieties to an aryl group as useful in these methods.
- cytokines participate in this response, including IL-1, IL-6, IL-8 and TNF. It appears that the activity of these cytokines in the regulation of inflammation rely at least in part on the activation of an enzyme on the cell signaling pathway, a member of the MAP kinase family generally known as p38 and alternatively known as CSBP and RK. This kinase is activated by dual phosphorylation after stimulation by physiochemical stress, treatment with lipopolysaccharides or with proinflammatory cytokines such as IL-1 and TNF. Therefore, inhibitors of the kinase activity of p38 are useful anti-inflammatory agents.
- rheumatoid arthritis rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions
- sepsis septic shock, endotoxic shock, Gram-negative sepsis, toxic shock syndrome, asthma, adult respiratory distress syndrome, stroke, reperfusion injury, CNS injuries such as neural trauma and ischemia, psoriasis, restenosis, cerebral malaria, chronic pulmonary inflammatory disease, chronic obstructive pulmonary disease, cystic fibrosis, silicosis, pulmonary sarcosis, bone fracture healing, bone resorption diseases such as osteoporosis, soft tissue damage, graft-versus-host reaction, Crohn's Disease, ulcerative colitis including inflammatory bowel disease (IBD) and pyresis.
- IBD inflammatory bowel disease
- the invention is directed to methods and compounds useful in treating conditions that are characterized by enhanced p38 activity. These conditions include inflammation, proliferative diseases, and certain cardiovascular disorders as well as Alzheimer's disease as further described below.
- each Z 2 is independently CR 1 , C(R 1 ) 2 , or N wherein each R 1 is independently hydrogen or noninterfering substituent;
- Z 3 is NR 7 , O, or S
- R 7 is hydrogen or a non-interfering substituent
- each of Z 4 and Z 5 is independently N or CR 1 wherein R 1 is as defined above and wherein at least one of Z 4 and Z 5 is N;
- each R 3 is independently a noninterfering substituent
- n 0-3;
- each of L 1 and L 2 is a linker
- each R 4 is independently a noninterfering substituent
- n 0-4;
- Z 1 is CR 5 or N wherein R 5 is hydrogen or a noninterfering substituent
- each of 1 and k is an integer from 0-2 wherein the sum of 1 and k is 0-3;
- A is a cyclic group substituted with 0-5 noninterfering substituents, wherein two said noninterfering substituents can form a fused ring;
- the distance between the atom of A linked to L 2 and the center of the ⁇ ring is preferably 4.5-24 ⁇ .
- the compounds of formula (1) are useful in treating conditions which are characterized by overactivity of p38 kinase, in particular the ⁇ -isoform.
- Conditions “characterized by enhanced p38 activity” include those where this enzyme is present in increased amount or wherein the enzyme has been modified to increase its inherent activity, or both.
- enhanced activity refers to any condition wherein the effectiveness of these proteins is undesirably high, regardless of the cause.
- the compounds of the invention are useful in conditions where p38 kinase shows enhanced activity. These conditions are those in which fibrosis and organ sclerosis are caused by, or accompanied by, inflammation, oxidation injury, hypoxia, altered temperature or extracellular osmolarity, conditions causing cellular stress, apoptosis or necrosis. These conditions include ischemia-reperfusion injury, congestive heart failure, progressive pulmonary and bronchial fibrosis, hepatitis, arthritis, inflammatory bowel disease, glomerular sclerosis, interstitial renal fibrosis, chronic scarring diseases of the eyes, bladder and reproductive tract, bone marrow dysplasia, chronic infectious or autoimmune states and traumatic or surgical wounds. These conditions, of course, would be benefited by compounds which inhibit p38. Methods of treatment with the compounds of the invention are further discussed below.
- the compounds useful in the invention are derivatives of azaindole.
- a “noninterfering substituent” is a substituent which leaves the ability of the compound of formula (1) to inhibit p38 activity qualitatively intact. Thus, the substituent may alter the degree of inhibition of p38. However, as long as the compound of formula (1) retains the ability to inhibit p38 activity, the substituent will be classified as “noninterfering.”
- a number of assays for determining the ability of any compound to inhibit p38 activity are available in the art. A whole blood assay for this evaluation is illustrated below: the gene for p38 has been cloned and the protein can be prepared recombinantly and its activity assessed, including an assessment of the ability of an arbitrarily chosen compound to interfere with this activity. The essential features of the molecule are tightly defined.
- noninterfering substituents can be substituted by conventional organic moieties as is understood in the art. It is irrelevant to the present invention to test the outer limits of such substitutions.
- the essential features of the compounds are those set forth with particularity herein.
- L 1 and L 2 are described herein as linkers that impart a distance between portions of the molecule.
- Typical linkers include substituted or unsubstituted alkylene, i.e., (CH 2 ) n , wherein the use of “n” is a generic designation for a number in general as in the “nth degree” or “where CH 2 occurs n times”, alkenylene, i.e., an alkylene moiety which contains a double bond, including a double bond at one terminus, and alkynylene, i.e., an alkylene moiety which contains a triple bond.
- Other suitable linkers include, for example, substituted alkenylene or alkenylenes, and carbonyl or sulfonyl moieties and the like.
- hydrocarbyl residue refers to a residue which contains only carbon and hydrogen.
- the residue may be aliphatic or aromatic, straight-chain, cyclic, branched, saturated or unsaturated.
- the hydrocarbyl residue when so stated however, may contain heteroatoms over and above the carbon and hydrogen members of the substituent residue.
- the hydrocarbyl residue when specifically noted as containing such heteroatoms, may also contain carbonyl groups, amino groups, hydroxyl groups and the like, or contain heteroatoms within the “backbone” of the hydrocarbyl residue.
- organic residue refers to a residue that does not contain carbon. Examples include, but are not limited to, halo, hydroxy, NO 2 or NH 2 .
- alkyl As used herein, the term “alkyl,” “alkenyl” and “alkynyl” include straight- and branched-chain and cyclic monovalent substituents. Examples include methyl, ethyl, isobutyl, cyclohexyl, cyclopentylethyl, 2-propenyl, 3-butynyl, and the like.
- the alkyl, alkenyl and alkynyl substituents contain 1-10C (alkyl) or 2-10C (alkenyl or alkynyl). Preferably they contain 1-6C (alkyl) or 2-6C (alkenyl or alkynyl).
- Heteroalkyl, heteroalkenyl and heteroalkynyl are similarly defined but may contain 1-2 O, S or N heteroatoms or combinations thereof within the backbone residue.
- acyl encompasses the definitions of alkyl, alkenyl, alkynyl and the related hetero-forms which are coupled to an additional residue through a carbonyl group.
- “Aromatic” moiety refers to a monocyclic or fused bicyclic moiety such as phenyl or naphthyl; “heteroaromatic” also refers to monocyclic or fused bicyclic ring systems containing one or more heteroatoms selected from O, S and N. The inclusion of a heteroatom permits inclusion of 5-membered rings as well as 6-membered rings.
- typical aromatic systems include pyridyl, pyrimidyl, indolyl, benzimidazolyl, benzotriazolyl, isoquinolyl, quinolyl, benzothiazolyl, benzofuranyl, thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl and the like.
- Any monocyclic or fused ring bicyclic system which has the characteristics of aromaticity in terms of electron distribution throughout the ring system is included in this definition.
- the ring systems contain 5-12 ring member atoms.
- arylalkyl and heteroalkyl refer to aromatic and heteroaromatic systems which are coupled to another residue through a carbon chain, including substituted or unsubstituted, saturated or unsaturated, carbon chains, typically of 1-6C. These carbon chains may also include a carbonyl group, thus making them able to provide substituents as an acyl moiety.
- the invention includes optically pure forms as well as mixtures of stereoisomers or enantiomers.
- L 1 and L 2 are linkers which space the substituent Ar from ring ⁇ at a distance in a range preferably from 4.5 to 24 ⁇ , preferably less than 24 ⁇ , more preferably less than 20 ⁇ , and still more preferably less than 15 ⁇ . The distance is measured from the center of the ⁇ ring to the atom of Ar to which the linker L 2 is attached.
- Typical, but nonlimiting, embodiments of L 1 and L 2 are CO and isosteres thereof which can be subsequently converted to an oxime, an oximeether, an oximeester, or a ketal, or optionally substituted isosteres, or longer chain forms.
- L 2 may be alkylene or alkenylene optionally substituted with noninterfering substituents or L 1 or L 2 may be or may include a heteroatom such as N, S or O.
- substituents include, but are limited to, a moiety selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroarylalkyl, NH-aroyl, arylacyl, heteroarylacyl, halo, OR, NR 2 , SR, SOR, SO 2 R, OCOR, NRCOR, NRCONR 2 , NRCOOR, OCONR 2 , RCO, COOR, alkyl-OOR, SO 3 R, CONR 2 , SO 2 NR 2 , NRSO 2 NR 2 , CN, CF 3 , R 3 Si, and
- Isosteres of CO and CH 2 include SO, SO 2 , or CHOH. CO and CH 2 are preferred.
- A is a cyclic moiety, including aryl, heteroaryl, cycloaliphatic and cycloheteroaliphatic that can be optionally substituted.
- A may be, for instance, cyclohexyl, piperazinyl, benzimidazolyl, morpholinyl, pyridyl, pyrimidyl, phenyl, naphthyl and the like.
- A is preferably substituted or unsubstituted aryl or heteroaryl, and more preferably optionally substituted phenyl.
- Each substituent on A is independently a hydrocarbyl residue (1-20C) containing 0-5 heteroatoms selected from O, S and N, or is an inorganic residue.
- Preferred substituents include those selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, NH-aroyl, arylacyl, heteroarylacyl, halo, OR, NR 2 , SR, SOR, SO 2 R, OCOR, NRCOR, NRCONR 2 , NRCOOR, OCONR 2 , RCO, COOR, alkyl-OOR, SO 3 R, CONR 2 , SO 2 NR 2 , NRSO 2 NR 2 , CN, CF 3 , R 3 Si, and NO 2 , wherein each R is independently H, alkyl,
- substituents include halo, alkyl (1-4C) and more preferably, fluoro, chloro and methyl. These substituents may occupy all available positions of the ring of A, preferably disubstituted, more preferably mono-substituted. These substituents may be optionally substituted with substituents similar to those listed. Of course some substituents, such as halo, are not further substituted, as known to one skilled in the art.
- Two substituents on A can be joined to form a fused, optionally substituted aromatic or nonaromatic, saturated or unsaturated ring which contains 3-8 members.
- L 1 and L 2 are a piperidine or piperazine type moiety of the following formula:
- Z 1 is N or CR 5 wherein R 5 is H or a noninterfering substituent.
- R 5 is H or a noninterfering substituent.
- Each of 1 and k is an integer from 0-2 wherein the sum of 1and k is 0-3.
- the noninterfering substituents R 5 include, without limitation, halo, alkyl, alkoxy, aryl, arylalkyl, aryloxy, heteroaryl, acyl, carboxy, or hydroxy.
- R 5 is H, alkyl, OR, NR 2 , SR or halo, where R is H or alkyl.
- R 5 can be joined with an R 4 substituent to form an optionally substituted non-aromatic saturated or unsaturated hydrocarbyl ring which contains 3-8 members and 0-3 heteroatoms such as O, N and/or S.
- Preferred embodiments include compounds wherein Z 1 is CH or N, and those wherein both 1 and k are 1.
- R 4 represents a noninterfering substituent such as a hydrocarbyl residue (1-20C) containing 0-5 heteroatoms selected from O, S and N.
- R 4 is alkyl, alkoxy, aryl, arylalkyl, aryloxy, heteroalkyl, heteroaryl, heteroarylalkyl, RCO, acyl, halo, CN, OR, NRCOR, NR, wherein R is H, alkyl (preferably 1-4C), aryl, or hetero forms thereof.
- Each appropriate substituent is itself unsubstituted or substituted with 1-3 substituents.
- the substituents are preferably independently selected from a group that includes alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, NH-aroyl, halo, OR, NR 2 , SR, SOR, SO 2 R, OCOR, NRCOR, NRCONR 2 , NRCOOR, OCONR 2 , RCO, COOR, alkyl-OOR, SO 3 R, CONR 2 , SO 2 NR 2 , NRSO 2 NR 2 , CN, CF 3 , R 3 Si, and NO 2 , wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof and wherein two of R 4 on adjacent positions can be joined to form a fused, optionally substituted aromatic or nonaromatic, saturated or unsaturated ring which contains 3-8
- R 4 may occur m times on the ring; m is an integer of 0-4.
- Preferred embodiments of R 4 comprise alkyl (1-4C), straight chain or branched, especially two alkyl substituents which may be further substituted.
- R 4 comprises two methyl groups at positions 2 and 5 or 3 and 6 of a piperidinyl or piperazinyl ring.
- the substituted forms may be chiral and an isolated enantiomer may be preferred.
- R 3 also represents a noninterfering substituent.
- substituents include hydrocarbyl residues (1-6C) containing 0-2 heteroatoms selected from O, S and/or N and inorganic residues.
- n is an integer of 0-3, preferably 0 or 1.
- the substituents represented by R 3 are independently halo, alkyl, heteroalkyl, OCOR, OR, NRCOR, SR, or NR 2 , wherein R is H, alkyl, aryl, or heteroforms thereof. More preferably R 3 substituents are selected from alkyl, alkoxy or halo, and most preferably methoxy, methyl, and chloro.
- n is 0 and the ⁇ ring is unsubstituted, except for L 1 or n is 1 and R 3 is halo or alkoxy, preferably methoxy.
- R 7 include H, optionally substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, arylacyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroarylalkyl, heteroarylacyl, or is SOR, SO 2 R, RCO, COOR, alkyl-COR, SO 3 R, CONR 2 , SO 2 NR 2 , CN, CF 3 , NR 2 , OR, alkyl-SR, alkyl-SOR, alkyl-SO 2 R, alkyl-OCOR, alkyl-COOR, alkyl-CN, alkyl-CONR 2 , or R 3 Si, wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof More preferably, R 7 is hydrogen or is alkyl (1-4C), preferably methyl or is acyl (1-4C), or is
- R 7 is also preferably a substituted alkyl wherein the preferred substituents are form ether linkages or contain sulfinic or sulfonic acid moieties.
- Other preferred substituents include sulfhydryl substituted alkyl substituents.
- Still other preferred substituents include CONR 2 wherein R is defined as above.
- R 1 Preferred embodiments of R 1 include hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, NH-aroyl, halo, OR, NR 2 , SR, SOR, SO 2 R, OCOR, NRCOR, NRCONR 2 , NRCOOR, OCONR 2 , RCO, COOR, alkyl-OOR, SO 3 R, CONR 2 , SO 2 NR 2 , NRSO 2 NR 2 , CN, CF 3 , R 3 Si, and NO 2 , wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof and two of R 1 can be joined to form a fused, optionally substituted aromatic or nonaromatic, saturated or unsaturated ring which contains 3-8 members.
- R 1 is H, alkyl, such as methyl, most preferably, the ring labeled a contains a double bond and CR 1 is CH or C-alkyl.
- Other preferable forms of R 1 include H, alkyl, acyl, aryl, arylalkyl, heteroalkyl, heteroaryl, halo, OR, NR 2 , SR, NRCOR, alkyl-OOR, RCO, COOR, and CN, wherein each R is independently H, alkyl, or aryl or heteroforms thereof.
- a particularly preferred embodiment of a single R 1 is —W i —COX j Y wherein Y is COR 2 or an isostere thereof and R 2 is hydrogen or a noninterfering substituent, each of W and X is a spacer of 2-6 ⁇ , and each of i and j is independently 0 or 1.
- Each of W and X is a spacer and may be, for example, optionally substituted alkyl, alkenyl, or alkynyl, each of i and j is 0 or 1.
- W and X are unsubstituted.
- j is 0 so that the two carbonyl groups are adjacent to each other.
- i is 0 so that the proximal CO is adjacent the ring.
- compounds wherein the proximal CO is spaced from the ring can readily be prepared by selective reduction of an initially glyoxal substituted ⁇ ring.
- the dotted line represents a double bond where the CR 1 in position 3- is that wherein R 1 is W i COX j Y, preferably COCOR 2 , and CR 1 in position 2 is CH.
- the noninterfering substituent represented by R 2 when R 2 is other than H, is a hydrocarbyl residue (1-20C) containing 0-5 heteroatoms selected from O, S and/or N or is an inorganic residue.
- R 2 is H, or is straight or branched chain alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroalkyl, heteroaryl, or heteroarylalkyl, each optionally substituted with halo, alkyl, heteroalkyl, SR, OR, NR 2 , OCOR, NRCOR, NRCONR 2 , NRSO 2 R, NRSO 2 NR 2 , OCONR 2 , CONR 2 , or R 3 Si wherein each R 2 is independently H, alkyl, alkenyl or aryl or the heteroatom-containing forms thereof, or wherein R 2 is OR, NR 2 , SR, NRCONR 2 , OCONR 2 , or R 3 Si wherein each
- R 2 is H, heteroarylalkyl, —NR 2 , heteroaryl, —COOR, —NHRNR 2 , heteroaryl-COOR, heteroaryloxy, —OR, heteroaryl-NR 2 , —NROR and alkyl.
- R 2 is isopropyl piperazinyl, methyl piperazinyl, dimethylamine, piperazinyl, isobutyl carboxylate, oxycarbonylethyl, benzimidazolyl, aminoethyldimethylamine, isobutyl carboxylate piperazinyl, oxypiperazinyl, ethylcarboxylate piperazinyl, methoxy, ethoxy, hydroxy, methyl, amine, aminoethyl pyrrolidinyl, aminopropanediol, piperidinyl, pyrrolidinyl-piperidinyl, or methyl piperidinyl, wherein each ring listed may optionally be substituted.
- Isosteres of COR 2 as represented by Y are defined as follows.
- the isosteres have varying lipophilicity and may contribute to enhanced metabolic stability.
- Y as shown, may be replaced by the isosteres in Table 1.
- isosteres include tetrazole, 1,2,3-triazole, 1,2,4-triazole and imidazole.
- the compounds of formula (1) may be supplied in the form of their pharmaceutically acceptable acid-addition salts including salts of inorganic acids such as hydrochloric, sulfuric, hydrobromic, or phosphoric acid or salts of organic acids such as acetic, tartaric, succinic, benzoic, salicylic, and the like. If a carboxyl moiety is present on the compound of formula (1), the compound may also be supplied as a salt with a pharmaceutically acceptable cation.
- the compounds of the invention may be synthesized by art-known methods.
- the following reaction schemes are illustrative:
- 2,6-difluoropyridine can be converted to carboxylic acid A through treatment with a base such as lithium diisopropylamide at ⁇ 78° C. in THF and then passing in a stream of dry CO 2 .
- Carboxylic acid A can be converted to amide B through treatment with standard coupling reagents such as TBTU or EDCI and the appropriately substituted amine.
- B is dissolved in alcoholic solvent such as ethanol, methanol, or isopropanol whereupon ammonia gas is passed through the solution. The solution is sealed and heated until conversion to C is complete.
- Compound D is obtained by treating C with K-O t Bu in the desired alcoholic solvent. Heating D in DMF with iodine and sodium periodate yields E.
- Acetyl chloride was added to a solution of E in THF and pyridine, yielding F.
- the trimethylsilylacetylene group was installed through treatment of F with trimethylsilyl acetylene in the presence of Pd(PPh 3 ) 2 Cl 2 , CuI, and an amine base.
- Cyclization to H is accomplished by refluxing a solution of G and tetrabutylammonium fluoride.
- H can be functionalized by treatment with a base such as NaH, KOH, or LiHMDS followed by addition of an appropriate electrophile to give I.
- I is then treated with oxalyl chloride in DCM, DCE, or chloroform.
- To the resulting intermediate is then added the desired nucleophile to give K.
- H can be converted to J in a similar manner.
- the indole nitrogen can be aminated with an N-amination reagent, such as those described in U.S. Provisional Patent Appln. 60/395,693 filed 11 Jul. 2002 entitled “Improved Reagents for N-Amination” and Tetrahedron Lett., vol. 23, No. 37, pages 3835-3836 1982, which are incorporated herein by reference, compound A reacts with an N-amination reactant to give the indole N-substituted compound B.
- an N-amination reagent such as those described in U.S. Provisional Patent Appln. 60/395,693 filed 11 Jul. 2002 entitled “Improved Reagents for N-Amination” and Tetrahedron Lett., vol. 23, No. 37, pages 3835-3836 1982, which are incorporated herein by reference
- N-aminating reagents are RONH 2 where R is an aromatic that is appropriately substituted with electron withdrawing groups such as mono or di-nitro groups; diarylphosphinyl; or a substituted sulfonyl group. Examples include but are not limited to (Ar)ONH 2 , (Ar 2 PO)ONH 2 , and (ROSO 2 )ONH 2 .
- 6-Amino-2-alkoxy-nicotinic acid esters can be prepared from 2,6-dichloronicotinic acid, which is first converted into ester A by heating in the appropriate alcohol with catalytic amounts of acid, such as hydrochloric or sulfuric acid.
- Compound B can be prepared by treating A with sodium alkoxides in dichloromethane. By heating B and 4-methoxybenzylamine in the presence of an amine base in a polar aprotic solvent such as N-methylpyrrolidinone compound C is secured. C is converted into D by heating in warmed TFA until deprotection is complete.
- Another method can involve treatment of 2,6-dichloro-3-trifluromethylpyridine with dibenzylamine and an amine base in N-methylpyrrolidinone at elevated temperatures resulting in compound A. Heating A and an appropriate sodium alkoxide in DMF yields compound B. Removal of the diphenyl protecting group can be facilitated by treating a solution of compound B in wet methanol with palladium hydroxide on carbon under a pressure of hydrogen to give C. C can be converted to D by heating it in methanol in the presence of sodium methoxide. The ester, E, is obtained through treatment of D with dilute hydrochloric acid in the appropriate alcoholic solvent.
- the TNF- ⁇ production correlates to the activity of p38- ⁇ kinase.
- Venous blood is collected from healthy male volunteers into a heparinized syringe and is used within 2 hours of collection.
- Test compounds are dissolved in 100% DMSO and 1 ⁇ l aliquots of drug concentrations ranging from 0 to 1 mM are dispensed into quadruplicate wells of a 24-well microtitre plate (Nunclon Delta SI, Applied Scientific, So. San Francisco, Calif.).
- Whole blood is added at a volume of 1 ml/well and the mixture is incubated for 15 minutes with constant shaking (Titer Plate Shaker, Lab-Line Instruments, Inc., Melrose Park, Ill.) at a humidified atmosphere of 5% CO 2 at 37° C.
- the reaction is stopped by placing the microtitre plates in an ice bath and plasma or cell-free supemates are collected by centrifugation at 3000 rpm for 10 minutes at 4° C.
- the plasma samples are stored at ⁇ 80° C. until assayed for TNF- ⁇ levels by ELISA, following the directions supplied by Quantikine Human TNF- ⁇ assay kit (R&D Systems, Minneapolis, Minn.).
- IC 50 values are calculated using the concentration of inhibitor that causes a 50% decrease as compared to a control.
- the enriched mononuclear cell assay begins with cryopreserved Human Peripheral Blood Mononuclear Cells (HPBMCs) (Clonetics Corp.) that are rinsed and resuspended in a warm mixture of cell growth media. The resuspended cells are then counted and seeded at 1 ⁇ 10 6 cells/well in a 24-well microtitre plate. The plates are then placed in an incubator for an hour to allow the cells to settle in each well.
- HPBMCs Human Peripheral Blood Mononuclear Cells
- each well contains HPBMCs, LPS and a test chemical compound.
- LPS Lipopolysaccharide
- ELISA Enzyme Linked Immunoassay
- IC 50 values are calculated using the concentration of inhibitor that causes a 50% decrease as compared to a control.
- the compounds of the invention are useful among other indications in treating conditions associated with inflammation.
- the compounds of formula (1) or their pharmaceutically acceptable salts are used in the manufacture of a medicament for prophylactic or therapeutic treatment of mammals, including humans, in respect of conditions characterized by excessive production of cytokines and/or inappropriate or unregulated cytokine activity.
- the compounds of the invention inhibit the production of cytokines such as TNF, IL-1, IL-6 and IL-8, cytokines that are important proinflammatory constituents in many different disease states and syndromes. Thus, inhibition of these cytokines has benefit in controlling and mitigating many diseases.
- the compounds of the invention are shown herein to inhibit a member of the MAP kinase family variously called p38 MAPK (or p38), CSBP, or SAPK-2. The activation of this protein has been shown to accompany exacerbation of the diseases in response to stress caused, for example, by treatment with lipopolysaccharides or cytokines such as TNF and IL-1.
- Inhibition of p38 activity is predictive of the ability of a medicament to provide a beneficial effect in treating diseases such as Alzheimer's, coronary artery disease, congestive heart failure, cardiomyopathy, myocarditis, vasculitis, restenosis, such as occurs following coronary angioplasty, atherosclerosis, IBD, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, multiple sclerosis, acute respiratory distress syndrome (ARDS), asthma, chronic obstructive pulmonary disease (COPD), chronic pulmonary inflammatory disease, cystic fibrosis, silicosis, pulmonary sarcosis, sepsis, septic shock, endotoxic shock, Gram-negative sepsis, toxic shock syndrome, heart and brain failure (stroke) that are characterized by ischemia and reperfusion injury, surgical procedures, such as transplantation procedures and graft rejections, cardiopulmonary bypass, coronary artery
- bone fracture healing like osteoporosis
- bone resorption diseases like osteoporosis
- soft tissue damage type II diabetes
- pyresis psoriasis
- cachexia viral diseases such as those caused by HIV, CMV, and Herpes, and cerebral malaria.
- p38 has been shown to comprise a group of MAP kinases designated p38- ⁇ , p38- ⁇ , p38- ⁇ and p38- ⁇ .
- Jiang, Y., et al., J Biol Chem (1996) 271:17920-17926 reported characterization of p38- ⁇ as a 372-amino acid protein closely related to p38- ⁇ .
- p38- ⁇ was preferentially activated by MAP kinase kinase-6 (MKK6) and preferentially activated transcription factor 2, thus suggesting that separate mechanisms for action may be associated with these forms.
- MKK6 MAP kinase kinase-6
- ATF-2 activated transcription factor-2
- the manner of administration and formulation of the compounds useful in the invention and their related compounds will depend on the nature of the condition, the severity of the condition, the particular subject to be treated, and the judgment of the practitioner; formulation will depend on mode of administration.
- the compounds of the invention are small molecules, they are conveniently administered by oral administration by compounding them with suitable pharmaceutical excipients so as to provide tablets, capsules, syrups, and the like.
- suitable formulations for oral administration may also include minor components such as buffers, flavoring agents and the like.
- the amount of active ingredient in the formulations will be in the range of 5%-95% of the total formulation, but wide variation is permitted depending on the carrier.
- Suitable carriers include sucrose, pectin, magnesium stearate, lactose, peanut oil, olive oil, water, and the like.
- the compounds useful in the invention may also be administered through suppositories or other transmucosal vehicles.
- formulations will include excipients that facilitate the passage of the compound through the mucosa such as pharmaceutically acceptable detergents.
- the compounds may also be administered topically, for topical conditions such as psoriasis, or in formulation intended to penetrate the skin.
- topical conditions such as psoriasis
- formulation intended to penetrate the skin include lotions, creams, ointments and the like which can be formulated by known methods.
- the compounds may also be administered by injection, including intravenous, intramuscular, subcutaneous or intraperitoneal injection.
- Typical formulations for such use are liquid formulations in isotonic vehicles such as Hank's solution or Ringer's solution.
- Alternative formulations include nasal sprays, liposomal formulations, slow-release formulations, and the like, as are known in the art.
- Any suitable formulation may be used.
- a compendium of art-known formulations is found in Remington's Pharmaceutical Sciences , latest edition, Mack Publishing Company, Easton, Pa. Reference to this manual is routine in the art.
- the dosages of the compounds of the invention will depend on a number of factors which will vary from patient to patient. However, it is believed that generally, the daily oral dosage will utilize 0.001-100 mg/kg total body weight, preferably from 0.01-50 mg/kg and more preferably about 0.01 mg/kg-10 mg/kg. The dose regimen will vary, however, depending on the conditions being treated and the judgment of the practitioner.
- the compounds of formula (1) can be administered as individual active ingredients, or as mixtures of several embodiments of this formula.
- the inhibitors of p38 kinase can be used as single therapeutic agents or in combination with other therapeutic agents.
- Drugs that could be usefully combined with these compounds include natural or synthetic corticosteroids, particularly prednisone and its derivatives, monoclonal antibodies targeting cells of the immune system, antibodies or soluble receptors or receptor fusion proteins targeting immune or non-immune cytokines, and small molecule inhibitors of cell division, protein synthesis, or mRNA transcription or translation, or inhibitors of immune cell differentiation or activation.
- the compounds of the invention may be used in humans, they are also available for veterinary use in treating animal subjects.
- 2,6-difluoropyridine-3-carboxylic acid (1) was prepared by using the method described by Rewcastle, G. W., et al., J Med. Chem . (1996) 39:1823-1835.
- 2,6-difluoropyridine-3-carboxylic acid 13.14 g was suspended in dichloromethane (200 mL) and was cooled to 0° C. To this, under nitrogen atmosphere, was added thionyl chloride (30.14 mL, 413.2 mmol) dropwise. The ice-bath was removed and the mixture was refluxed for 3 h. The solvent was removed in vacuo. The product was taken up in dichloromethane (200 mL), stirred in an ice-bath and 4-fluorobenzylpiperidine hydrochloride (20.93 g, 91 mmol) was added followed by the dropwise addition of DIPEA (28.7 mL, 165.3 mmol).
- N- ⁇ 5-[4-(4-Fluoro-benzyl)-piperidine-1-carbonyl]-3-iodo-6-methoxy-pyridin-2yl ⁇ -acetamide (4.9 g, 9.59 mmol) was taken in dry dichloromethane (100 mL) and TEA (1.6 mL, 11.51 mmol) was added. The mixture was cooled in an ice-bath and Pd(PPh 3 ) 2 Cl 2 (35 mg, 0.05 mmol) and CuI (19 mg, 0.10 mmol) were added. To the stirred mixture was then added dropwise trimethylsilyl acetylene (1.49 mL, 10.55 mmol).
- N- ⁇ 5-[4-(4-Fluoro-benzyl)-piperidine-1-carbonyl]-6-methoxy-3-trimethylsilanylethynyl-pyridin-2-yl ⁇ -acetamide (4.24 g, 8.8 mmol) was dissolved in dry THF (50 mL). Tetrabutylammonium fluoride (1M solution in THF, 17.6 mL, 17.6 mmol) was added and the mixture refluxed with stirring for 3 h. The solvent was removed under reduced pressure and the residue was taken in water and extracted with dichloromethane (3 ⁇ 75 mL). The combined extracts were dried over sodium sulfate and evaporated.
- Acetyl chloride (48 mg, 0.62 mmol) was added to a solution of (6-Amino-5-iodo-2-methoxy-pyridin-3-yl)-[4-(4-fluoro-benzyl)-2R,5S-dimethyl-piperazin-1-yl]-methanone (235 mg, 0.47 mmol) and pyridine (0.057 mL, 0.7 mmol) in dichloromethane (10 mL) at RT. The reaction mixture was stirred at RT overnight, and then treated with water. The organic layer was separated, dried and concentrated. The residue was purified by chromatography on silica gel eluting with EtOAc:hexane (1:1) to give 150 mg (59%) of the desired product as a colorless oil. M+H + (541).
- Examples 26-30 are provided using an alternative method to synthetic scheme 1, as described in schemes 3-5.
- 6-Amino-2-methoxy-nicotinic acid methyl ester (20 g, 109.89 mmol) was taken in DMF (100 mL) and iodine (22.4 g, 88 mmol) and NaIO 4 (9.42 g, 44 mmol) were added. The mixture was stirred at 50° C. for 5 h under a nitrogen atmosphere. It was then poured into water and the product was extracted with ethyl acetate. The extract was decolorized using aqueous sodium thiosulphate solution. It was further washed with water, dried over sodium sulfate and concentrated. The crystallized product was collected by filtration. Further concentration of the mother liquor provided another crop to yield 22.25 g of the desired product. LCMS: 309.
- 6-Amino-5-iodo-2-methoxy-nicotinic acid methyl ester (19.04 g, 61.82 mmol) was taken in dichloromethane (190 mL) and triethylamine (13 mL, 93 mmol) and Pd(PPh) 2 Cl 2 (220 mg, 0.31 mmol) and CuI (411 mg, 2.16 mmol) were added.
- the mixture was cooled in an ice-bath and trimethylsilylacetylene (9.61 mL, 68 mmol) was added dropwise. The mixture was stirred over ice for another 30 min after which the ice-bath was removed and stirring continued for another 5 h.
- 16-Amino-2-methoxy-5-trimethylsilanylethynylnicotinic acid methyl ester (24.63 g, 88.6 mmol) was taken in dichloromethane (250 mL) and pyridine (14.3 mL, 177.2 mmol) was added. The mixture was cooled in an ice-bath and acetyl chloride (7.56 mL, 106.32 mmol) was added dropwise. After 1 h the ice-bath was removed and stirring continued under nitrogen for 20 h. The reaction mixture was washed with water, dried and evaporated.
- 6-Methoxy-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methyl ester (2.06 g, 10 mmol) was taken in methanol (50 mL) and 10% aqueous NaOH (16 mL), and water (10 mL) were added. The mixture was then refluxed for 2 h. It was evaporated to remove the methanol, diluted with water and acidified with 10% HCl. The precipitated product was extracted with ethyl acetate, dried over sodium sulfate and evaporated to yield 1.93 g of the desired product.
- LCMS 193.
- 6-Methoxy-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid (395 mg, 2 mmol) and 1-[1-(4-fluoro-phenyl)-ethyl]-3-methyl-piperazine (888 mg, 4 mmol) were dissolved in dry DMF (15 mL) and TBTU (1.28 g, 4 mmol) was added followed by TEA (600 mg, 6 mmol). The mixture was stirred for 20 h. It was poured into water and the product was extracted out with ethyl acetate.
- the 6-amino-2-methyl-nicotinic acid (1.0 g) was dissolved in MeOH and then cooled to 0° C. in an ice-water bath. HCl gas was then passed through the solution for 15 min. The reaction was warmed to RT and stirred overnight. After evaporating the MeOH, the residue was neutralized with saturated solution of Na 2 CO 3 and extracted with EtOAc. The combined organic layers were washed with water and brine then dried over Na 2 SO 4 Removing solvent give 500 mg crude product that was carried on to the next step without further purification.
- TBAF 6-acetylamino-2-methyl-5-trimethylsilanylethynyl-nicotinic acid methyl ester (200 mg). Reaction was heated under reflux for 4 h. After removing the THF, the residue was dissolved in EtOAc and wash with water and brine. The solvent was removed and the residue was purified by silica gel column eluding with 10-30% EtOAc in DCM to give 70 mg pure product.
- the compounds provided herein exhibit varying levels of activity towards p38 kinase.
- compounds from Examples 1-5, 7-9, 16, 17, 19-22, 26-29, and 31-36 each exhibit an IC 50 value of 1 ⁇ M or less in the diluted Whole Blood Assay described herein.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention is directed to methods to inhibit p38 kinase, preferably p38-α using compounds which are azaindoles wherein the azaindoles are coupled through a piperidine or piperazine type linker to another cyclic moiety.
Description
This application claims priority to U.S. Provisional Patent Application No. 60/417,599, filed Oct. 9, 2002, which is hereby incorporated by reference in its entirety.
The invention relates to compounds useful in treating various disorders associated with enhanced activity of kinase p38. More specifically, it concerns compounds that are related to azaindole coupled through piperazine or piperidine moieties to an aryl group as useful in these methods.
A large number of chronic and acute conditions have been recognized to be associated with perturbation of the inflammatory response. A large number of cytokines participate in this response, including IL-1, IL-6, IL-8 and TNF. It appears that the activity of these cytokines in the regulation of inflammation rely at least in part on the activation of an enzyme on the cell signaling pathway, a member of the MAP kinase family generally known as p38 and alternatively known as CSBP and RK. This kinase is activated by dual phosphorylation after stimulation by physiochemical stress, treatment with lipopolysaccharides or with proinflammatory cytokines such as IL-1 and TNF. Therefore, inhibitors of the kinase activity of p38 are useful anti-inflammatory agents.
PCT applications WO98/06715, WO98/07425, and WO 96/40143, all of which are incorporated herein by reference, describe the relationship of p38 kinase inhibitors with various disease states. As mentioned in these applications, inhibitors of p38 kinase are useful in treating a variety of diseases associated with chronic inflammation. These applications list rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, sepsis, septic shock, endotoxic shock, Gram-negative sepsis, toxic shock syndrome, asthma, adult respiratory distress syndrome, stroke, reperfusion injury, CNS injuries such as neural trauma and ischemia, psoriasis, restenosis, cerebral malaria, chronic pulmonary inflammatory disease, chronic obstructive pulmonary disease, cystic fibrosis, silicosis, pulmonary sarcosis, bone fracture healing, bone resorption diseases such as osteoporosis, soft tissue damage, graft-versus-host reaction, Crohn's Disease, ulcerative colitis including inflammatory bowel disease (IBD) and pyresis.
The above-referenced PCT applications disclose compounds which are p38 kinase inhibitors said to be useful in treating these disease states. These compounds are either imidazoles or are indoles substituted at the 3- or 4-position with a piperazine ring linked through a carboxamide linkage. Additional compounds which are conjugates of piperazines with indoles are described as insecticides in WO97/26252, also incorporated herein by reference.
Certain aroyl/phenyl-substituted piperazines and piperidines which inhibit p38-α kinase are described in PCT publication WO00/2074 published 9 Mar. 2000. In addition, indolyl substituted piperidines and piperazines which inhibit this enzyme are described in PCT publication No. WO99/61426 published 2 Dec. 1999. Carbolene derivatives of piperidine and piperazine as p38-α inhibitors are described in PCT publication WO 00/59904 published 12 Oct. 2000. Additional substitutions on similar compounds are described in PCT publication WO00/71535 published 30 Nov. 2000. The disclosure of these documents is incorporated herein by reference.
The invention is directed to methods and compounds useful in treating conditions that are characterized by enhanced p38 activity. These conditions include inflammation, proliferative diseases, and certain cardiovascular disorders as well as Alzheimer's disease as further described below.
Compounds of the invention have been found to inhibit p38 kinase, the α-isoform in particular, and are thus useful in treating diseases mediated by these activities. The compounds of the invention are of the formula
and the pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof, wherein
each Z2 is independently CR1, C(R1)2, or N wherein each R1 is independently hydrogen or noninterfering substituent;
Z3 is NR7, O, or S;
R7 is hydrogen or a non-interfering substituent;
each of Z4 and Z5 is independently N or CR1 wherein R1 is as defined above and wherein at least one of Z4 and Z5 is N;
each R3 is independently a noninterfering substituent;
n is 0-3;
each of L1 and L2 is a linker;
each R4 is independently a noninterfering substituent;
m is 0-4;
Z1 is CR5 or N wherein R5 is hydrogen or a noninterfering substituent;
each of 1 and k is an integer from 0-2 wherein the sum of 1 and k is 0-3;
A is a cyclic group substituted with 0-5 noninterfering substituents, wherein two said noninterfering substituents can form a fused ring; and
the distance between the atom of A linked to L2 and the center of the α ring is preferably 4.5-24 Å.
The compounds of formula (1) are useful in treating conditions which are characterized by overactivity of p38 kinase, in particular the α-isoform. Conditions “characterized by enhanced p38 activity” include those where this enzyme is present in increased amount or wherein the enzyme has been modified to increase its inherent activity, or both. Thus, “enhanced activity” refers to any condition wherein the effectiveness of these proteins is undesirably high, regardless of the cause.
The compounds of the invention are useful in conditions where p38 kinase shows enhanced activity. These conditions are those in which fibrosis and organ sclerosis are caused by, or accompanied by, inflammation, oxidation injury, hypoxia, altered temperature or extracellular osmolarity, conditions causing cellular stress, apoptosis or necrosis. These conditions include ischemia-reperfusion injury, congestive heart failure, progressive pulmonary and bronchial fibrosis, hepatitis, arthritis, inflammatory bowel disease, glomerular sclerosis, interstitial renal fibrosis, chronic scarring diseases of the eyes, bladder and reproductive tract, bone marrow dysplasia, chronic infectious or autoimmune states and traumatic or surgical wounds. These conditions, of course, would be benefited by compounds which inhibit p38. Methods of treatment with the compounds of the invention are further discussed below.
The Invention Compounds
The compounds useful in the invention are derivatives of azaindole.
In the description above, certain positions of the molecule are described as permitting “noninterfering substituents.” This terminology is used because the substituents in these positions generally speaking are not relevant to the essential activity of the molecule taken as a whole. A wide variety of substituents can be employed in these positions, and it is well within ordinary skill to determine whether any particular arbitrary substituent is or is not “noninterfering.”
As used herein, a “noninterfering substituent” is a substituent which leaves the ability of the compound of formula (1) to inhibit p38 activity qualitatively intact. Thus, the substituent may alter the degree of inhibition of p38. However, as long as the compound of formula (1) retains the ability to inhibit p38 activity, the substituent will be classified as “noninterfering.” A number of assays for determining the ability of any compound to inhibit p38 activity are available in the art. A whole blood assay for this evaluation is illustrated below: the gene for p38 has been cloned and the protein can be prepared recombinantly and its activity assessed, including an assessment of the ability of an arbitrarily chosen compound to interfere with this activity. The essential features of the molecule are tightly defined. The positions which are occupied by “noninterfering substituents” can be substituted by conventional organic moieties as is understood in the art. It is irrelevant to the present invention to test the outer limits of such substitutions. The essential features of the compounds are those set forth with particularity herein.
In addition, L1 and L2 are described herein as linkers that impart a distance between portions of the molecule. Typical linkers include substituted or unsubstituted alkylene, i.e., (CH2)n, wherein the use of “n” is a generic designation for a number in general as in the “nth degree” or “where CH2 occurs n times”, alkenylene, i.e., an alkylene moiety which contains a double bond, including a double bond at one terminus, and alkynylene, i.e., an alkylene moiety which contains a triple bond. Other suitable linkers include, for example, substituted alkenylene or alkenylenes, and carbonyl or sulfonyl moieties and the like.
As used herein, “hydrocarbyl residue” refers to a residue which contains only carbon and hydrogen. The residue may be aliphatic or aromatic, straight-chain, cyclic, branched, saturated or unsaturated. The hydrocarbyl residue, when so stated however, may contain heteroatoms over and above the carbon and hydrogen members of the substituent residue. Thus, when specifically noted as containing such heteroatoms, the hydrocarbyl residue may also contain carbonyl groups, amino groups, hydroxyl groups and the like, or contain heteroatoms within the “backbone” of the hydrocarbyl residue.
As used herein, “inorganic residue” refers to a residue that does not contain carbon. Examples include, but are not limited to, halo, hydroxy, NO2 or NH2.
As used herein, the term “alkyl,” “alkenyl” and “alkynyl” include straight- and branched-chain and cyclic monovalent substituents. Examples include methyl, ethyl, isobutyl, cyclohexyl, cyclopentylethyl, 2-propenyl, 3-butynyl, and the like. Typically, the alkyl, alkenyl and alkynyl substituents contain 1-10C (alkyl) or 2-10C (alkenyl or alkynyl). Preferably they contain 1-6C (alkyl) or 2-6C (alkenyl or alkynyl). Heteroalkyl, heteroalkenyl and heteroalkynyl are similarly defined but may contain 1-2 O, S or N heteroatoms or combinations thereof within the backbone residue.
As used herein, “acyl” encompasses the definitions of alkyl, alkenyl, alkynyl and the related hetero-forms which are coupled to an additional residue through a carbonyl group.
“Aromatic” moiety refers to a monocyclic or fused bicyclic moiety such as phenyl or naphthyl; “heteroaromatic” also refers to monocyclic or fused bicyclic ring systems containing one or more heteroatoms selected from O, S and N. The inclusion of a heteroatom permits inclusion of 5-membered rings as well as 6-membered rings. Thus, typical aromatic systems include pyridyl, pyrimidyl, indolyl, benzimidazolyl, benzotriazolyl, isoquinolyl, quinolyl, benzothiazolyl, benzofuranyl, thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl and the like. Any monocyclic or fused ring bicyclic system which has the characteristics of aromaticity in terms of electron distribution throughout the ring system is included in this definition. Typically, the ring systems contain 5-12 ring member atoms.
Similarly, “arylalkyl” and “heteroalkyl” refer to aromatic and heteroaromatic systems which are coupled to another residue through a carbon chain, including substituted or unsubstituted, saturated or unsaturated, carbon chains, typically of 1-6C. These carbon chains may also include a carbonyl group, thus making them able to provide substituents as an acyl moiety.
When the compounds of formula (1) contain one or more chiral centers, the invention includes optically pure forms as well as mixtures of stereoisomers or enantiomers.
With respect to the portion of the compound between the atom of Ar bound to L2 and ring α, L1 and L2 are linkers which space the substituent Ar from ring α at a distance in a range preferably from 4.5 to 24 Å, preferably less than 24 Å, more preferably less than 20 Å, and still more preferably less than 15 Å. The distance is measured from the center of the α ring to the atom of Ar to which the linker L2 is attached. Typical, but nonlimiting, embodiments of L1 and L2 are CO and isosteres thereof which can be subsequently converted to an oxime, an oximeether, an oximeester, or a ketal, or optionally substituted isosteres, or longer chain forms. L2, in particular, may be alkylene or alkenylene optionally substituted with noninterfering substituents or L1 or L2 may be or may include a heteroatom such as N, S or O. Such substituents include, but are limited to, a moiety selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroarylalkyl, NH-aroyl, arylacyl, heteroarylacyl, halo, OR, NR2, SR, SOR, SO2R, OCOR, NRCOR, NRCONR2, NRCOOR, OCONR2, RCO, COOR, alkyl-OOR, SO3R, CONR2, SO2NR2, NRSO2NR2, CN, CF3, R3Si, and NO2, wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof, wherein two substituents can be joined to form a carbonyl moiety or an oxime, oximeether, oximeester or ketal of said carbonyl moiety.
Isosteres of CO and CH2, include SO, SO2, or CHOH. CO and CH2 are preferred.
A is a cyclic moiety, including aryl, heteroaryl, cycloaliphatic and cycloheteroaliphatic that can be optionally substituted. A may be, for instance, cyclohexyl, piperazinyl, benzimidazolyl, morpholinyl, pyridyl, pyrimidyl, phenyl, naphthyl and the like. A is preferably substituted or unsubstituted aryl or heteroaryl, and more preferably optionally substituted phenyl.
Each substituent on A is independently a hydrocarbyl residue (1-20C) containing 0-5 heteroatoms selected from O, S and N, or is an inorganic residue. Preferred substituents include those selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, NH-aroyl, arylacyl, heteroarylacyl, halo, OR, NR2, SR, SOR, SO2R, OCOR, NRCOR, NRCONR2, NRCOOR, OCONR2, RCO, COOR, alkyl-OOR, SO3R, CONR2, SO2NR2, NRSO2NR2, CN, CF3, R3Si, and NO2, wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof, and wherein two of said optional substituents on adjacent positions can be joined to form a fused, optionally substituted aromatic or nonaromatic, saturated or unsaturated ring which contains 3-8 members. More preferred substituents include halo, alkyl (1-4C) and more preferably, fluoro, chloro and methyl. These substituents may occupy all available positions of the ring of A, preferably disubstituted, more preferably mono-substituted. These substituents may be optionally substituted with substituents similar to those listed. Of course some substituents, such as halo, are not further substituted, as known to one skilled in the art.
Two substituents on A can be joined to form a fused, optionally substituted aromatic or nonaromatic, saturated or unsaturated ring which contains 3-8 members.
Between L1 and L2 is a piperidine or piperazine type moiety of the following formula:
Z1 is N or CR5 wherein R5 is H or a noninterfering substituent. Each of 1 and k is an integer from 0-2 wherein the sum of 1and k is 0-3. The noninterfering substituents R5 include, without limitation, halo, alkyl, alkoxy, aryl, arylalkyl, aryloxy, heteroaryl, acyl, carboxy, or hydroxy. Preferably, R5 is H, alkyl, OR, NR2, SR or halo, where R is H or alkyl. Additionally, R5 can be joined with an R4 substituent to form an optionally substituted non-aromatic saturated or unsaturated hydrocarbyl ring which contains 3-8 members and 0-3 heteroatoms such as O, N and/or S. Preferred embodiments include compounds wherein Z1 is CH or N, and those wherein both 1 and k are 1.
R4 represents a noninterfering substituent such as a hydrocarbyl residue (1-20C) containing 0-5 heteroatoms selected from O, S and N. Preferably R4 is alkyl, alkoxy, aryl, arylalkyl, aryloxy, heteroalkyl, heteroaryl, heteroarylalkyl, RCO, acyl, halo, CN, OR, NRCOR, NR, wherein R is H, alkyl (preferably 1-4C), aryl, or hetero forms thereof. Each appropriate substituent is itself unsubstituted or substituted with 1-3 substituents. The substituents are preferably independently selected from a group that includes alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, NH-aroyl, halo, OR, NR2, SR, SOR, SO2R, OCOR, NRCOR, NRCONR2, NRCOOR, OCONR2, RCO, COOR, alkyl-OOR, SO3R, CONR2, SO2NR2, NRSO2NR2, CN, CF3, R3Si, and NO2, wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof and wherein two of R4 on adjacent positions can be joined to form a fused, optionally substituted aromatic or nonaromatic, saturated or unsaturated ring which contains 3-8 members, or R4 is ═O or an oxime, oximeether, oximeester or ketal thereof. R4 may occur m times on the ring; m is an integer of 0-4. Preferred embodiments of R4 comprise alkyl (1-4C), straight chain or branched, especially two alkyl substituents which may be further substituted. Most preferably R4 comprises two methyl groups at positions 2 and 5 or 3 and 6 of a piperidinyl or piperazinyl ring. The substituted forms may be chiral and an isolated enantiomer may be preferred.
R3 also represents a noninterfering substituent. Such substituents include hydrocarbyl residues (1-6C) containing 0-2 heteroatoms selected from O, S and/or N and inorganic residues. n is an integer of 0-3, preferably 0 or 1. Preferably, the substituents represented by R3 are independently halo, alkyl, heteroalkyl, OCOR, OR, NRCOR, SR, or NR2, wherein R is H, alkyl, aryl, or heteroforms thereof. More preferably R3 substituents are selected from alkyl, alkoxy or halo, and most preferably methoxy, methyl, and chloro. Most preferably, n is 0 and the α ring is unsubstituted, except for L1 or n is 1 and R3 is halo or alkoxy, preferably methoxy.
Preferred embodiments of R7 include H, optionally substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, arylacyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroarylalkyl, heteroarylacyl, or is SOR, SO2R, RCO, COOR, alkyl-COR, SO3R, CONR2, SO2NR2, CN, CF3, NR2, OR, alkyl-SR, alkyl-SOR, alkyl-SO2R, alkyl-OCOR, alkyl-COOR, alkyl-CN, alkyl-CONR2, or R3Si, wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof More preferably, R7 is hydrogen or is alkyl (1-4C), preferably methyl or is acyl (1-4C), or is COOR wherein R is H, alkyl, alkenyl of aryl or hetero forms thereof. R7 is also preferably a substituted alkyl wherein the preferred substituents are form ether linkages or contain sulfinic or sulfonic acid moieties. Other preferred substituents include sulfhydryl substituted alkyl substituents. Still other preferred substituents include CONR2 wherein R is defined as above.
It is preferred that the indicated dotted line represents a double bond; however, compounds which contain a saturated β ring are also included within the scope of the invention.
Preferred embodiments of R1 include hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, NH-aroyl, halo, OR, NR2, SR, SOR, SO2R, OCOR, NRCOR, NRCONR2, NRCOOR, OCONR2, RCO, COOR, alkyl-OOR, SO3R, CONR2, SO2NR2, NRSO2NR2, CN, CF3, R3Si, and NO2, wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof and two of R1 can be joined to form a fused, optionally substituted aromatic or nonaromatic, saturated or unsaturated ring which contains 3-8 members. Most preferably, R1 is H, alkyl, such as methyl, most preferably, the ring labeled a contains a double bond and CR1 is CH or C-alkyl. Other preferable forms of R1 include H, alkyl, acyl, aryl, arylalkyl, heteroalkyl, heteroaryl, halo, OR, NR2, SR, NRCOR, alkyl-OOR, RCO, COOR, and CN, wherein each R is independently H, alkyl, or aryl or heteroforms thereof.
A particularly preferred embodiment of a single R1 is —Wi—COXjY wherein Y is COR2 or an isostere thereof and R2 is hydrogen or a noninterfering substituent, each of W and X is a spacer of 2-6 Å, and each of i and j is independently 0 or 1. Each of W and X is a spacer and may be, for example, optionally substituted alkyl, alkenyl, or alkynyl, each of i and j is 0 or 1. Preferably, W and X are unsubstituted. Preferably, j is 0 so that the two carbonyl groups are adjacent to each other. Preferably, also, i is 0 so that the proximal CO is adjacent the ring. However, compounds wherein the proximal CO is spaced from the ring can readily be prepared by selective reduction of an initially glyoxal substituted β ring. In the most preferred embodiments of the invention, the dotted line represents a double bond where the CR1 in position 3- is that wherein R1 is WiCOXjY, preferably COCOR2, and CR1 in position 2 is CH.
The noninterfering substituent represented by R2, when R2 is other than H, is a hydrocarbyl residue (1-20C) containing 0-5 heteroatoms selected from O, S and/or N or is an inorganic residue. Preferred are embodiments wherein R2 is H, or is straight or branched chain alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroalkyl, heteroaryl, or heteroarylalkyl, each optionally substituted with halo, alkyl, heteroalkyl, SR, OR, NR2, OCOR, NRCOR, NRCONR2, NRSO2R, NRSO2NR2, OCONR2, CONR2, or R3Si wherein each R2 is independently H, alkyl, alkenyl or aryl or the heteroatom-containing forms thereof, or wherein R2 is OR, NR2, SR, NRCONR2, OCONR2, or NRSO2NR2, wherein each R is independently H, alkyl, alkenyl or aryl or the heteroatom-containing forms thereof, and wherein two R attached to the same atom may form a 3-8 member ring and wherein said ring may further be substituted by alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, each optionally substituted, or by halo, SR, OR, NR2, OCOR, NRCOR, NRCONR2, NRSO2R, NRSO2NR2, OCONR2, or R3Si wherein each R is independently H, alkyl, alkenyl or aryl or the heteroatom-containing forms thereof wherein two R attached to the same atom may form a 3-8 member ring, optionally substituted as above defined.
Other preferred embodiments of R2 are H, heteroarylalkyl, —NR2, heteroaryl, —COOR, —NHRNR2, heteroaryl-COOR, heteroaryloxy, —OR, heteroaryl-NR2, —NROR and alkyl. Most preferably R2 is isopropyl piperazinyl, methyl piperazinyl, dimethylamine, piperazinyl, isobutyl carboxylate, oxycarbonylethyl, benzimidazolyl, aminoethyldimethylamine, isobutyl carboxylate piperazinyl, oxypiperazinyl, ethylcarboxylate piperazinyl, methoxy, ethoxy, hydroxy, methyl, amine, aminoethyl pyrrolidinyl, aminopropanediol, piperidinyl, pyrrolidinyl-piperidinyl, or methyl piperidinyl, wherein each ring listed may optionally be substituted.
Isosteres of COR2 as represented by Y are defined as follows.
The isosteres have varying lipophilicity and may contribute to enhanced metabolic stability. Thus, Y, as shown, may be replaced by the isosteres in Table 1.
TABLE 1 |
Acid Isosteres |
Names of | ||
Groups | Chemical Structures | Substitution Groups (SG) |
tetrazole |
|
n/a |
1,2,3-triazole |
|
H; SCH3; COCH3; Br; SOCH3;SO2CH3; NO2; CF3; CN; COOMe |
1,2,4-triazole |
|
H; SCH3; COCH3; Br; SOCH3;SO2CH3; NO2 |
imidazole |
|
H; SCH3; COCH3; Br; SOCH3;SO2CH3; NO2 |
Thus, isosteres include tetrazole, 1,2,3-triazole, 1,2,4-triazole and imidazole.
The compounds of formula (1) may be supplied in the form of their pharmaceutically acceptable acid-addition salts including salts of inorganic acids such as hydrochloric, sulfuric, hydrobromic, or phosphoric acid or salts of organic acids such as acetic, tartaric, succinic, benzoic, salicylic, and the like. If a carboxyl moiety is present on the compound of formula (1), the compound may also be supplied as a salt with a pharmaceutically acceptable cation.
Synthesis of the Invention Compounds
The compounds of the invention may be synthesized by art-known methods. The following reaction schemes are illustrative:
2,6-difluoropyridine can be converted to carboxylic acid A through treatment with a base such as lithium diisopropylamide at −78° C. in THF and then passing in a stream of dry CO2. Carboxylic acid A can be converted to amide B through treatment with standard coupling reagents such as TBTU or EDCI and the appropriately substituted amine. B is dissolved in alcoholic solvent such as ethanol, methanol, or isopropanol whereupon ammonia gas is passed through the solution. The solution is sealed and heated until conversion to C is complete. Compound D is obtained by treating C with K-OtBu in the desired alcoholic solvent. Heating D in DMF with iodine and sodium periodate yields E. Acetyl chloride was added to a solution of E in THF and pyridine, yielding F. The trimethylsilylacetylene group was installed through treatment of F with trimethylsilyl acetylene in the presence of Pd(PPh3)2Cl2, CuI, and an amine base. Cyclization to H is accomplished by refluxing a solution of G and tetrabutylammonium fluoride. At this point H can be functionalized by treatment with a base such as NaH, KOH, or LiHMDS followed by addition of an appropriate electrophile to give I. I is then treated with oxalyl chloride in DCM, DCE, or chloroform. To the resulting intermediate is then added the desired nucleophile to give K. H can be converted to J in a similar manner.
The indole nitrogen can be aminated with an N-amination reagent, such as those described in U.S. Provisional Patent Appln. 60/395,693 filed 11 Jul. 2002 entitled “Improved Reagents for N-Amination” and Tetrahedron Lett., vol. 23, No. 37, pages 3835-3836 1982, which are incorporated herein by reference, compound A reacts with an N-amination reactant to give the indole N-substituted compound B.
Examples of N-aminating reagents are RONH2 where R is an aromatic that is appropriately substituted with electron withdrawing groups such as mono or di-nitro groups; diarylphosphinyl; or a substituted sulfonyl group. Examples include but are not limited to (Ar)ONH2, (Ar2PO)ONH2, and (ROSO2)ONH2.
An alternate method to prepare 6-alkoxy-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid amides is provided in Scheme 3. Heating A in DMF with iodine and sodium periodate yields B. This can be coupled with trimethylsilylacetylene in the presence of Pd(PPh3)2Cl2, CuI, and an amine base to provide C. Acetyl chloride is added to a solution of C in THF and pyridine to yield D. Cyclization is effected by heating D at reflux in the presence of tetrabutylammonium fluoride in THF, resulting in E. E can be converted to its corresponding carboxylic acid by treatment with aqueous base. Coupling of F with substituted amines under standard conditions using reagents like TBTU or EDCI results in compounds such as G.
Various 6-Amino-2-alkoxy-nicotinic acid esters can be prepared from 2,6-dichloronicotinic acid, which is first converted into ester A by heating in the appropriate alcohol with catalytic amounts of acid, such as hydrochloric or sulfuric acid. Compound B can be prepared by treating A with sodium alkoxides in dichloromethane. By heating B and 4-methoxybenzylamine in the presence of an amine base in a polar aprotic solvent such as N-methylpyrrolidinone compound C is secured. C is converted into D by heating in warmed TFA until deprotection is complete.
Another method can involve treatment of 2,6-dichloro-3-trifluromethylpyridine with dibenzylamine and an amine base in N-methylpyrrolidinone at elevated temperatures resulting in compound A. Heating A and an appropriate sodium alkoxide in DMF yields compound B. Removal of the diphenyl protecting group can be facilitated by treating a solution of compound B in wet methanol with palladium hydroxide on carbon under a pressure of hydrogen to give C. C can be converted to D by heating it in methanol in the presence of sodium methoxide. The ester, E, is obtained through treatment of D with dilute hydrochloric acid in the appropriate alcoholic solvent.
Assays for p38 α Kinase Inhibition
For each of the assay procedures described below, the TNF-α production correlates to the activity of p38-α kinase.
A. Human Whole Blood Assay for p38 Kinase Inhibition
Venous blood is collected from healthy male volunteers into a heparinized syringe and is used within 2 hours of collection. Test compounds are dissolved in 100% DMSO and 1 μl aliquots of drug concentrations ranging from 0 to 1 mM are dispensed into quadruplicate wells of a 24-well microtitre plate (Nunclon Delta SI, Applied Scientific, So. San Francisco, Calif.). Whole blood is added at a volume of 1 ml/well and the mixture is incubated for 15 minutes with constant shaking (Titer Plate Shaker, Lab-Line Instruments, Inc., Melrose Park, Ill.) at a humidified atmosphere of 5% CO2 at 37° C. Whole blood is cultured either undiluted or at a final dilution of 1:10 with RPMI 1640 (Gibco 31800+NaHCO3, Life Technologies, Rockville, Md. and Scios, Inc., Sunnyvale, Calif.). At the end of the incubation period, 10 μl of LPS (E. coli 0111:B4, Sigrna Chemical Co., St. Louis, Mo.) is added to each well to a final concentration of 1 or 0.1 μg/ml for undiluted or 1:10 diluted whole blood, respectively. The incubation is continued for an additional 2 hours. The reaction is stopped by placing the microtitre plates in an ice bath and plasma or cell-free supemates are collected by centrifugation at 3000 rpm for 10 minutes at 4° C. The plasma samples are stored at −80° C. until assayed for TNF-α levels by ELISA, following the directions supplied by Quantikine Human TNF-α assay kit (R&D Systems, Minneapolis, Minn.).
IC50 values are calculated using the concentration of inhibitor that causes a 50% decrease as compared to a control.
B. Enriched Mononuclear Cell Assay for p38 Kinase Inhibition
The enriched mononuclear cell assay, the protocol of which is set forth below, begins with cryopreserved Human Peripheral Blood Mononuclear Cells (HPBMCs) (Clonetics Corp.) that are rinsed and resuspended in a warm mixture of cell growth media. The resuspended cells are then counted and seeded at 1×106 cells/well in a 24-well microtitre plate. The plates are then placed in an incubator for an hour to allow the cells to settle in each well.
After the cells have settled, the media is aspirated and new media containing 100 ng/ml of the cytokine stimulatory factor Lipopolysaccharide (LPS) and a test chemical compound is added to each well of the microtitre plate. Thus, each well contains HPBMCs, LPS and a test chemical compound. The cells are then incubated for 2 hours, and the amount of the cytokine Tumor Necrosis Factor Alpha (TNF-α) is measured using an Enzyme Linked Immunoassay (ELISA). One such ELISA for detecting the levels of TNF-α is commercially available from R&D Systems. The amount of TNF-α production by the HPBMCs in each well is then compared to a control well to determine whether the chemical compound acts as an inhibitor of cytokine production.
LPS induced cytokine synthesis in HPBMCs
-
- Cryopreserved HPBMC (cat#CC-2702 Clonetics Corp)
- LGM-3 media (cat#CC-3212 Clonetics Corp)
- LPS stock 10 μg/ml (Cat. No. L 2630 serotype 0111:B4 Sigma)
- Human TNF-α ELISA (R&D Systems)
- DNase I (10 mg/ml stock)
Preparation of cells.
-
- LGM-3 media warmed to 37° C.
- 5 μl of DNase I stock added to 10 ml media.
- Cells thawed rapidly and dispersed into above.
- Centrifuge 200×g×10 min @ RT.
- Pellet up in 10 ml sterile PBS.
- Centrifuge 200×g×10 min @ RT.
- Pellet resuspended in 10 ml LGM-3 then diluted to 50 ml with LGM-3.
- Perform cell count.
- Adjust to 1×E06 cells/well.
- Seed 1 ml/well of a 24 well plate.
- Place plate in incubator to plate down for 1 hour.
Preparation of incubation media.
-
- LGM-3 containing 100 ng/ml LPS (e.g. 50 ml media plus 0.5 ml LPS stock)
- Aliquot into 2 ml aliquots and add 1000×inhibitor dilutions.
Incubation
When cells have plated down, aspirate media away and overlay with 1 ml relevant incubation media. Return plate to incubator for 2 hours or 24 hours. Remove supernatants after incubation to a labeled tube and either perform TNF (or other) ELISA immediately or freeze for later assay.
IC50 values are calculated using the concentration of inhibitor that causes a 50% decrease as compared to a control.
Administration and Use
The compounds of the invention are useful among other indications in treating conditions associated with inflammation. Thus, the compounds of formula (1) or their pharmaceutically acceptable salts are used in the manufacture of a medicament for prophylactic or therapeutic treatment of mammals, including humans, in respect of conditions characterized by excessive production of cytokines and/or inappropriate or unregulated cytokine activity.
The compounds of the invention inhibit the production of cytokines such as TNF, IL-1, IL-6 and IL-8, cytokines that are important proinflammatory constituents in many different disease states and syndromes. Thus, inhibition of these cytokines has benefit in controlling and mitigating many diseases. The compounds of the invention are shown herein to inhibit a member of the MAP kinase family variously called p38 MAPK (or p38), CSBP, or SAPK-2. The activation of this protein has been shown to accompany exacerbation of the diseases in response to stress caused, for example, by treatment with lipopolysaccharides or cytokines such as TNF and IL-1. Inhibition of p38 activity, therefore, is predictive of the ability of a medicament to provide a beneficial effect in treating diseases such as Alzheimer's, coronary artery disease, congestive heart failure, cardiomyopathy, myocarditis, vasculitis, restenosis, such as occurs following coronary angioplasty, atherosclerosis, IBD, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, multiple sclerosis, acute respiratory distress syndrome (ARDS), asthma, chronic obstructive pulmonary disease (COPD), chronic pulmonary inflammatory disease, cystic fibrosis, silicosis, pulmonary sarcosis, sepsis, septic shock, endotoxic shock, Gram-negative sepsis, toxic shock syndrome, heart and brain failure (stroke) that are characterized by ischemia and reperfusion injury, surgical procedures, such as transplantation procedures and graft rejections, cardiopulmonary bypass, coronary artery bypass graft, CNS injuries, including open and closed head trauma, inflammatory eye conditions such as conjunctivitis and uveitis, acute renal failure, glomerulonephritis, inflammatory bowel diseases, such as Crohn's disease or ulcerative colitis, graft vs. host disease, bone fracture healing, bone resorption diseases like osteoporosis, soft tissue damage, type II diabetes, pyresis, psoriasis, cachexia, viral diseases such as those caused by HIV, CMV, and Herpes, and cerebral malaria.
Within the last several years, p38 has been shown to comprise a group of MAP kinases designated p38-α, p38-β, p38-γ and p38-δ. Jiang, Y., et al., J Biol Chem (1996) 271:17920-17926 reported characterization of p38-β as a 372-amino acid protein closely related to p38-α. In comparing the activity of p38-α with that of p38-β, the authors state that while both are activated by proinflammatory cytokines and environmental stress, p38-β was preferentially activated by MAP kinase kinase-6 (MKK6) and preferentially activated transcription factor 2, thus suggesting that separate mechanisms for action may be associated with these forms.
Kumar, S., et al., Biochem Biophys Res Comm (1997) 235:533-538 and Stein, B., et al, J Biol Chem (1997) 272:19509-19517 reported a second isoform of p38-β, p38-β2, containing 364 amino acids with 73% identity to p38-α. All of these reports show evidence that p38-β is activated by proinflammatory cytokines and environmental stress, although the second reported p38-β isoform, p38-β2, appears to be preferentially expressed in the CNS, heart and skeletal muscle compared to the more ubiquitous tissue expression of p38-α. Furthermore, activated transcription factor-2 (ATF-2) was observed to be a better substrate for p38-β2 than for p38-α, thus suggesting that separate mechanisms of action may be associated with these forms. The physiological role of p38-β1 has been called into question by the latter two reports since it cannot be found in human tissue and does not exhibit appreciable kinase activity with the substrates of p38-α.
The identification of p38-γ was reported by Li, Z., et al., Biochem Biophys Res Comm (1996) 228:334-340 and of p38-δ by Wang, X., et al., J Biol Chem (1997) 272:23668-23674 and by Kumar, S., et al, Biochem Biophys Res Comm (1997) 235:533-538. The data suggest that these two p38 isoforms (γ and ε) represent a unique subset of the MAPK family based on their tissue expression patterns, substrate utilization, response to direct and indirect stimuli, and susceptibility to kinase inhibitors.
The manner of administration and formulation of the compounds useful in the invention and their related compounds will depend on the nature of the condition, the severity of the condition, the particular subject to be treated, and the judgment of the practitioner; formulation will depend on mode of administration. As the compounds of the invention are small molecules, they are conveniently administered by oral administration by compounding them with suitable pharmaceutical excipients so as to provide tablets, capsules, syrups, and the like. Suitable formulations for oral administration may also include minor components such as buffers, flavoring agents and the like. Typically, the amount of active ingredient in the formulations will be in the range of 5%-95% of the total formulation, but wide variation is permitted depending on the carrier. Suitable carriers include sucrose, pectin, magnesium stearate, lactose, peanut oil, olive oil, water, and the like.
The compounds useful in the invention may also be administered through suppositories or other transmucosal vehicles. Typically, such formulations will include excipients that facilitate the passage of the compound through the mucosa such as pharmaceutically acceptable detergents.
The compounds may also be administered topically, for topical conditions such as psoriasis, or in formulation intended to penetrate the skin. These include lotions, creams, ointments and the like which can be formulated by known methods.
The compounds may also be administered by injection, including intravenous, intramuscular, subcutaneous or intraperitoneal injection. Typical formulations for such use are liquid formulations in isotonic vehicles such as Hank's solution or Ringer's solution.
Alternative formulations include nasal sprays, liposomal formulations, slow-release formulations, and the like, as are known in the art.
Any suitable formulation may be used. A compendium of art-known formulations is found in Remington's Pharmaceutical Sciences, latest edition, Mack Publishing Company, Easton, Pa. Reference to this manual is routine in the art.
The dosages of the compounds of the invention will depend on a number of factors which will vary from patient to patient. However, it is believed that generally, the daily oral dosage will utilize 0.001-100 mg/kg total body weight, preferably from 0.01-50 mg/kg and more preferably about 0.01 mg/kg-10 mg/kg. The dose regimen will vary, however, depending on the conditions being treated and the judgment of the practitioner.
It should be noted that the compounds of formula (1) can be administered as individual active ingredients, or as mixtures of several embodiments of this formula. In addition, the inhibitors of p38 kinase can be used as single therapeutic agents or in combination with other therapeutic agents. Drugs that could be usefully combined with these compounds include natural or synthetic corticosteroids, particularly prednisone and its derivatives, monoclonal antibodies targeting cells of the immune system, antibodies or soluble receptors or receptor fusion proteins targeting immune or non-immune cytokines, and small molecule inhibitors of cell division, protein synthesis, or mRNA transcription or translation, or inhibitors of immune cell differentiation or activation.
As implied above, although the compounds of the invention may be used in humans, they are also available for veterinary use in treating animal subjects.
The following examples are intended to illustrate but not to limit the invention, and to illustrate the use of the above Reaction Schemes.
2,6-difluoropyridine-3-carboxylic acid (1) was prepared by using the method described by Rewcastle, G. W., et al., J Med. Chem. (1996) 39:1823-1835.
2,6-difluoropyridine-3-carboxylic acid (13.14 g) was suspended in dichloromethane (200 mL) and was cooled to 0° C. To this, under nitrogen atmosphere, was added thionyl chloride (30.14 mL, 413.2 mmol) dropwise. The ice-bath was removed and the mixture was refluxed for 3 h. The solvent was removed in vacuo. The product was taken up in dichloromethane (200 mL), stirred in an ice-bath and 4-fluorobenzylpiperidine hydrochloride (20.93 g, 91 mmol) was added followed by the dropwise addition of DIPEA (28.7 mL, 165.3 mmol). This was removed from the ice-bath and stirring continued for an additional 2 h at RT. The reaction mixture was poured into water and the organic layer was separated. The water layer was further extracted with dichloromethane (100 mL). The combined organic extracts was dried over sodium sulfate and evaporated. The residue was purified on a column of silica gel, eluting with ethyl acetate-hexane (20-50% ethyl acetate, gradient) to yield 23.58 g of the desired product. LCMS: 335, M+1
(2,6-Difluoro-pyridin-3-yl)-[4-(4-fluoro-benzyl)-piperidin-1-yl]-methanone (23.58 g) was dissolved in methanol (120 mL) in a sealed tube. This was cooled in a dry ice-acetone bath and a stream of ammonia gas was passed through the solution for about 5 min after which the reaction vessel was sealed. The mixture was heated in an oil bath at 60° C. for 20 h. The solvent was removed in vacuo and the residue was dissolved in dichloromethane and washed with water. The organic layer was dried over sodium sulfate and evaporated. The residue was purified on a column of silica gel eluting with ethyl acetate-hexane (50-70% ethyl acetate, gradient). The second major fraction contained the desired isomer (5.98 g, 25%). LCMS: 332, M +1
(6-Amino-2-fluoro-pyridin-3-yl)-[4-(4-fluoro-benzyl)-piperidin-1-yl]-methanone (5.86 g, 17.7 mmol) was taken in methanol (60 mL). Potassium-t-butoxide (9.9 g, 85.5 mmol) was added and the mixture was refluxed for 6 h. The methanol was removed under reduced pressure and the residue was extracted from water with ethyl acetate. After drying over sodium sulfate it was evaporated and the residue was purified on a column of silica gel with ethyl acetate-hexane (50-70%, gradient) as eluent to yield 5.46 g (90%) of the desired product. LCMS: 344, M+1
(6-Amino-2-methoxy-pyridin-3-yl)-[4-(4-fluoro-benzyl)-piperidin-1-yl]-methanone (5.44 g, 15.86 mmol) of was dissolved in dry DMF (70 mL). Iodine (3.23 g, 12.70 mmol, 0.8 eq.) was added followed by sodium periodate (1.36 g, 6.34 mmol, 0.4 eq.). The mixture was heated at 50° C. under nitrogen with stirring for 4.5 h. It was then poured into water and extracted with ethyl acetate (3×100 mL). The combined extract was washed with dilute sodium thiosulfate solution to remove the excess iodine. The ethyl acetate extract was dried over sodium sulfate and evaporated. The residue was purified on a column of silica gel eluting with ethyl acetate-hexane (20-40% ethyl acetate, gradient) to yield 6.46 g (86.8%) of the desired product. LCMS: 470, M+1
(6-Amino-5-iodo-2-methoxy-pyridin-3-yl)-[4-(4-fluoro-benzyl)-piperidin-1-yl]-methanone (6.46 g, 13.8 mmol) was taken in dry THF (100 mL). Pyridine (1.7 mL, 20.7 mmol) was added and the mixture was cooled in an ice-bath. To this mixture was added dropwise under nitrogen acetyl chloride (1.3 mL, 18 mmol) in dry THF (10 mL). After the addition, the ice-bath was removed and stirring continued at RT for another 20 h. The solvent was removed under reduced pressure and the residue was taken up in water and extracted with dichloromethane (3×100 mL). The combined extracts were dried over sodium sulfate and evaporated. The residue was purified on a column of silica gel eluting with ethyl acetate-hexane (40-70% ethyl acetate, gradient) to yield 4.91 g (69.6%) of the desired product. LCMS: 511.
N-{5-[4-(4-Fluoro-benzyl)-piperidine-1-carbonyl]-3-iodo-6-methoxy-pyridin-2yl}-acetamide (4.9 g, 9.59 mmol) was taken in dry dichloromethane (100 mL) and TEA (1.6 mL, 11.51 mmol) was added. The mixture was cooled in an ice-bath and Pd(PPh3)2Cl2 (35 mg, 0.05 mmol) and CuI (19 mg, 0.10 mmol) were added. To the stirred mixture was then added dropwise trimethylsilyl acetylene (1.49 mL, 10.55 mmol). The reaction mixture was removed from ice-bath and stirring continued for 20 h at RT. The reaction mixture was filtered to remove the solids and the filtrate was evaporated to dryness. The residue was purified on a column of silica gel eluting it with ethyl acetate-hexane (20-50% ethyl acetate, gradient), to yield 4.24 g (92%) of the desired compound. LCMS: 481.
N-{5-[4-(4-Fluoro-benzyl)-piperidine-1-carbonyl]-6-methoxy-3-trimethylsilanylethynyl-pyridin-2-yl}-acetamide (4.24 g, 8.8 mmol) was dissolved in dry THF (50 mL). Tetrabutylammonium fluoride (1M solution in THF, 17.6 mL, 17.6 mmol) was added and the mixture refluxed with stirring for 3 h. The solvent was removed under reduced pressure and the residue was taken in water and extracted with dichloromethane (3×75 mL). The combined extracts were dried over sodium sulfate and evaporated. The residue was purified in a column of silica gel, eluting it with ethyl acetate-hexane (20-50% ethyl acetate, gradient) to yield 2.7 g of the desired product. LCMS: 368, M+1
[4-(4-Fluoro-benzyl)-piperidin-1-yl]-(6-methoxy-1H-pyrrolo[2,3-b]pyridin-5-yl)-methanone (368 mg, 1 mmol) was dissolved in dry dichloromethane (5 mL). It was cooled in an ice-bath and oxalyl chloride (4.5 mL, 2 M solution in dichloromethane) was added. The mixture was stirred for 1 h at 0° C. and for another 4 h at room temperature. It was evaporated to dryness, redissolved in dichloromethane and treated with pyrrolidine (3 mmol). After stirring for 30 min, water was added and the product was extracted with dichloromethane (3×25 mL). The combined extracts were dried over sodium sulfate. After evaporation of the solvent, the product was purified via radial chromatography using chloroform-methanol (0-3% methanol) to yield 340 mg of the desired product. LCMS: 493, M+1.
Prepared using the same method described in Example 1, Step I using [4-(4-Fluoro-benzyl)-piperidin-1-yl]-(6-methoxy-1H-pyrrolo[2,3-b]pyridin-5-yl)-methanone and substituting dimethylamine for pyrrolidine. LCMS: 467, M+1.
Prepared using the same method described in Example 1, Step I using [4-(4-Fluoro-benzyl)-piperidin-1-yl]-(6-methoxy-1H-pyrrolo[2,3-b]pyridin-5-yl)-methanone and substituting methylamine for pyrrolidine. LCMS: 453, M+1.
Preparation of 1-{5-[4-(4-Fluoro-benzyl)-piperidine-1-carbonyl]-6-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl}-2-(3-hydroxy-pyrrolidin-1-yl)-ethane-1,2-dione
Prepared using the same method described in Example 1, Step I using [4-(4-Fluoro-benzyl)-piperidin-1-yl]-(6-methoxy-1H-pyrrolo[2,3-b]pyridin-5-yl)-methanone and substituting 3-hydroxypyrrolidine for pyrrolidine. LCMS: 509, M+1.
Prepared using the same method described in Example 1, Step I using [4-(4-Fluoro-benzyl)-piperidin-1-yl]-(6-methoxy-1H-pyrrolo[2,3-b]pyridin-5-yl)-methanone and substituting ethanolamine for pyrrolidine. LCMS: 483, M+1.
Prepared using the same method described in Example 1, Step I using [4-(4-Fluoro-benzyl)-piperidin-1-yl]-(6-methoxy-1H-pyrrolo[2,3-b]pyridin-5-yl)-methanone and substituting methylethylamine for pyrrolidine. LCMS: 481, M+1.
This compound was prepared according to the procedure in Example 1, Step I using pyrrolidin-1-ylaamine in place of pyrrolidine. M+H+(508).
Prepared according to the procedure in Example 1, Step I using ammonia in place of pyrrolidine. M+H+(439).
Preparation of N-Ethyl-2-{5-[4-(4-fluoro-benzyl)-piperidine-1-carbonyl]-6-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl}-2-oxo-acetamide
Prepared according to the procedure in Example 1, Step I using ethylamine in place of pyrrolidine. M+H+(467).
To a solution of [4-(4-Fluoro-benzyl)-piperidin-1-yl]-(6-methoxy-1H-pyrrolo[2,3-b]pyridin-5-yl)-methanone (100 mg, 0.27 mmol) and ground KOH (76 mg, 1.36 mmol) in anhydrous acetone (15 mL) was added iodomethane (96 mg, 0.675 mmol) at 0° C. The reaction mixture was warmed to RT slowly and stirred overnight. The solvent was removed, and the residue was treated with water and extracted with EtOAc. The combined organic layer was washed with brine, dried and concentrated. The residue was purified by chromatography on silica gel eluting with EtOAc:hexane (1:1) to give the desired product 100 mg (98% yield) as a white solid. M+H+(382).
To a solution of [4-(4-Fluoro-benzyl)-piperidin-1-yl]-(6-methoxy-1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-methanone (100 mg, 0.26 mmol) in anhydrous CH2Cl2 (15 mL) was added oxalyl chloride (0.52 mL, 1.05 mmol, 2 M in CH2Cl2) at RT. The reaction mixture was stirred for 4 h. The reaction mixture was concentrated under reduced pressure. The residue was dried under vacuum for I h and dissolved in CH2Cl2 (15 mL). An excess amount of pyrrolidine (74 mg, 1.04 mmol) was added to the reaction mixture. After stirring for 1 h, the reaction mixture was treated with water. The organic layer was separated and washed with brine, dried and concentrated. The residue was purified by chromatography on silica gel eluting with CH2Cl2:MeOH (95:5) to give the desired product (70 mg) in 53% yield as a white solid. M+H+(507).
The synthesis of the following compounds can be carried out in a manner similar to the procedure described in Example 10.
To a solution of [4-(4-Fluoro-benzyl)-piperidin-1-yl]-(6-methoxy-1H-pyrrolo[2,3-b]pyridin-5-yl)-methanone (150 mg, 0.41 mmol) and ground KOH (114 mg, 2 mmol) in anhydrous acetone (15 mL) was added MOM chloride (82 mg, 1 mmol) at 0° C. The reaction mixture was warmed to RT slowly and stirred overnight. The solvent was removed, and the residue was treated with water and extracted with EtOAc. The combined organic layer was washed with brine, dried and concentrated. The residue was purified by chromatography on silica gel eluting with EtOAc:hexane (1:1) to give the desired product 130 mg (77% yield) as a white solid. M+H+(411).
This compound was prepared according to the procedure in Example 10, Step B. M+H+(537).
The synthesis of the following compounds can be carried out in a manner similar to re described in Example 12.
To a solution of 1-{5-[4-(4-Fluoro-benzyl)-piperidine-1-carbonyl]-6-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl}-2-pyrrolidin-1-yl-ethane-1,2-dione (76 mg, 0.154 mmol) in DMF (10 mL) was added 2,5-dinitro benzohydroxylamine (40 mg, 0.2 mmol) and K2CO3 (43 mg, 0.308 mmol). The reaction mixture was stirred at RT for 6 h, then treated with water (20 mL). The resulting mixture was extracted with EtOAc, washed with brine, dried (Na2SO4) and concentrated. The residue was purified by chromatography on silica gel eluting with 2% MeOH in CH2Cl2 to give 57 mg (73%) of the desired product as a white solid. M+H+(508).
The synthesis of the following compounds can be carried out in a manner similar to the procedure described in Example 14.
To a solution of 2,6-difluoropyridine-3-carboxylic acid (4.16 g, 26.2 mmol) and 4-fluorobenzyl-2S,5R-dimethyl piperazine (4.8 g, 21.8 mmol) in dimethylformamide was added TBTU (10.5 g, 32.7 nmol) followed by triethylamine (9 mL, 65.4 mmol). The reaction mixture was stirred overnight at RT and then poured into ice water. The precipitate formed was filtered and dissolved in dichloromethane. Two scoops of silica gel were added to the solution. The mixture was concentrate under reduced pressure. The residue was dry loaded on silica gel column eluting with EtOAc:hexane (4:6) to give 4 g (42%) of the desired product as a white solid. M+H+(364).
Ammonium gas (2 mL) was condensed and added to a cold solution of (2,6-Difluoro-pyridin-3-yl)-[4-(4-fluoro-benzyl)-2R,5S-dimethyl-piperazin-1-yl]-methanone (2 g, 8.26 mmol) in methanol (20 mL) in a Parr pressure reaction vessel at −78° C. The reaction vessel was sealed immediately and warmed to RT. The reaction mixture was heated at 60° C. overnight and cooled to −78° C. The reaction vessel was opened and the reaction mixture was then concentrated. The residue was purified by chromatography on silica gel eluting with EtOAc:hexane (1:1) then EtOAc:hexane (4:1) to give 750 mg (25%) of the undesired regioisomer, followed by 800 mg (27%) of the desired product as a white solid. M+H+(361).
Potassium tert-butoxide (2.5 g, 22.2 mmol) was added to a solution of (6-Amino-2-fluoro-pyridin-3-yl)-[4-(4-fluoro-benzyl)-2R,5S-dimethyl-piperazin-1-yl]-methanone (1.6 g 4.44 mmol) in anhydrous methanol (10 mL) at RT. The reaction mixture was refluxed overnight and then concentrated. The residue was treated with water and the resulting mixture was extracted with EtOAc. The combined organic extracts were washed with brine, dried and concentrated. The residue was purified by chromatography on silica gel eluting with EtOAc:hexane (2:1) to give 1.3 g (79%) of the desired product as a white foam. M+H+(361).
Method 1: To a solution of (6-Amino-2-methoxy-pyridin-3-yl)-[4-(4-fluoro-benzyl)-2R,5S-dimethyl-piperazin-1-yl]-methanone (800 mg, 2.15 mmol) in anhydrous DMF (20 mL) was added iodine (557 mg, 2.15 mmol) and sodium periodate (238 mg, 1.11 mmol). The reaction mixture was heated up at 50° C. overnight. The reaction mixture was poured into ice water and a solution of sodium thiosulfate (10%) was added to destroy the excess iodine. The precipitate formed was filtered. The crude product was purified by chromatography on silica gel (pre-treated with Et3N) eluting with EtOAc:hexane (1:2) to give 522 mg (52%) of the desired product as a white foam. M+H+(499).
Method 2: Benzyltrimethylammonium dichloroiodate (1.46 g, 4.2 mmol) was added to a solution of (6-Amino-2-methoxy-pyridin-3-yl)-[4-(4-fluoro-benzyl)-2R,5S-dimethyl-piperazin-1-yl]-methanone (1.2 g, 3.2 mmol) and calcium carbonate (1.1 g, 11 mmol) in anhydrous dichloromethane (25 mL) at RT. The reaction mixture was stirred overnight. The organic layer was washed with water and 10% sodium thiosulfate, dried and concentrated. The residue was purified by chromatography on silica gel eluting with EtOAc:hexane (1:2) to give 910 mg (57%) of the desired product as a white foam. M+H+(499).
Acetyl chloride (48 mg, 0.62 mmol) was added to a solution of (6-Amino-5-iodo-2-methoxy-pyridin-3-yl)-[4-(4-fluoro-benzyl)-2R,5S-dimethyl-piperazin-1-yl]-methanone (235 mg, 0.47 mmol) and pyridine (0.057 mL, 0.7 mmol) in dichloromethane (10 mL) at RT. The reaction mixture was stirred at RT overnight, and then treated with water. The organic layer was separated, dried and concentrated. The residue was purified by chromatography on silica gel eluting with EtOAc:hexane (1:1) to give 150 mg (59%) of the desired product as a colorless oil. M+H+(541).
To a solution of N-{5-[4-(4-Fluoro-benzyl)-2R,5S-dimethyl-piperazine-1-carbonyl]-3-iodo-6-methoxy-pyridin-2-yl}-acetamide (100 mg, 0.185 mmol), palladium bis(triphenylphosphane) dichloride (65 mg, 0.09 mmol), copper iodide (2 mg, 0.01 mmol) in anhydrous dichloromethane (5 mL) was added trimethlsilyacetylene (18 mg, 0.185 mmol) dropwise at 0° C. The reaction mixture was stirred at RT overnight, filtered through a plug of celite and concentrated. The residue was taken up into ethyl acetate, and washed with water and brine, dried and concentrated. The residue was purified by chromatography on silica gel eluting with EtOAc:hexane (1:1) to give 90 mg (96%) of the desired product. M+H+(511).
A mixture of N-{5-[4-(4-Fluoro-benzyl)-2R,5S-dimethyl-piperazine-1-carbonyl]-6-methoxy-3-trimethylsilanylethynyl-pyridin-2-yl}-acetamide (350 mg, 0.686 mmol) and tetrabutylammonium fluoride (1.37 mL, 1.37 mmol, 1.0 M in THF) in anhydrous THF was heated at reflux for 4 h. The reaction mixture was concentrated and the residue was taken up into ethyl acetate. The organic layer was washed with water, brine, dried and concentrated. The residue was purified by chromatography on silica gel eluting with EtOAc:hexane (4:6) to give 170 mg (63%) of the desired product as a colorless oil. M+H+(397).
To a solution of [4-(4-Fluoro-benzyl)-2R,5S-dimethyl-piperazin-1-yl]-(6-methoxy-1H-pyrrolo[2,3-b]pyridin-5-yl)-methanone (170 mg, 0.43 mmol) in anhydrous CH2Cl2 (15 mL) was added oxalyl chloride (0.86 mL, 1.72 mmol, 2 M in CH2Cl2) at RT. The reaction mixture was stirred overnight. The reaction mixture was concentrated under reduced pressure. The residue was dried under vacuum for 1 h and dissolved in CH2Cl2. An excess amount of pyrrolidine (122 mg, 1.72 mmol) was added to the reaction mixture. Stirred for 1 h, the reaction mixture was treated with water. The organic layer was separated and washed with brine, dried and concentrated. The residue was purified by chromatography on silica gel eluting with CH2Cl2:MeOH (95:5) to give the desired product (150 mg) in 67% yield as a white solid. M+H+(521).
Prepared according to the procedure in Example 16, Step H using ammonia in place of pyrrolidine. M+H+(468).
Prepared according to the procedure in Example 16, Step H using methylamine in place of pyrrolidine. M+H+(482)
Prepared similarly to Example 26 (below) however, using sodium ethoxide instead of sodium methoxide in step E and coupling with 4-fluorobenzyl-2S,5R-dimethyl piperazine in place of 1-[1-(4-fluoro-phenyl)-ethyl]-3-methyl-piperazine in Step M. M+H+(496)
Prepared according to the procedure in Example 16, Step H using dimethylamine in place of pyrrolidine. M+H+(496).
Prepared according to the procedure in Example 16, Step H using methylethylamine in place of pyrrolidine. M+H+(510).
Prepared according to the procedure in Example 16, Step H using 3-hydroxypyrrolidine in place of pyrrolidine. M+H+(538).
The synthesis of the following compounds can be carried out in a manner similar to the procedure described in Example 10.
The synthesis of the following compounds can be carried out in a manner similar to the procedure described in Example 12.
The synthesis of the following compounds can be carried out in a manner similar to the procedure described in Example 14.
Examples 26-30 are provided using an alternative method to synthetic scheme 1, as described in schemes 3-5.
4-Fluoro-α-methylbenzyl alcohol (7 g, 6.3 ml, 50 mmol) was added to 50 mL 48% aqueous solution of HBr at 0° C. The solution was allowed to stir 3 h at RT, at which time it was extracted with hexane. After drying and concentration, 10 g of a colorless oil was obtained. M+H+(203).
To 6.4 g 1-(4-fluorophenyl)-ethyl bromine in 100 mL DMF was added the piperazine. The mixture was then stirred overnight at room temperature. The solution was evaporated and the residue was then filtrated on a small quantity of silica gel, washing with ethyl acetate and methanol. Purification was carried out using flash chromatography, CHCl3/MeOH/Et3N=90/8/2 (or AcOEt/MeOH=90/10). 6.2 g (90%) of pure compound (mixture inseparable of two diasteromers) was obtained. M+H+(223).
To the mixture of two diastereomers (1 g, 4.5 mmol) in methanol (2.5 mL), was added a solution of L-tartaric acid (1.4 g, 9 mmol) in methanol (4.2 mL). Crystallization is effected by keeping the resulting mixture at 0° C. over 30 h. The resulting material was filtered and then 15% NaOH was added to the mother liquid. The free base was extracted with ethyl acetate. Upon concentrated the resulting colorless oil was recrystallized in hexane two or three times until the desired purity is obtained (determined by proton NMR). M+H+(223).
To a solution of 2,6-dichloronicotinic acid (30 g, 0.16 mol) in 150 mL methanol was added 3 mL of con. H2SO4 and the mixture was refluxed for 12 h. The methanol was evaporated off and the residue was dissolved in ethyl acetate, washed with water, 10% sodium carbonate solution, brine, dried with sodium sulfate and evaporated to yield the desired product (29.0 g, 87%) as white solid.
To a solution of 2,6-Dichloro-nicotinic acid methyl ester (20.0 g, 0.1 mol) in dichlomethane (80 ml) at 0° C. was added NaOMe (8.1 g, 0.15 mol) slowly and stirred at 0° C. for 3 h. The reaction mixture was diluted with water, the organic layer was dried with sodium sulfate and evaporated to give an oily product which slowly solidified into a white solid (14.0 g, 70%).
To a solution of 6-Chloro-2-methoxy-nicotinic acid methyl ester (18.5.0 g, 0.092 mol) in 50 mL of NMP was added p-methoxybenzylamine (19.0 g, 0.14 mol) and triethylamine (10.0 g, 0.1 mol). The mixture was heated to 70° C. for 4 h, cooled and diluted with water and extracted with ethyl acetate, washed with water, brine, dried with sodium sulfate, and evaporated to get an oil which was precipitated with ethylacetate/hexane mixture (1:1). This was then filtered and dried to yield 15 g (60%) of the target compound.
To the 2-methoxy-6-(4-methoxy-benzylamino)-nicotinic acid methyl ester was added TFA (50 mL) and the mix was warmed to 40° C. for 4 h. Most of the TFA was evaporated off and the residue was suspended in ethyl acetate/20% potassium carbonate and filtered through a celite pad. The organic layer was separated, dried with sodium sulfate and evaporated to get 5.4 g (65%) of the product as white solid.
6-Amino-2-methoxy-nicotinic acid methyl ester (20 g, 109.89 mmol) was taken in DMF (100 mL) and iodine (22.4 g, 88 mmol) and NaIO4 (9.42 g, 44 mmol) were added. The mixture was stirred at 50° C. for 5 h under a nitrogen atmosphere. It was then poured into water and the product was extracted with ethyl acetate. The extract was decolorized using aqueous sodium thiosulphate solution. It was further washed with water, dried over sodium sulfate and concentrated. The crystallized product was collected by filtration. Further concentration of the mother liquor provided another crop to yield 22.25 g of the desired product. LCMS: 309.
6-Amino-5-iodo-2-methoxy-nicotinic acid methyl ester (19.04 g, 61.82 mmol) was taken in dichloromethane (190 mL) and triethylamine (13 mL, 93 mmol) and Pd(PPh)2Cl2 (220 mg, 0.31 mmol) and CuI (411 mg, 2.16 mmol) were added. The mixture was cooled in an ice-bath and trimethylsilylacetylene (9.61 mL, 68 mmol) was added dropwise. The mixture was stirred over ice for another 30 min after which the ice-bath was removed and stirring continued for another 5 h. It was filtered to remove the solids and evaporated to dryness. The product was purified on a column of silica eluting it with ethyl acetate-hexane (0 to 20% ethyl acetate, gradient) to yield 15.69 g of the desired product. LCMS: 279.
16-Amino-2-methoxy-5-trimethylsilanylethynylnicotinic acid methyl ester (24.63 g, 88.6 mmol) was taken in dichloromethane (250 mL) and pyridine (14.3 mL, 177.2 mmol) was added. The mixture was cooled in an ice-bath and acetyl chloride (7.56 mL, 106.32 mmol) was added dropwise. After 1 h the ice-bath was removed and stirring continued under nitrogen for 20 h. The reaction mixture was washed with water, dried and evaporated. The residue was purified in a column of silica gel eluting with ethyl acetate-hexane (0 to 30% ethyl acetate, gradient) to yield 23.42 g of the desired product. LCMS: 321.
6-Acetylamino-2-methoxy-5-trimethylsilanylethynyl-nicotinic acid methyl ester (18 g, 56.25 mmol) of was dissolved in dry THF (50 mL) and TBAF (1M solution in THF, 225 mL, 225 mmol) was added and the mixture refluxed for 20 h. The volatiles were removed and the residue was extracted with dichloromethane from water. The extract was dried over sodium sulfate, concentrated and purified on a column of silica gel, eluting it with ethyl acetate-hexane (0 to 25% ethyl acetate, gradient) to yield 10.0 g of the desired product. LCMS: 207.
6-Methoxy-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methyl ester (2.06 g, 10 mmol) was taken in methanol (50 mL) and 10% aqueous NaOH (16 mL), and water (10 mL) were added. The mixture was then refluxed for 2 h. It was evaporated to remove the methanol, diluted with water and acidified with 10% HCl. The precipitated product was extracted with ethyl acetate, dried over sodium sulfate and evaporated to yield 1.93 g of the desired product. LCMS: 193.
6-Methoxy-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid (395 mg, 2 mmol) and 1-[1-(4-fluoro-phenyl)-ethyl]-3-methyl-piperazine (888 mg, 4 mmol) were dissolved in dry DMF (15 mL) and TBTU (1.28 g, 4 mmol) was added followed by TEA (600 mg, 6 mmol). The mixture was stirred for 20 h. It was poured into water and the product was extracted out with ethyl acetate. The extract was dried, evaporated and purified on a column of silica gel eluting it with ethyl acetate-hexane (20-40% ethyl acetate, Gradient) to yield 510 mg of the desired product. LCMS: 397.
{4-[1-(4-Fluoro-phenyl)-ethyl]-2-methyl-piperazin-1-yl}-(6-methoxy-1H-pyrrolo[2,3-b]pyridin-5-yl)-methanone (510 mg, 1.28 mmol) was taken in dry dichloromethane (10 mL) and was cooled in an ice-bath. Oxalylchloride (2 M solution in dichloromethane, 5 mL) was added and the mixture stirred under nitrogen for 1 h. The ice-bath was removed and stirring continued for another 6 h at RT. It was evaporated to dryness and resuspended in dry dichlormethane (15 mL) and was cooled in an ice bath. Methylamine (2 M solution in THF, 5 mL) was added via a syringe and stirring was continued for 30 min. This was poured into water and the product was extracted with dichloromethane. The extract was dried, evaporated and the residue was purified by radial chromatography using CHCl3-methanol (0 to 3% methanol) as eluant to yield 310 mg of the desired product. LCMS: 482.
The crude material was dissolved in acetonitrile (600 mL) and potassium iodide (45.2 g, 272 mmol), potassium carbonate (37.7 g, 272 mmol) and α-bromodiphenylmethane (73.9 g, 299 mmol) were added. The mixture was stirred at room temperature overnight and the solvent was removed. The residue was taken up in EtOAc, washed with 5% potassium carbonate, brine, dried over sodium sulfate and concentrated. This material was dissolved in 4 M HCl in dioxane and stirred for 1 h. After removal of the solvent, the residue was dissolved in EtOAc, washed with 10% NaOH, brine, dried over sodium sulfate and concentrated to give crude 1-benzhydryl-2S,5R-dimethyl-piperazine which was purified using flash chromatography (EtOAc/hexanes) to give 37 g pure 1-benzhydryl-2S,5R-dimethyl-piperazine. M+H+(281).
Prepared from 6-Methoxy-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid and 1-Benzhydryl-2S,5R-dimethyl-piperazine according to the procedure described in Example 26, Step M. M+H+(455).
Prepared according to the procedure in Example 16, Step H using dimethylamine in place of pyrrolidine. M+H+(554).
Prepared according to the procedure in Example 27, Step C using methylamine in place of dimethylamine. M+H+(540).
Prepared according to the procedure in Example 27, Step C using pyrrolidine in place of dimethylamine. M+H+(580).
Prepared according to the procedure in Example 27, Step C using cyclopentylamine in place of pyrrolidine. M+H+(594).
Prepared similarly to Example 26 however, coupling with 4-fluorobenzyl-3R-methyl piperazine in place of 1-[1-(4-fluoro-phenyl)-ethyl]-3-methyl-piperazine in Step M. M+H+(468)
Prepared similarly to Example 26 however, coupling with 4-fluorobenzyl-3R-methyl piperazine in place of 1-[1-(4-fluoro-phenyl)-ethyl]-3-methyl-piperazine in Step M and using ammonia in place of methylamine in Step N. M+H+(454).
Prepared similarly to Example 26 however, using sodium ethoxide instead of sodium methoxide in step E, coupling with 4-fluorobenzyl-2S,5R-dimethyl piperazine in place of 1-[1-(4-fluoro-phenyl)-ethyl]-3-methyl-piperazine in Step M, and using ammonia in place of methylamine in Step N. M+H+(482).
Prepared similarly to Example 26 however, using sodium ethoxide instead of sodium methoxide in step E and coupling with 4-fluorobenzyl-piperidine in place of 1-[1-(4-fluoro-phenyl)-ethyl]-3-methyl-piperazine in Step M. M+H+(467).
Prepared similarly to Example 26 however, using sodium ethoxide instead of sodium methoxide in step E, coupling with 4-fluorobenzyl-piperidine in place of 1-[1-(4-fluoro-phenyl)-ethyl]-3-methyl-piperazine in Step M, and using ammonia in place of methylamine in Step N. M+H+(453).
Preparation of 2-{5-[4-(4-Fluoro-benzyl)-2R,5S-dimethyl-piperazine-1-carbonyl]-6-methyl-1H-pnrrolo[2,3-b]pyridin-3-yl}-N,N-dimethyl-2-oxo-acetamide
To the degassed DMF solution of aminopyridine (2 g), Zn(CN)2 (753 mg) and 1,1-bis(diphenylphosphoino)ferrocene (DPPF) (711 mg) was added Pd2(dba)3 (489 mg). The reaction was heated to 130° C. in a sealed tube for 3 days. The reaction was then cooled to 85° C. and diluted with 200 ml NH4Cl (Sat'd), H2O and NH2OH (4:4:1). The mixture was then stirred for overnight at 85° C. After cooling to RT, the reaction mixture was filtered and the filtrate was extracted with EtOAc. The combined organic layers was washed with water, brine, and then dried over Na2SO4. After removing solvent, the residue was purified with normal phase silica gel column eluting with 0-50% EtOAc in Hexane.
Ba(OH)2 (1.28 g) was added to the H2O suspension (10 ml) of the cyanopyridine (1.0 g). The reaction was the heated to 95° C. for 2 h. The reaction was diluted by adding hot water followed by the addition of celite. While the temperature was held at 95° C., CO2 gas was passed through the reaction mixture for 30 min to saturate the reaction mixture until the pH=8-9. The reaction was filtered and the filter cake was washed with hot water three times. The combined water solution was evaporated under vacuum and gave 1.0 g of a white solid as the crude product.
The 6-amino-2-methyl-nicotinic acid (1.0 g) was dissolved in MeOH and then cooled to 0° C. in an ice-water bath. HCl gas was then passed through the solution for 15 min. The reaction was warmed to RT and stirred overnight. After evaporating the MeOH, the residue was neutralized with saturated solution of Na2CO3 and extracted with EtOAc. The combined organic layers were washed with water and brine then dried over Na2SO4 Removing solvent give 500 mg crude product that was carried on to the next step without further purification.
To a DMF solution of 6-Amino-2-methyl-nicotinic acid methyl ester (500 mg) was added iodine (644 mg), NaIO4 (754 mg) sequentially. The reaction was then heated to 50° C. overnight. After cooling down to RT, NaHS2O3 was added to the reaction until the reaction mixture turned a light yellow color. The mixture was diluted with water and then extracted with EtOAc. The organic layers were combined and washed with water, brine, and dried over Na2SO4. Removing the solvent gave 900 mg crude product.
At 0° C., the acetyl chloride (0.22 ml) was added to the DCM solution of 6-amino-5-iodo-2-methyl-nicotinic acid methyl ester (900 mg) followed by the addition of pyridine (0.38 ml). The reaction was stirred at 0° C. for 1 h, diluted with DCM and washed with water, Na2CO3 (Sta'd), water twice and brine. The crude product was purified with column eluding with 25% EtOAc in DCM to give 200 mg product.
To the DCM solution of 6-acetylamino-5-iodo-2-methyl-nicotinic acid methyl ester (200 mg) was added CuI (17 mg), PdCl2(PPh3)2 (63 mg), TMS acetylene (88 mg), and TEA (2.5 mL) sequentially. The reaction was stirred overnight at RT then diluted with DCM. The mixture was filtered through celite and washed with water and brine then dried over Na2SO4. The solvent was evaporated the residue was purified by silica gel column eluding with 5% EtOAc in DCM and gave 200 mg product.
TBAF (1.3 ml, 1.0M/THF) was added to the THF solution of 6-acetylamino-2-methyl-5-trimethylsilanylethynyl-nicotinic acid methyl ester (200 mg). Reaction was heated under reflux for 4 h. After removing the THF, the residue was dissolved in EtOAc and wash with water and brine. The solvent was removed and the residue was purified by silica gel column eluding with 10-30% EtOAc in DCM to give 70 mg pure product.
The MeOH suspension of 6-methyl-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methyl ester (70 mg) and K2CO3 (76 mg) was heated under refluxing for 4 h. The reaction mixture was then cooled to 0° C. and HCl (6N) was added dropwise until pH 3 was obtained. After removing the MeOH the residue was washed with hot MeOH three times. The combined MeOH solution was evaporated under vacuum to give a yellow solid 120 mg as crude product. The crude product was used directly in the next step.
Prepared from 6-methyl-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid and 1-(4-Fluoro-benzyl)-2S,5R-dimethyl-piperazine according to the procedure described in
Prepared from [4-(4-fluoro-benzyl)-2R,5S-dimethyl-piperazin-1-yl]-(6-methyl-1H -pyrrolo[2,3-b]pyridin-5-yl)-methanone and dimethylamine according to the procedure described in Example 26, Step N. M+H+(480).
The synthesis of the following compounds can be carried out in a manner similar to the procedure described in Example 36.
The compounds provided herein exhibit varying levels of activity towards p38 kinase. For example, compounds from Examples 1-5, 7-9, 16, 17, 19-22, 26-29, and 31-36 each exhibit an IC50 value of 1 μM or less in the diluted Whole Blood Assay described herein.
Claims (16)
1. A compound of the formula:
or a pharmaceutically acceptable salt thereof,
wherein R2 is H, or is straight or branched chain alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroalkyl, heteroaryl, or heteroarylalkyl, each optionally substituted with halo, alkyl, heteroalkyl, SR, OR, NR2, OCOR, NRCOR, NRCONR2, NRSO2R, NRSO2NR2, OCONR2, CN, COOR, CONR2, COR, or R3Si wherein each R is independently H, alkyl, alkenyl or aryl, or
wherein R2 OR, NR2, SR, NRCONR2, OCONR2, or NRSO2NR2, wherein each R is independently H, alkyl, alkenyl, aryl, heteroalkyl, heteroalkenyl, heteroaryl or heteroarylalkyl, and wherein two R attached to the same atom may form a 3-8 member ring and wherein said ring may further be substituted by alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroalkyl, heteroalkenyl, heteroaryl, heteroarylalkyl, or optionally substituted with halo, SR, OR, NR2, OCOR, NRCOR, NRCONR2, NRSO2R, NRSO2NR2, OCONR2, or R3Si wherein each R is independently H, alkyl, alkenyl or aryl wherein two R attached to the same atom may form a 3-8 member ring, optionally substituted as above defined;
Z3 is NR7, O, or S;
R7 is hydrogen or is optionally substituted alkyl, optionally substituted acyl, OR, or NR2 wherein each R is independently H, alkyl, alkenyl or aryl;
one of Z4 and Z5 is N and the other of Z4 and Z5 is CH;
each R3 is halo, alkyl, heteroalkyl, OCOR, OR, NRCOR, SR, or NR2, wherein R is H, alkyl, alkenyl, aryl, heteroalkyl, heteroalkenyl, heteroaryl or heteroarylalkyl;
n is 0-3;
L1 CO, SO, SO2, CHOH or CH2;
L2 is alkylene (1-4C) or alkenylene (1-4C) optionally substituted with a moiety selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, NH-aroyl, halo, OR, NR2 SR, SOR, SO2R, OCOR, NRCOR, NRCONR2, NRCOOR, OCONR2, RCO, COOR, alkyl-OOR, SO3R, CONR2, SO2NR2, NRSO2NR2, CN, CF3, R3Si, and NO2, wherein each R is independently H, alkyl, alkenyl or aryl, and wherein two substituents on L2 can be joined to form a non-aromatic saturated or unsaturated ring that includes 0-3 heteroatoms which are O, S and/or N and which contains 3 to 8 members or said two substituents can be joined to form a carbonyl moiety or an oxime, oximeether, oximeester or ketal of said carbonyl moiety;
each R4 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, NH-aroyl, halo, OR, NR2, SR, SOR, SO2R, OCOR, NRCOR, NRCONR2, NRCOOR, OCONR2, RCO, COOR, alkyl-OOR, SO3R, CONR2, SO2NR2, NRSO2NR2, CN, CF3, R3Si, and NO2, wherein each R is independently H, alkyl, alkenyl, aryl, heteroalkyl, heteroalkenyl, heteroaryl or heteroarylalkyl, or R4 is ═O or an oxime, oximeether, oximeester or ketal thereof;
m is 0-4; and
A is a cyclic group optionally substituted with 0-5 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, NH-aroyl, halo, OR, NR2, SR, SOR, SO2R, OCOR, NRCOR, NRCONR2, NRCOOR, OCONR2, RCO, COOR, alkyl-OOR, SO3R, CONR2, SO2NR2, NRSO2NR2, CN, CF3, R3Si, and NO2, wherein each R is independently H, alkyl, alkenyl, aryl, heteroalkyl, heteroalkenyl, heteroaryl or heteroarylalkyl.
2. The compound of claim 1 wherein R7 is H, or is optionally substituted alkyl, optionally substituted acyl, OR, or NR2 wherein each R is independently H, alkyl, alkenyl or aryl.
3. The compound of claim 1 wherein L1 is CO.
4. The compound of claim 1 wherein L2 is unsubstituted alkylene.
5. The compound of claim 4 wherein L2 is unsubstituted methylene.
6. The compound of claim 1 wherein A is optionally substituted phenyl.
7. The compound of claim 6 wherein said optional substitution is by halo, OR, or alkyl.
8. The compound of claim 7 wherein said phenyl is unsubstituted or has a single substituent.
9. The compound of claim 1 wherein each R4 is halo, OR, or alkyl.
10. The compound of claim 9 wherein m is 0, 1, or 2.
11. The compound of claim 10 wherein m is 2 and both R4 are alkyl.
12. The compound of claim 1 wherein R3 is halo or alkoxy.
13. The compound of claim 1 wherein Z4 is N and Z5 CH.
14. The compound of claim 1 wherein Z5 is N and Z4 is CH.
16. A pharmaceutical composition which composition comprises
a therapeutically effective amount of at least one compound of claim 1 and at least one pharmaceutically acceptable excipient.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/683,656 US7393851B2 (en) | 2002-10-09 | 2003-10-09 | Azaindole derivatives as inhibitors of p38 kinase |
US10/830,834 US20050043212A1 (en) | 2002-10-09 | 2004-04-22 | Differential inhibition of p38 map kinase isoforms |
US11/107,027 US20050288299A1 (en) | 2002-10-09 | 2005-04-15 | Azaindole derivatives as inhibitors of p38 kinase |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41759902P | 2002-10-09 | 2002-10-09 | |
US10/683,656 US7393851B2 (en) | 2002-10-09 | 2003-10-09 | Azaindole derivatives as inhibitors of p38 kinase |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/830,834 Continuation-In-Part US20050043212A1 (en) | 2002-10-09 | 2004-04-22 | Differential inhibition of p38 map kinase isoforms |
US11/107,027 Continuation-In-Part US20050288299A1 (en) | 2002-10-09 | 2005-04-15 | Azaindole derivatives as inhibitors of p38 kinase |
Publications (2)
Publication Number | Publication Date |
---|---|
US20040176598A1 US20040176598A1 (en) | 2004-09-09 |
US7393851B2 true US7393851B2 (en) | 2008-07-01 |
Family
ID=32094045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/683,656 Active 2024-11-23 US7393851B2 (en) | 2002-10-09 | 2003-10-09 | Azaindole derivatives as inhibitors of p38 kinase |
Country Status (12)
Country | Link |
---|---|
US (1) | US7393851B2 (en) |
EP (1) | EP1560582A4 (en) |
JP (1) | JP2006505552A (en) |
CN (1) | CN1713910A (en) |
AU (1) | AU2003279230A1 (en) |
BR (1) | BR0315233A (en) |
CA (1) | CA2501947A1 (en) |
MX (1) | MXPA05003817A (en) |
NZ (1) | NZ539390A (en) |
PL (1) | PL376374A1 (en) |
RU (1) | RU2005114010A (en) |
WO (1) | WO2004032874A2 (en) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1388541A1 (en) | 2002-08-09 | 2004-02-11 | Centre National De La Recherche Scientifique (Cnrs) | Pyrrolopyrazines as kinase inhibitors |
AU2003279230A1 (en) | 2002-10-09 | 2004-05-04 | Scios Inc. | AZAINDOLE DERIVATIVES AS INHIBITORS OF p38 KINASE |
US20050288299A1 (en) * | 2002-10-09 | 2005-12-29 | Mavunkel Babu J | Azaindole derivatives as inhibitors of p38 kinase |
US7244441B2 (en) | 2003-09-25 | 2007-07-17 | Scios, Inc. | Stents and intra-luminal prostheses containing map kinase inhibitors |
US20060052390A1 (en) * | 2003-12-24 | 2006-03-09 | Scios, Inc. | Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition |
US20060079461A1 (en) * | 2003-12-24 | 2006-04-13 | Scios, Inc. | Treatment of multiple myeloma by inhibition of p38 MAP kinase |
US20050162122A1 (en) * | 2004-01-22 | 2005-07-28 | Dunn Glenn M. | Fuel cell power and management system, and technique for controlling and/or operating same |
US7674907B2 (en) * | 2004-07-23 | 2010-03-09 | Amgen Inc. | Furanopyridine derivatives and methods of use |
US7452993B2 (en) | 2004-07-27 | 2008-11-18 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
MX2007001127A (en) | 2004-07-27 | 2007-07-11 | Sgx Pharmaceuticals Inc | Pyrrolo-pyridine kinase modulators. |
US7361764B2 (en) | 2004-07-27 | 2008-04-22 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
US7709645B2 (en) | 2004-07-27 | 2010-05-04 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
US7626021B2 (en) | 2004-07-27 | 2009-12-01 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
FR2876582B1 (en) | 2004-10-15 | 2007-01-05 | Centre Nat Rech Scient Cnrse | USE OF PYRROLO-PYRAZINE DERIVATIVES FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF MUCOVISCIDOSIS AND DISEASES ASSOCIATED WITH A DEFECT OF ADDRESSING PROTEINS IN CELLS |
WO2006112828A1 (en) * | 2005-04-15 | 2006-10-26 | Scios, Inc. | Azaindole derivatives as inhibitors of p38 kinase |
WO2007015866A2 (en) * | 2005-07-20 | 2007-02-08 | Kalypsys, Inc. | Inhibitors of p38 kinase and methods of treating inflammatory disorders |
CN101300241A (en) | 2005-10-21 | 2008-11-05 | 埃科特莱茵药品有限公司 | Piperazine derivatives as antimalarial agents |
CN101331131A (en) * | 2005-12-16 | 2008-12-24 | 霍夫曼-拉罗奇有限公司 | Pyrrolo [2, 3-b] pyridine derivatives as h3 receptor modulators |
WO2008013823A2 (en) * | 2006-07-26 | 2008-01-31 | Scios Inc. | Co-crystals of (2r-trans)-6-chloro-5-[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-n,n,1-trimethyl-alpha-oxo-1h-indole-3-acetamide |
EP2066619A2 (en) * | 2006-11-02 | 2009-06-10 | Arete Therapeutics, INC. | Soluble epoxide hydrolase inhibitors |
EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
WO2009041591A1 (en) * | 2007-09-28 | 2009-04-02 | Kyowa Hakko Kirin Co., Ltd. | Fused pyridine derivative |
DE102008052943A1 (en) | 2008-10-23 | 2010-04-29 | Merck Patent Gmbh | azaindole derivatives |
US8889688B2 (en) | 2010-01-05 | 2014-11-18 | Actelion Pharmaceuticals Ltd. | Piperazines as antimalarial agents |
US8324239B2 (en) | 2010-04-21 | 2012-12-04 | Novartis Ag | Furopyridine compounds and uses thereof |
WO2013062857A1 (en) * | 2011-10-25 | 2013-05-02 | Merck Sharp & Dohme Corp. | Piperidinyl alkyne orexin receptor antagonists |
KR20150132437A (en) | 2013-03-15 | 2015-11-25 | 액테리온 파마슈티칼 리미티드 | Novel acrylamide derivatives as antimalarial agents |
US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
CN116284011A (en) | 2015-10-16 | 2023-06-23 | 艾伯维公司 | Process for preparing imidazo [1,2-a ] pyrrolo [2,3-e ] pyrazines and solid forms thereof |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
WO2017151409A1 (en) | 2016-02-29 | 2017-09-08 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods |
HRP20221196T1 (en) | 2017-10-05 | 2022-12-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
CN113874015B (en) | 2018-12-21 | 2024-05-24 | 细胞基因公司 | Thienopyridine inhibitors of RIPK2 |
CN113470165B (en) * | 2021-06-17 | 2022-09-16 | 南昌大学 | Soft tissue modeling method based on radial basis point interpolation method and mass point spring method |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996040143A1 (en) | 1995-06-07 | 1996-12-19 | Smithkline Beecham Corporation | Imidazole compounds |
WO1997026252A1 (en) | 1996-01-19 | 1997-07-24 | Fmc Corporation | Insecticidal n-heterocyclylalkyl- or n-[(polycyclyl)-alkyl]-n'-substituted piperazines |
WO1998006715A1 (en) | 1996-08-09 | 1998-02-19 | Smithkline Beecham Corporation | Novel piperazine containing compounds |
WO1998007425A1 (en) | 1996-08-21 | 1998-02-26 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
WO1999061426A1 (en) | 1998-05-22 | 1999-12-02 | Scios Inc. | Heterocyclic compounds and methods to treat cardiac failure and other disorders |
WO2000012074A2 (en) | 1998-08-28 | 2000-03-09 | Scios Inc. | Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase |
WO2000059904A2 (en) | 1999-03-24 | 2000-10-12 | Scios Inc. | Compounds and methods to treat cardiac failure and other disorders |
WO2000071535A1 (en) | 1999-05-21 | 2000-11-30 | Scios Inc. | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE |
US6476045B2 (en) | 2000-07-13 | 2002-11-05 | Merck Sharp & Dohme Ltd. | Azaindole derivatives and their use as therapeutic agents |
US20020183319A1 (en) | 1999-12-21 | 2002-12-05 | Congxin Liang | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
US6649636B1 (en) * | 1999-12-03 | 2003-11-18 | Pfizer Inc. | Heteroaryl phenyl pyrazole compounds as anti-inflammatory/analgesic agents |
WO2004032874A2 (en) | 2002-10-09 | 2004-04-22 | Scios Inc. | AZAINDOLE DERIVATIVES AS INHIBITORS OF p38 KINASE |
US6897207B2 (en) * | 2001-06-21 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Azaindoles |
US20050209269A1 (en) * | 2003-12-24 | 2005-09-22 | Pharmacia Italia S.P.A. | Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
US20050256151A1 (en) * | 2003-12-24 | 2005-11-17 | Pharmacia Italia S.P.A. | Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
US20060046977A1 (en) * | 2004-07-23 | 2006-03-02 | Nunes Joseph J | Furanopyridine derivatives and methods of use |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2237100T3 (en) * | 1998-05-26 | 2005-07-16 | Arkema | STRUCTURES THAT INCLUDE HALF-DENSITY POLYETHYLENEES AND BINDERS USED IN THESE STRUCTURES. |
EP1339708A2 (en) * | 2000-11-20 | 2003-09-03 | Scios Inc. | Indole-type inhibitors of p38 kinase |
EP1341782A2 (en) * | 2000-11-20 | 2003-09-10 | Scios Inc. | Inhibitors of p38 kinase |
JP2004533989A (en) * | 2000-11-20 | 2004-11-11 | サイオス インコーポレイテッド | Piperidine / piperazine type inhibitors of p38 kinase |
-
2003
- 2003-10-09 AU AU2003279230A patent/AU2003279230A1/en not_active Abandoned
- 2003-10-09 CN CNA2003801038970A patent/CN1713910A/en active Pending
- 2003-10-09 NZ NZ539390A patent/NZ539390A/en unknown
- 2003-10-09 US US10/683,656 patent/US7393851B2/en active Active
- 2003-10-09 MX MXPA05003817A patent/MXPA05003817A/en unknown
- 2003-10-09 JP JP2004543672A patent/JP2006505552A/en active Pending
- 2003-10-09 EP EP03770722A patent/EP1560582A4/en not_active Withdrawn
- 2003-10-09 RU RU2005114010/04A patent/RU2005114010A/en not_active Application Discontinuation
- 2003-10-09 PL PL03376374A patent/PL376374A1/en unknown
- 2003-10-09 BR BR0315233-2A patent/BR0315233A/en not_active IP Right Cessation
- 2003-10-09 CA CA002501947A patent/CA2501947A1/en not_active Abandoned
- 2003-10-09 WO PCT/US2003/032171 patent/WO2004032874A2/en active Application Filing
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996040143A1 (en) | 1995-06-07 | 1996-12-19 | Smithkline Beecham Corporation | Imidazole compounds |
WO1997026252A1 (en) | 1996-01-19 | 1997-07-24 | Fmc Corporation | Insecticidal n-heterocyclylalkyl- or n-[(polycyclyl)-alkyl]-n'-substituted piperazines |
WO1998006715A1 (en) | 1996-08-09 | 1998-02-19 | Smithkline Beecham Corporation | Novel piperazine containing compounds |
WO1998007425A1 (en) | 1996-08-21 | 1998-02-26 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
WO1999061426A1 (en) | 1998-05-22 | 1999-12-02 | Scios Inc. | Heterocyclic compounds and methods to treat cardiac failure and other disorders |
WO2000012074A2 (en) | 1998-08-28 | 2000-03-09 | Scios Inc. | Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase |
WO2000059904A2 (en) | 1999-03-24 | 2000-10-12 | Scios Inc. | Compounds and methods to treat cardiac failure and other disorders |
WO2000071535A1 (en) | 1999-05-21 | 2000-11-30 | Scios Inc. | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE |
US6649636B1 (en) * | 1999-12-03 | 2003-11-18 | Pfizer Inc. | Heteroaryl phenyl pyrazole compounds as anti-inflammatory/analgesic agents |
US20020183319A1 (en) | 1999-12-21 | 2002-12-05 | Congxin Liang | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
US6476045B2 (en) | 2000-07-13 | 2002-11-05 | Merck Sharp & Dohme Ltd. | Azaindole derivatives and their use as therapeutic agents |
US6897207B2 (en) * | 2001-06-21 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Azaindoles |
WO2004032874A2 (en) | 2002-10-09 | 2004-04-22 | Scios Inc. | AZAINDOLE DERIVATIVES AS INHIBITORS OF p38 KINASE |
US20050209269A1 (en) * | 2003-12-24 | 2005-09-22 | Pharmacia Italia S.P.A. | Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
US20050256151A1 (en) * | 2003-12-24 | 2005-11-17 | Pharmacia Italia S.P.A. | Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
US20060046977A1 (en) * | 2004-07-23 | 2006-03-02 | Nunes Joseph J | Furanopyridine derivatives and methods of use |
Non-Patent Citations (26)
Title |
---|
Bundgaard "design of prodrugs" p. 1, 27-28 (1986). * |
Buzzetti et al. "Preparation and formulation . . . " CA 124:260834 (1996). * |
Colvin et al., Tetrahedron Lett. (1982) 23(37):3835-3836. |
Ewing et al. "Substituted piperazinone . . . " CA 131:130007 (1999). * |
Furuya et al. "Preparation of thieno . . . " Ca 124:202226 (1995). * |
Houpis et al. "Synthesis of functionalized . . . " CA 122:105718 (1995). * |
International Search Report mailed on Apr. 13, 2004 for PCT patent application No. PCT/US03/32171 filed on Oct. 9, 2003, 4 pages. |
International Search Report Mailed on Aug. 18, 2005 for PCT/US2005/12969 filed on Apr. 15, 2005. |
Janssens et al. "Bicyclic heterocycliyl . . . " Ca 104:68856 (1986). * |
Jiang et al., J. Biol. Chem. (1996) 271:17920-17926. |
Kim et al. "Piperazinecarboxamide . . . " CA 125:58548 (1996). * |
King "Bioisosters . . . " Med. chem. principle and Practice p. 206-208 (1994). * |
Kumar et al., Biochem. Biophys. Res. Comm. (1997) 235:533-538. |
Ledeboer et al. "Pyrrolopyridines . . . " CA 146:27814 (2006). * |
Li et al., Biochem. Biophys. Res. Comm. (1996) 228:334-340. |
Mavunkel et al., Bioorganic and Medicinal Chemistry Letters, 2003, vol. 13, pp. 3087-3090. |
Ngo et al., In the Protein Folding Problem and Tertiary Structure Prediction, 1994, Merz et al., (ed.), Birkhauser, Boston, MA, pp. 433 and 492-495, Ref-U, Form-892. |
Patani et al. "Bioisosterism . . . " Chem Rev. v90 p. 3147, 3168 (1990). * |
Rewcastle et al., J. Med. Chem. (1996) 39:1823-1835. |
Saavedra et al. "preparation of thienopyridine . . . " CAS AN 2007:17769 (2007). * |
Salom et al. "Preparation of . . . " CA 143:347150 (2005). * |
Salom et al. "Preparation of pyrrolo[2,3-b]pyridine . . . " CA 143:133351 (2005). * |
Stein et al., J. Biol. Chem. (1997) 272:19509-19517. |
Suzuki et al. "preparation of condensed . . . " Ca 127:135807 (1997). * |
U.S. Appl. No. 60/395,693, filed Jul. 11, 2002. |
Wang et al., J. Biol. Chem. (1997) 272:23668-23674. |
Also Published As
Publication number | Publication date |
---|---|
NZ539390A (en) | 2007-05-31 |
WO2004032874A3 (en) | 2004-10-28 |
EP1560582A2 (en) | 2005-08-10 |
AU2003279230A1 (en) | 2004-05-04 |
WO2004032874A2 (en) | 2004-04-22 |
JP2006505552A (en) | 2006-02-16 |
RU2005114010A (en) | 2006-01-20 |
MXPA05003817A (en) | 2005-07-13 |
BR0315233A (en) | 2005-08-23 |
EP1560582A4 (en) | 2008-03-12 |
PL376374A1 (en) | 2005-12-27 |
US20040176598A1 (en) | 2004-09-09 |
CN1713910A (en) | 2005-12-28 |
CA2501947A1 (en) | 2004-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7393851B2 (en) | Azaindole derivatives as inhibitors of p38 kinase | |
US6696443B2 (en) | Piperidine/piperazine-type inhibitors of p38 kinase | |
US6821966B2 (en) | Inhibitors of p38 kinase | |
US6867209B1 (en) | Indole-type derivatives as inhibitors of p38 kinase | |
US20050171183A1 (en) | Indole-type inhibitors of p38 kinase | |
HRP20010854A2 (en) | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE | |
US20070161649A1 (en) | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE | |
US7488744B2 (en) | Indole-type derivatives as inhibitors of p38 kinase | |
US20050288299A1 (en) | Azaindole derivatives as inhibitors of p38 kinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SCIOS, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DUGAR, SUNDEEP;REEL/FRAME:016134/0718 Effective date: 20040510 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 12 |